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1 SUMMARY 
The PI3K signalling pathway is known to be fundamental for cell proliferation, growth, and survival, 
and to contribute to cancer development. Its deregulation and contribution to carcinogenesis has been 
well documented and reviewed in the past. PI3Ks are downstream effectors of receptor tyrosine 
kinases located at the cellular membrane, which play a central role in the regulation of cellular 
activities including cell proliferation and survival, growth, cell cycle control, metabolism, cell 
adhesion, and motility. Targeting different components of the RTK/PI3K pathway with 
pharmacological inhibitors has already been shown to be a promising approach in cancer treatment. 
Inhibitors of the RTK/PI3K pathway have reached the clinical stage in some cases and the 
development of new small molecule inhibitors is still an ongoing process. 
Lung cancer is the leading cause of cancer-related mortality in the Western world and every year 
approximately 1.4 million people are diagnosed with lung cancer. Small cell lung cancer is the most 
aggressive of all lung cancer types, accounts for approximately 15% of all lung cancer cases and is 
almost entirely related to tobacco smoking. It is characterized by rapid growth and early metastasis. 
Although SCLC initially responds to therapy most of the patients relapse. Due to metastasis and 
resistance to chemotherapy the clinical outcome is very poor and SCLC patients show an overall 5-
year survival of less than 5%. Consequently, novel therapeutic strategies are urgently required for 
SCLC. The molecular mechanisms responsible for lung cancer formation have been extensively 
studied. A striking event in the development of cancer is the escape of atypical cells from the normal 
growth control and their transformation into a malignant and invasive phenotype. Numerous genetic 
and molecular alterations have been reported to be associated with the development of SCLC, 
including autocrine signalling loops, oncogene activation and loss of tumour-suppressor genes. These 
genetic and molecular aberrations result in a lack of response to negative growth regulatory signals 
and the continuous presence of positive signals that regulate growth, motility, and invasion. 
The PI3K/Akt/mTOR pathway has been demonstrated to play a key role in SCLC cell proliferation, 
survival, chemoresistance and migration. Mutations in PIK3CA and gene amplification were reported 
in primary SCLC, as well as increased expression of PIK3CA at the mRNA and protein level. Broad 
specificity PI3K/mTOR inhibitors have shown anti-tumour activity in SCLC models in vitro and in 
vivo.  
Thus, we sought to investigate the particular role of the class IA PI3K isoform p110α and the potential 
of targeting class IA PI3Ks with isoform-specific inhibitors and RNAi.  
SCLC patient samples displayed over-expression of p110α and p110β, and increased over-expression 
of p110α correlated with advanced-staged SCLC, which was not the case for p110β. 
Targeting p110α by RNAi or isoform-specific inhibitors had more pronounced effects on SCLC cell 
responses, than in the case of p110β or p110δ, indicating a selective role for p110α in SCLC. We 
found impaired cell viability and activation status of classical PI3K downstream targets, such as Akt, 
S6 and 4EBP1, as well as decreased transcript levels of the pro-angiogenic marker VEGFA.  
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Furthermore, we hypothesized that p110α may control the expression of a selective subset of genes 
implicated in SCLC cell proliferation and/or survival. Indeed, targeting p110α affected the expression 
of the Bcl2 family of proteins at the transcript and protein level. Importantly, the Bcl-2 family of 
proteins has been previously shown to play a crucial role in the survival of SCLC cell lines in vitro 
and in vivo. In the present study, pro-apoptotic proteins, such as Bad and Bax, were found to be up-
regulated, whereas the anti-apoptotic Bcl2 and BclXL were down-regulated. Additionally, the p110α 
inhibitors induced increases in both SCLC apoptosis and autophagy, which is consistent with Bcl2 
being a target of p110α. Bcl-2 is a key regulator of both apoptosis and autophagy, and its expression is 
controlled by the transcription factor NFκB. In fact, we found deregulation in the NFκB transcriptional 
network and reduced protein expression upon p110α inhibition. Its specific role in SCLC in view of its 
association with p110α and the Bcl2 family proteins appears to be an interesting topic for future 
research. 
Finally, we confirmed our results in vivo. SCLC tumour formation was impaired by p110α inhibition 
and accompanied by affected vascularization. 
In summary, we demonstrated that the class IA PI3K isoform p110α is a critical mediator controlling 
SCLC tumour growth, proliferation, and survival processes. 
 
In a second project we evaluated the potential of targeting the IGF-IR/PI3K signalling axis in the 
embryonal tumours neuroblastoma, the most common extracranial tumour in children and 
medulloblastoma, the most frequent childhood brain tumour. 
Activation and deregulation of the IGF-IR/PI3K signalling system has been reported to be present in 
NB and MB, including autocrine signalling loops, over-expression and genetic alteration found in 
genes encoding PI3K signalling components. 
By treating NB and MB cells with R1507 (Roche), a specific humanised monoclonal antibody against 
the IGF-IR, or targeting the class IA PI3K p110α with the specific inhibitor PIK75, we wanted to gain 
knowledge about their impact on cell viability, survival, expression and phosphorylation status of IGF-
IR/PI3K downstream signalling targets, as well as their effects on chemoresistance. We observed cell 
line-specific responses and a generally larger number of NB and MB cell lines responded to PIK75 
than to R1507. This might be due to PI3K activation downstream of numerous RTKs expressed in NB 
and MB, suggesting that combinatorial approaches of RTK inhibition and classical chemotherapeutic 
treatments are superior to targeting one single RTK. In addition, PI3K isoforms appear to be targets of 
choice for further drug development.  
In the present study, we demonstrated that targeting the class I PI3K isoform p110α in embryonal 
tumours clearly has advantages as an anti-cancer approach over the inhibition of the IGF-IR in vitro. 
Zusammenfassung 
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2 ZUSAMMENFASSUNG 
Die Phosphatidylinositol-3-Kinase-(PI3K)-Signaltransduktionkaskade spielt eine elementare Rolle in 
der Zellproliferation, dem Zellwachstum und ihrem Überleben, ist jedoch auch bekannt dafür, 
karzinogene Prozesse zu fördern. Deregulierung innerhalb des PI3K-Signaltransduktionswegs und sein 
Beitrag zur Tumorgenese wurden in der Vergangenheit bereits oft dokumentiert und diskutiert. PI3K 
sind Rezeptortyrosinkinasen (RTK) nachgeschaltete, an der zellulären Plasmamembran befindliche 
Effektormoleküle, die eine zentrale Rolle in der Regulation zellulärer Prozesse übernehmen. Das 
Targeting unterschiedlicher Komponenten des RTK/PI3K-Signalwegs mit pharmakologischen 
Inhibitoren wurde bereits als vielversprechender Ansatz für die Krebsbehandlung dargestellt. 
Inhibitoren der RTK/PI3K-Signalkaskade haben in einigen Fällen die klinische Phase der Forschung 
erreicht, und die Entwicklung neuartiger „small-molecule“-Inhibitoren dauert an. 
Lungenkrebs ist die führende Ursache der Krebs-zugrundeliegenden Sterblichkeit in der westlichen 
Welt. Etwa 1.4 Mio Menschen sind jährlich von der Diagnose Lungenkrebs betroffen. Das kleinzellige 
Lungenkarzinom (SCLC), der aggressivste aller Lungenkrebsarten, beläuft sich auf etwa 15% der 
Lungenkrebsfälle und ist beinahe vollständig auf Zigarettenkonsum zurückzuführen. SCLC ist durch 
extrem schnelles Wachstum und frühzeitige Metastasierung gekennzeichnet. Obwohl SCLC zunächst 
auf die angewandten Therapien anspricht, erleiden die meisten Patienten einen Rückfall. Der schlechte 
klinische Verlauf entsteht durch Metastasierung und Chemotherapie-Resistenzen; SCLC-Patienten 
zeigen eine 5-Jahres-Überlebenrate von unter 5%. Demzufolge werden neuartige Strategien für die 
Behandlung von SCLC dringend benötigt. Die molekularen Mechanismen, die der Entwicklung von 
Lungenkrebs zugrunde liegen, wurden bereits intensiv untersucht. Ein augenscheinlich beachtliches 
Ereignis der Tumorgenese ist, dass sich atypische Zellen der zellulären Wachstumskontrolle entziehen 
und infolgedessen einen bösartigen und invasiven Phänotyp ausprägen. 
Zahlreiche mit der Entwicklung des kleinzelligen Lungenkarzinoms zusammenhängende genetische 
und molekulare Veränderungen wurden bereits beschrieben, wie beispielsweise die autokrine 
Signalübertragung, die Aktivierung von Onkogenen und der Verlust von Tumorsuppressorgenen. 
Diese Abweichungen führen zu einer verminderten Zellantwort auf negative Wachstumssignale und 
die kontinuierliche Präsenz positiver Signale, die das Wachstum, die Motilität und die Fähigkeit zum 
invasiven Wachstum regulieren. 
Der PI3K/Akt/mTOR-Signalkaskade wurde bereits eine Schlüsselrolle in der  Zellproliferation, dem 
Zellüberleben, der Chemotherapie-Resistenz und der Migration von SCLC-Krebszellen nachgewiesen. 
Primäre SCLC-Tumore weisen Mutationen im Gen PIK3CA und Genamplifikationen sowie eine 
erhöhte Expression der PIK3CA-Transkripte und -Proteine auf. PI3K/mTOR-Inhibitoren mit 
breitgefächertem Wirkungsspektrum zeigten Antitumoreffekte in SCLC Modellen in vitro und in vivo.  
Uns darauf beziehend, fokussierten wir in diesem Projekt die Rolle der Klasse-IA-PI3K-Isoform p110α 
im kleinzelligen Lungenkarzinom und das Potenzial des Targetings von Klasse-IA-PI3K mit RNA-
Interferenz und Isoform-spezifischen Inhibitoren. 
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SCLC-Gewebeproben wiesen eine Überexpression von p110α und p110β auf. Im Gegensatz zu p110β 
korrelierte eine ansteigende p110α-Überexpression mit fortgeschrittenem SCLC.  
Das Targeting von p110α zeigte einen deutlich stärkeren Effekt auf SCLC Zellantworten  gegenüber 
dem Targeting von p110β und p110δ. Wir konnten eingeschränkte Zellviabilität und beeinträchtigten 
Aktivierungszustand verschiedener PI3K-nachgeschalteter Moleküle (PI3K-„Downstream-Moleküle“) 
feststellen, wie beispielsweise Akt, S6 und 4EBP1 sowie verminderte Transkriptlevel des 
Angiogenese-Faktors VEGFA.  
Wir stellten die Hypothese auf, dass p110α die Genexpression in SCLC kontrollieren könne. In der Tat 
führte das Targeting von p110α zu einer Beeinträchtigung der Expression der Bcl2-Protein-Familie auf 
dem Transkript- und Proteinlevel. Es konnte bereits vorher gezeigt werden, dass die Bcl2-Protein-
Familie eine elementare Rolle im Überleben von SCLC-Zellen spielt. Wir zeigten, dass 
proapoptotische Proteine, wie Bad und Bax, heraufreguliert wurden, während die antiapoptotischen 
Proteine Bcl2 und BclXL herunterreguliert waren. Zusätzlich induzierten die p110α Inhibitoren 
Apoptose und Autophagie, was unserer Annahme von Bcl2 als einem p110α-„Downstream-Target“ 
entspricht, da es sich bei Bcl2 um einen Schlüsselregulator von Apoptose und Autophagie handelt. Die 
Bcl2-Expression wird durch den Transkriptionsfaktor NFκB kontrolliert. Tatsächlich konnten wir 
zeigen, dass die Hemmung von p110α das transkriptionelle Netzwerk um NFκB deregulierte und die 
Expression des NFκB-Proteins verminderte. Die Rolle von NFκB als „p110α-Downstream-Target“ im 
Zusammenhang mit der Regulation der Bcl2-Proteine im kleinzelligen Lungenkarzinom erscheint ein 
interessantes Thema für die zukünftige Forschung zu sein. 
Zu guter Letzt konnten wir unsere Ergebnisse in einem in vivo Versuch bestätigen. Das SCLC 
Wachstum konnte durch das Targeting von p110α gesenkt werden und war von beeinträchtigter 
Vaskularisierung begleitet. 
Zusammenfassend konnten wir in der hier vorliegenden Studie zeigen, dass es sich bei der Klasse-IA-
PI3K-Isoform p110α um einen entscheidenden Signalmediator handelt, der SCLC Tumorwachstums-, 
Proliferations- und Zellüberlebensprozesse kontrolliert.  
 
In einer weiteren Studie untersuchten wir das Potenzial des Targetings der IGF-IR/PI3K-Signalachse 
in zwei embryonalen Tumoren: Neuroblastom (NB), der am häufigsten auftretende extracranielle 
Tumor bei Kindern, und Medulloblastom (MB), der häufigste Hirntumor bei Kindern. 
Aktivierung und Deregulierung des IGF-IR/PI3K-Signal-Systems konnten bereits in NB und MB 
gezeigt werden, einschließlich autokriner Signaltransduktion, Überexpression und genetischer 
Veränderungen in Genen, die für PI3K-Signalmoleküle kodieren. 
Durch die Behandlung von NB- und MB-Zellen mit R1507 (Roche), einem monoklonalen IGF-IR-
Antikörper oder PIK75, einem spezifischen Klasse-IA-PI3K-Isoform-p110α-Inhibitor, erhofften wir 
uns Einsicht in die Wirkweise der Behandlung auf Zellviabilität, Aktivierungszustand verschiedener 
PI3K-„Downstream-Moleküle“ und ihren Effekt auf Chemoresistenz. 
Zusammenfassung 
5 
Wir beobachteten Zelllinien-spezifische Reaktionen und einen generell stärkeren Effekt von PIK75 im 
Vergleich zu R1507. Dieser könnte darauf zurückzuführen sein, dass die PI3K-Aktivierung vielen 
verschiedenen RTK nachgeschaltet ist. Dies führt zu der Annahme, dass Behandlungsansätze aus einer 
Kombination von RTK-Inhibitoren und klassischen Chemotherapeutika Vorteile gegenüber des 
alleinigen Targetings einer einzelnen RTK besitzen. Zusätzlich scheinen PI3K-Isoformen „Targets der 
Wahl“ für die weitere Medikamentenentwicklung zu sein. 
In der hier vorliegenden in vitro-Studie konnten wir zeigen, dass wir mit dem Targeting der Klasse-IA-
PI3K-Isoform p110α in embryonalen Tumoren einen deutlich höheren Effekt auf Wachstums- und 
Überlebensprozesse embryonaler Tumorzellen erzielen konnten als mit dem Targeting von IGF-IR.
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3 INTRODUCTION 
 
3.1 PHOSPHATIDYLINOSITOL-3 KINASES 
PI3Ks are a family of evolutionary conserved lipid kinases which phosphorylate the 3-hydroxyl group 
of the inositol ring of three species of phosphatidylinositol (PtdIns) lipid substrates in the plasma 
membrane of the cell: PtdIns, PtdIns-4-phosphate, and PtdIns-4,5-bisphosphate, thereby producing 
second messengers such as PtdIns(3)P (PI(3)P), PtdIns(3,4)P2 (PI(3,4)P2), and PtdIns(3,4,5)P3 
(PI(3,4,5)P3) (1). These second messenger molecules recruit multiple target proteins involved in 
complex downstream signalling cascades to the plasma membrane, which bind these PtdIns through 
specific lipid-binding domains, namely pleckstrin homology (PH) domain, phox homology (PX) 
domain, and FYVE (Fab-1, YGL023, Vps27, and EEA1) zinc finger domain, resulting in initiation of 
signalling pathways providing proliferation, survival, and motility signals (2-4). The PI3K signalling 
pathway, fundamental for cell proliferation, growth, and survival, is known to play a crucial role in 
embryonic development and immunity, but is known as well to contribute to the development of major 
human diseases, such as cancer, inflammation, and diabetes. Its deregulation and contribution to 
carcinogenesis has been well documented and reviewed in the past (5). The PI3Ks are major 
downstream effectors of receptor tyrosine kinases (RTKs), which will be described below, and G 
protein-coupled receptors (GPCRs).  
Central components of cell signalling networks are receptor tyrosine kinases (RTKs) located at the 
cellular membrane, playing a central role in the regulation of fundamental cellular activities including 
cell proliferation and survival, growth, cell cycle control, metabolism, cell adhesion, and motility. 
Approximately 60 RTKs have been identified, all sharing a similar structure (6). They are sub-
classified according to primary structure, ligand affinity, and induction of biological response. RTKs 
contain an N-terminal extracellular domain for ligand binding, a single α-helix transmembrane 
domain, and a C-terminal domain with a juxtamembrane regulatory regions and tyrosine kinase 
activity located in the cellular cytoplasm. The majority of RTKs are presented as monomers (7) and 
activation upon ligand binding induces conformational alterations followed by dimerization of 
receptor subunits and leads to auto-phosphorylation of specific tyrosine residues within the 
cytoplasmic domains (8). The auto-phosphorylation of RTKs leads to recruitment and activation of a 
variety of signal transducers, which recognise phosphorylated tyrosine residues and bind via SH2 (Src 
homology 2) and PTB (phosphotyrosine binding) domains (9), either directly to the receptor or by 
binding to other adaptor and docking proteins, such as Grb2 and Shc, or IRS1 and Gab-1. These 
proteins act as interaction partners or as intermediates recruiting multiple signalling molecules, finally 
activating several downstream signalling cascades through important mediators, such as 
PI3K/Akt/mTOR or Ras/Raf/MEK/Erk, triggering signals to promote cell proliferation, prevent 
apoptosis, and increase cell migration. Dysfunctional RTK signalling has been shown to be critical for 
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the development and progression of many types of cancer and the involvement of RTKs in 
tumourigenesis has led to the design of new drugs that specifically inhibit RTK activity. Targeting 
different components of the RTK/PI3K pathway with pharmacological inhibitors or neutralizing 
antibodies has already been shown to be a promising approach in cancer treatment (5, 10, 11). 
Inhibitors of the RTK/PI3K pathway have reached the clinical stage in some cases and the 
development of new small molecule inhibitors is still on-going. 
 
CLASSIFICATION OF PI3K FAMILY MEMBERS 
The family of PI3Ks has been divided into three classes according to their structural characteristics 
and lipid substrate preferences and comprises 8 catalytic isoforms in human (12).  
 
 
Figure 1. The Classification of the PI3K Family Members. 
 
Class I PI3Ks. Class I PI3Ks are subdivided into class IA (p110α, p110β, p110δ) and class IB (p110γ) 
based on the type of receptor they are activated by, the regulatory subunits they are connecting, and 
their activation mechanism. They mainly generate the second messenger PtdIns(3,4,5)P3 in vivo (1, 
12). Class IA PI3Ks are activated by RTKs (12) and certain oncogenes such as the small G protein Ras, 
and consist of heterodimers comprising a catalytic subunit and a regulatory subunit. In mammals, the 
catalytic p110 subunits are encoded by three genes: PIK3CA, PIK3CB, and PIK3CD. The catalytic 
p110 subunit possesses an N-terminal p85-binding domain, a Ras-binding domain that mediates Ras-
dependent activation, a C2 domain, a phosphatidylinositol kinase homology (PIK) domain and a 
catalytic domain. The catalytic subunit undergoes constitutive association with one of the regulatory 
subunits p85α, p55α, p50α, p85β, or p55γ, which are generated by alternative splicing of the three 
genes PIK3R1, PIK3R2 and PIK3R3 (13-16). In response to growth factor-stimulated receptor 
activation the PI3K is recruited to the plasma membrane via direct interaction of its regulatory subunit 
with tyrosine phosphate residues of the activated receptor or associated adaptor proteins (via Src 
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homology-2 (SH2) domains) (1). Finally, the close proximity to its lipid substrates and the release of 
the basal inhibition of p110 through p85 is necessary to activate its catalytic activity. The class IB 
PI3K is a heterodimer consisting of the unique catalytic subunit p110γ and its regulatory subunit p101 
and is only found to be present in mammals. The Gβγ subunit of trimeric G proteins downstream of 
activated GPCRs binds to the regulatory subunit and in turn activates p110γ (17). Another regulatory 
subunit, named p84 (also p87PIKAP) PI3K adaptor protein, have been identified (18). The PI3K class IB 
signalling plays an important role in activation, growth and proliferation of immune cells (19). In 
mammals, class I PI3Ks are present in all cell types throughout the body (20), with p110δ and p110γ 
being highly enriched in leucocytes (19, 21). The role of the class I PI3Ks in human diseases is the 
best characterized among the three classes of PI3Ks.  
Class II PI3Ks. Class II PI3Ks are monomers, consisting of a single catalytic subunit (PI3KC2α, 
PI3KC2β, PI3KC2γ) and lack a regulatory subunit. Preferentially, class II PI3Ks phosphorylate PtdIns 
and PtdIns(4)P and are activated by RTKs, cytokine receptors and integrins. Unlike the well-
characterized class I PI3Ks, which have been extensively studied over the last 25 years, much less is 
known about the cellular functions of class II PI3Ks. Mammalian cell studies suggested they might 
have important roles in biological processes, such as cell migration, glucose metabolism, exocytosis, 
smooth muscle contraction, and apoptosis (22).  
Class III PI3Ks. Class III PI3Ks were first described in Saccharomyces cerevisae and are 
heterodimers consisting of the regulatory subunit p150 (Vps15) and the catalytic subunit Vps34 
(homologue of the yeast vacuolar protein sorting-associated protein 34). The only substrate they 
phosphorylate is PtdIns, generating PtdIns(3)P, which is an important regulator of membrane 
trafficking (23, 24). The class III PI3K has been shown to be a nutrient-dependent lipid kinase 
mediating signalling through mTOR, indicating a possible contribution to cell growth control 
processes (25, 26). Furthermore, it has been implicated to be involved in phagosome formation, 
transport at the nuclear membrane, and to be an important regulator for autophagy, the cellular 
response to nutrient starvation (27).  
 
THE CLASS IA PI3K SIGNALLING PATHWAY 
Activation of PI3K is initiated by binding of various growth factors to their specific receptors. Class IA 
PI3K are recruited to RTKs at the plasma membrane as heterodimers, consisting of a regulatory (p85) 
and a catalytic subunit (p110). The p85 regulatory subunit binds to phosphotyrosine residues in the 
cytoplasmic domain of RTKs through its Src-homology 2 (SH2) domains, which leads to PI3K 
activation (12, 28). As a consequence, the second messenger phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) is generated through phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2). A direct 
antagonist of PI3K is the phosphatase and tensin homologue deleted on chromosome 10 (PTEN). 
PTEN directly reverses the activity of PI3K by dephosphorylating PIP3 into PIP2 and therefore plays 
an important role as a negative controlling element of incoming signals. PIP3 transduces activating 
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signals by binding to pleckstrin homology (PH) domains of proteins, thereby recruiting them to the 
cell membrane. One centrally important downstream mediator of the PI3K signalling cascade is the 
serine/threonine kinase Akt (murine thymoma viral oncogene homolog 1). Akt is recruited to the 
membrane via PIP3 which is binding to its PH domain, followed by phosphorylation leading to its 
activation by the phosphoinositid-dependent kinase 1 (PDK1) at threonine 308 and at serine 473 by 
the mammalian target of rapamycin complex 2 (mTORC2). Activated Akt then mediates signals 
promoting cellular growth and survival and suppresses pro-apoptotic signals. Akt phosphorylates 
several intracellular proteins, including forkhead box O transcription factors (FoxO), the BCL2-
associated agonist of cell death (BAD), and the glycogen synthase kinase 3 (GSK3), to promote cell 
cycle entry and cell survival (29). The proteins TSC1 (Hamartin) and TSC2 (Tuberin) form a complex 
that inhibits the activity of the small G-protein ras homologue enriched in brain (Rheb), which is 
necessary for mTOR complex 1 (mTORC1) activation. The Akt-mediated phosphorylation of TSC2 
releases Rheb from its inhibited state. Rheb then accumulates in a GTP-bound state and can directly 
activate mTORC1, which phosphorylates the p70S6 kinase (S6K1) and the eukaryotic translation 
initiation factor 4E binding protein 1 (4EBP1), leading to increased protein translation (30) (Figure 2). 
 
 
 
Figure 2 Scheme of the Class I PI3K Signalling Pathway Activation. 
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3.2 CELL DEATH MECHANISMS 
Death and degradation of cells is part of the normal self-renewal machinery in healthy eukaryotic 
organisms keeping a balance between continuous cycling of growth, proliferation, and cell death. 
Cytoplasmic organelles also constantly undergo reorganisation and destruction within the cells. Three 
main types of processes with the ability to finally lead to cell death have been identified, namely 
apoptosis, autophagy, and necrosis. Necrosis, even though now thought to be initiated and regulated 
under particular circumstances, has been traditionally described as an accidental type of cell death, 
whereas the so called programmed type of cell death, apoptosis, is an evolutionary highly conserved 
biochemical mechanism, protecting the organism from damaged cell accumulation, keeping 
homeostasis, and controlling cell fate. Autophagy, actually functional as a pro-survival mechanism, 
has a particular role in the biology of normal or cancer cells, playing a not yet fully understood Janus 
role between a cell survival and cell death mechanism. The regulation and involvement of apoptosis 
and autophagy in cellular biology and the contribution of their deregulation to key events in 
carcinogenesis will be summarized below. 
 
PROGRAMMED CELL DEATH - APOPTOSIS 
Apoptosis is one type of the programmed cell death (PCD) mechanisms characterized by series of 
biochemical events that lead to a variety of morphological changes, finally resulting in principal 
shrinkage of the cell and its nucleus, subsequently to cleavage of cytoskeletal proteins and collapse of 
subcellular components, as well as nuclear fragmentation, chromatin condensation, chromosomal 
DNA fragmentation, and the formation of plasma-membrane blebs (31). During animal tissue pattern 
formation PCD is required for the removal of unnecessary or excess cells. Apoptosis plays the main 
role in the regulation of tissue homeostasis and represents an important negative regulatory event 
protecting the organism from genome instability, therefore contributing to prevention from 
carcinogenesis, or in turn to death of cancer cells. Thus, deregulation in apoptotic processes has been 
described as one of the hallmarks of cancer (32). Mechanisms that confer increased resistance to 
apoptotic signals may occur at many different levels of apoptotic regulation, causing (acquired) 
resistance to anti-cancer treatments. This can be illustrated by the observation that more than 50% of 
neoplasms harbour defects in the apoptosis machinery. Overexpression of several pro-survival Bcl2 
family proteins and mutations in the tumour-suppressor gene TP53 are the best characterized among 
these abnormalities (33).  
Apoptosis is divided into two different pathways, the extrinsic, so called death-receptor pathway and 
the intrinsic pathway, regulated by mitochondrial involvement. 
Death Receptor Pathway. The extrinsic cell death pathway is activated when members of the tumour 
necrosis factor (TNF) super-family bind to “death receptors” localized at the cell membrane. Ligation 
of these receptors initiates the formation of the multiprotein death-inducing signalling complex (DISC) 
(34). DISC formation triggers the activation of Caspase-8, which then triggers either direct cleavage of 
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the downstream target Caspase-3, inducing apoptosis without involvement of mitochondria (35), or 
leads to apoptosis via a process involving mitochondrial cytochrome c release.  
Mitochondrial Death Pathway. The interplay between pro-apoptotic and anti-apoptotic members of 
the Bcl2 family at the mitochondria regulates the execution of the intrinsic apoptotic pathway. 
Overwhelming cell damage caused by intracellular reactive oxygen species (ROS), DNA damage, or 
deprivation of growth factors is detected by intracellular sensors. Increased permeability of the 
mitochondrial membrane induced by apoptotic triggers results in the release of pro-apoptotic proteins 
(e.g. cytochrome c) into the cytosol. The subsequent formation of the apoptosome by recruitment of 
Apaf1 and pro-caspase 9 leads to the activation of caspase 9, which in turn activates caspases 3, 6, and 
7, proteases that herald demolition of the cell by cleaving numerous substrate proteins and activating 
DNases (31, 33). 
 
 
Figure 3 The intrinsic and the extrinsic apoptotic pathways. 
 
BCL2 FAMILY MEMBERS AND THE REGULATION OF APOPTOSIS BY PI3K/AKT  
The balance between pro-apoptotic and anti-apoptotic Bcl2 family members controls the 
mitochondrial apoptotic pathway. To date, 25 members of the Bcl2 family of proteins have been 
identified (36). These proteins are localized to the mitochondria, the smooth endoplasmic reticulum 
(37), and perinuclear membranes (38). Bcl2 family proteins are characterized by the presence of up to 
four relatively short sequence motifs, which are termed Bcl2 homology domains (BH) (36). In human, 
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Bcl2 family members can be divided into three subfamilies based on structural and functional features 
(39). The anti-apoptotic subfamily (Bcl2, BclXL, BclW, Mcl1, Bfl1/A1, and BclB) suppress apoptosis 
and contain all four Bcl2 homology domains (designated BH1-4). Some pro-apoptotic proteins, such 
as BAX, BAK, and BOK, contain Bcl2 homology 1-3 domains and are termed ‘‘multidomain 
proteins’’, whereas other pro-apoptotic proteins termed as ‘‘BH3-only’’ proteins, such as BIM, BAD, 
and BID, contain only the BH3 domain (40). The molecular surface of the anti-apoptotic Bcl2 proteins 
possesses a hydrophobic groove, the BH3 binding cleft, capable of binding the BH3 domain of the 
pro-apoptotic proteins. 
The complex interplay of pro-apoptotic BH3 domains and the BH3-binding groove of anti-apoptotic 
proteins regulates the pro-apoptotic activity of Bcl2 family members (41).  
The anti-apoptotic Bcl2-family members are mainly localized in the mitochondrial outer membrane, 
but have been found as well in the membranes of the endoplasmatic reticulum (ER) and the nucleus. 
They stabilize the mitochondrial membrane and prevent cytochrome release and its subsequent 
binding to the apoptosis activating factor 1 (Apaf1). By contrast, the pro-apoptotic proteins of the Bcl2 
family are usually localized in the cytosol or the cytoskeleton.  
The onset of apoptosis and the mechanisms by which cells undergo cell death was shortly described 
above. Activation of PI3K and downstream activation of Akt play critical roles in keeping cells alive 
by blocking apoptotic pathways. PI3K/Akt signalling activation can block proteins triggering pro-
apoptotic signals, and conversely promotes the expression of a subset of proteins mediating anti-
apoptotic signals. In these regulatory processes, Akt plays a key role in the transduction of anti-
apoptotic signals transmitted via PI3Ks (42, 43).  
Akt has been demonstrated to phosphorylate the pro-apoptotic protein Bad, thereby mediating its 
inactivation through its binding to the cytosolic 14-3-3 proteins (44-47). Active Bad is able to capture 
Bcl2, and therefore to promote apoptosis upon freeing Bax from its inhibited state by Bcl2. Also Bax, 
the key regulator of the mitochondrial permeability leading to the release of cytochrome c into the 
cytoplasm, can be directly regulated by Akt via phosphorylation at Ser184 (48) and indirectly via the 
inhibition of GSK3 (49, 50), which phosphorylates Bax at Ser163 (51) leading to its activation. 
Furthermore, Akt suppresses the degradation of the anti-apoptotic Mcl1, which is promoted by GSK3 
(52, 53). 
Additionally, Akt regulates transcription factors, which are involved in the transcriptional regulation 
of apoptotic proteins. The forkhead transcription factors are negatively regulated by Akt (54-58). Their 
phosphorylation by Akt leads to sequestration and degradation in the cytoplasm (56). Active FoxO 
increases the expression of the Fas death receptor ligand FasL (59) and the pro-apoptotic BH3-only 
protein Bim (60). The latter was shown to promote apoptosis by binding to pro-survival Bcl2-family 
members, but has also been reported to directly mediate activation of Bax (61, 62).  
Another transcription factor known to regulate genes involved in cell survival processes is NfκB (63). 
The expression of the pro-survival proteins Bcl2 and BclXL is known to be positively regulated by 
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NFκB (64-70), as well as several inhibitors of apoptosis (IAPs) (71). NfκB remains in the cytoplasm 
and is inactive when it is bound to its associated inhibitory molecule IκB (inhibitor of NFκB) (72). IκB 
is phosphorylated by a kinase complex consisting of the IκB kinases IKKα and IKKβ, leading to its 
ubiquitination and degradation, thereby releasing NFκB and allowing its translocation into the nucleus. 
The IKKα can be activated by multiple kinases, one of which is Akt (73, 74).  
Furthermore, the tumour suppressor p53 is indirectly regulated by Akt. Upon irreversible DNA-
damage p53 can regulate apoptosis by a combination of events, including up-regulation of pro-
apoptotic proteins, such as Bim and PUMA. The activity of p53 can be attenuated by a regulatory 
protein called Mdm2 (murine double minute 2), which can translocate into the nucleus upon Akt 
phosphorylation and promote the ubiquitination of p53 (75).  
All together, these observations illustrate the importance of PI3K signalling in apoptosis regulation 
processes and its importance as pro-survival pathway. 
 
AUTOPHAGY - CELL SURVIVAL AND PROGRAMMED CELL DEATH MECHANISM 
Autophagy was originally identified as a survival mechanism subsequent to starvation-induced cellular 
stress. It is a lysosomal degradation pathway for the breakdown of intracellular proteins and organelles 
and a highly regulated cellular process controlled by the evolutionary conserved autophagy-related 
(ATG) genes. In healthy cells, autophagy functions as a catabolic process by which cells recycle their 
own non-essential, redundant, or damaged organelles and macromolecular components. Beyond this 
homeostatic function, autophagy is a process by which the cells can adapt their metabolism to 
starvation or cellular stress. The functional relationship between autophagy and apoptosis is complex. 
Depending on the cellular context, autophagy may occur as a stress response to pro-apoptotic signals 
and thereby can interfere with the action of chemotherapeutic agents or radiotherapy, causing 
increased survival of the tumour cells. The mechanisms by which autophagy promotes cell survival 
are not restricted to its role in maintaining cellular energy homeostasis during starvation. Autophagy is 
also involved in removing damaged mitochondria and other organelles. In this context, autophagy can 
promote cell survival also during aging, infectious diseases and neurodegenerative processes. In fact, 
increasing evidence underlines the cyto-protective role of autophagy that allows to increase tumour 
cell survival under conditions of metabolic stress and hypoxia as well as to escape chemotherapy-
induced cell death. 
Autophagy is mediated by proteins named as autophagy-related (ATG) proteins (76) and can be 
divided into several stages: Induction, autophagosome nucleation, expansion and completion followed 
by lysosome fusion, degradation, and recycling (77). Approximately 30 ATG genes have been 
identified so far. Activation of the class III PI3K (Vps34) and Beclin1 (ATG6) are crucially required 
to recruit proteins and lipids for initiation of autophagosome formation mediated by ATG1-ATG13-
ATG17, the modification and cleavage phosphatidylethanolamine(PE)-LC3-I to LC3-II by ATG4-
ATG7-ATG3, as well as the transportation and elongation of the autophagosome by the ATG16-
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ATg5-ATG12 complex (78, 79). Downstream of the class III PI3K, mTOR plays an important role as 
in the survival response initiated by withdrawal of growth factors or starvation and has been shown to 
act as a negative regulator of autophagy (27, 80). 
However, there is also clear evidence for a role of autophagy in programmed cell death. As autophagy 
may often occur under conditions of stress, such as nutrient deprivation, finally causing cellular death, 
the concept of autophagy as a programmed cell death mechanism has been developing. This idea was 
mainly proposed after the observation that dying cells often display increased expression of autophagy 
markers, as well as morphological features of an autophagic phenotype. Accumulating evidence points 
to a complex interplay between the apoptotic and autophagic machinery, with autophagy playing an 
intermediate role finally resulting in apoptosis induction, or independently mediating cell death signals 
on its own followed by directly mediated autophagic cell death (81-83). However, the molecular 
mechanisms underlying the latter and its regulating processes have still to be investigated. 
 
3.3 LUNG CANCER 
Lung cancer is the leading cause of cancer-related mortality in the Western world and every year 
approximately 1.4 million people are diagnosed with lung cancer (84). Most commonly, lung cancer 
development is related to multiple genetic changes caused by exposure to carcinogens, for instance 
those found in tobacco smoke. Lung cancer can be divided into two main subtypes – non-small cell 
lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC). These subtypes differ not only in 
frequency of occurrence and prognosis, but also in biological behaviour, histological background, and 
characteristic genetic alterations.  
Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, and is commonly 
related to tobacco smoking. In 9-15% of cases it is caused by exposure to other carcinogenic factors, 
such as polycyclic hydrocarbons, asbestos, or radon. Squamous cell carcinoma (SCC), 
adenocarcinoma (AC), and large cell lung carcinoma (LCLC) are the three most common types of 
NSCLC. The current treatment of NSCLC includes surgery, radiotherapy, and platinum-based 
chemotherapy. At the time of presentation at least 40% of patients are diagnosed with an advanced 
stage of disease (85), whereas less than 25% show early stage disease (stage I) (86). Surgery, with 
lobectomy or pneumonectomy being the most common surgical resections, remains the standard of 
care for patients with early stage NSCLC able to safely undergo surgery (86). The treatment of 
advanced NSCLC, which is mostly inoperable and therefore incurable, is aimed at controlling the 
disease to prolong life and sustain life quality, and commonly includes a combination of radio- and 
chemotherapy. An increasing progress in the optimisation of chemotherapeutic regimens in 
combination with targeted therapies against individual activated oncogenes has led to an improvement 
of NSCLC outcome, but the median 5-year survival rate nowadays is still only 15% (87).       
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3.4 SMALL CELL LUNG CANCER 
 
HISTORY & CHARACTERISTICS 
Small cell lung cancer accounts for approximately 15% of all lung cancer cases and is almost entirely 
(95%) related to tobacco smoking (88). It is characterized by rapid growth and early metastasis. Thus, 
surgical resection is rarely possible. Chemotherapy with etoposide- and platinum-based agents and in 
some cases also radiotherapy remain as the treatment options of choice (88-90). Although SCLC 
initially responds to therapy, most of the patients relapse. Due to metastasis and resistance to 
chemotherapy the clinical outcome is very poor and SCLC patients show an overall 5-year survival of 
less than 5% (89), with 90-95% of affected individuals dying of the disease within 5 years (88). 
However, the initial therapeutic response is followed by relapse and progressive development of 
chemotherapy resistance, and therefore the outcome is still very poor (91, 92). A slight decrease was 
observed in the incidence of SCLC cases over the last two decades, which could be explained by a 
decreasing number of smokers and changes in cigarette compositions, thus confirming the idea that 
SCLC is a highly preventable disease. 
SCLC was first described in 1926 as lung cancer by Barnard as “oat-celled sarcomas of the 
mediastinum” (93). Together with the typical carcinoid (TC), atypical carcinoid (AC), and large cell 
neuroendocrine cancer (LCNEC), SCLC completes the subgroup of neuroendocrine tumours of the 
lung sharing common morphological, immunohistochemical and molecular characteristics. The 
histological criteria of SCLC include: the small size of the cells, limited cytoplasm, a nucleus with fine 
granulation, absent or faint nucleoli, a high level of mitosis, and frequent areas of necrosis (94). 
 
DIAGNOSIS & STAGING  
SCLC symptoms may occur due to local complications and distant metastases. At clinical 
presentation, SCLC patients often suffer from symptoms such as cough, chest pain, shortness of 
breath, and hoarseness of voice. Furthermore, indirect symptoms such as weight loss are commonly 
observed. The diagnostic and staging procedure for SCLC presently includes biopsies obtained from 
bronchoscopy, computed tomography (CT) scan of the chest and the abdomen, CT scan or magnetic 
resonance imaging (MRI) of the brain, radionuclide bone scans, and bone marrow aspiration. Also 
fluorodeoxyglucose (18F) positron emission tomography (FDG-PET) and monoclonal antibody 
imaging are suggested to be potential initial staging tools with high accuracy compared to the 
currently used staging modalities used in SCLC (95, 96). 
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Figure 4 SCLC Imaging. A Coloured X-ray of the chest of a patient with small cell lung cancer (orange tumours, upper left, 
right lung). B Coloured CT scan in axial section through the chest showing cancerous lymph nodes (adenomegaly, yellow) as 
the primary site of SCLC. (Pictures adapted from www.sciencephoto.com) 
 
Two different systems have been developed to analyse and characterize SCLC tumour stage.  
i) According to the Veterans Administration Lung Group (VALSG) two-staged classification, first 
introduced in the 1950s, SCLC tumours are characterized as LD (limited disease) or ED (extensive 
disease). LD-SCLC represents about one third of the patients and is defined as disease confined to a 
localized tumour in one hemithorax, the mediastinum, and the supraclavicular lymph nodes, thus 
theoretically accessible within a “tolerable” RT portal. Among patients with limited stage disease, the 
median survival is about 23 months and the proportion surviving beyond 5 years is 12–17% (97). 
However at presentation, the majority of patients, (i. e. two thirds), show ED-staged SCLC, which is 
defined by locally advanced disease and/or metastatic spread. These patients have a median survival of 
7–12 months and the proportion alive at 5 years is 2%. 
ii) The classical TNM (tumour, nodule/regional lymph nodes, metastatic spread) staging system which 
was developed by Denoix in 1946 has remained as the traditional classification of primary NSCLC. As 
it requires accurate surgical lymph node sampling and at time of presentation two third of SCLC 
patients show locally advanced or metastatic disease and are rarely considered to be surgical 
candidates, the TNM staging system has not been routinely applied. The International Association for 
the Study of Lung Cancer (IASLC) has published the 7th edition of the TNM classification which 
seems more accurate in identifying patient subgroups. Limited disease should be based on this 
classification, corresponding to TxNxM0 patients and extensive disease corresponds to TxNxM1a and 
TxNxM1b patients (96, 98). 
 
TREATMENT & PROGNOSIS  
SCLC prognosis may be in part determined by clinical, radiological or biological factors assessed 
before any treatment. The most important prognostic factor is limited disease spread. SCLC patients 
with LD-staged SCLC, good performance status, female gender, age <60 years, normal LDH 
(lactatdehydrogenase), and stage I disease are associated with more favourable prognosis. In terms of 
prognosis, poor performance status, extensive disease, and weight loss at the time of diagnosis are 
important adverse indicators for ED-SCLC (96, 99).  
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Surgery as first-line treatment for LD-staged SCLC still remains controversial. Initially it was the 
treatment of choice for all lung cancers. But 30 years ago, it was mostly abandoned after a randomized 
clinical trial in which radiotherapy showed an advantage upon surgery on the 5 year survival in SCLC 
patients with limited disease. Nowadays, the most favoured therapeutic approaches for LD are 
combination therapies consisting of chemotherapy involving cisplatin or carboplatin with etoposide 
and thoracic radiation (chemoradiotherapy). Additionally, prophylactic cranial irradiation (PCI) is 
successfully applied to prevent the high risk of brain metastases. There is also the opinion rising that 
surgery should again play a role as primary treatment followed by chemotherapy for T1N0 and 
possibly in T2N0 or included as adjuvant treatment in an approach of multimodality treatments (96, 
99, 100).  
ED-staged SCLC is usually treated with a combination of chemotherapies (cisplatin + etoposide = EP) 
as first-line settings. Different first-line settings were applied and studied and compared to EP 
treatment in clinical trials, e. g. cyclophosphamide + doxorubicin + vincristine (CAV), irinotecan + 
cisplatin (IP), or EP + paclitaxel. Overall, only IP treatment resulted in similar effects compared to EP, 
but increased the incidence of gastrointestinal toxicities, and EP continues to be the treatment of 
choice for ED-staged SCLC patients. Radiotherapy is applied as palliative care and prevention of brain 
and bone metastasis, but does not prolong survival (96, 99, 100).  
Although SCLC is a highly chemoresponsive disease, the development of treatment resistance remains 
a problem and the majority of patients (80% LD patients, almost all ED patients) relapse. Second-line 
treatment in refractory or resistant SCLC includes, beside the re-treatment with the original regimen, 
also topotecan regimens, based on the performance status (PS) of the patient. Even though 
improvements in chemotherapy regimens have been made and a better understanding of SCLC 
biology could be developed, the survival of SCLC patients has not greatly improved in the last 25 
years. The development of resistance to chemotherapy and metastasis are commonly recognized as 
important causes of poor clinical outcome in SCLC (96, 99, 100). 
 
MOLECULAR PATHOGENESIS & GENETIC ALTERATIONS 
The molecular mechanisms responsible for lung cancer formation have been extensively studied. A 
striking event in the development of cancer is the escape of atypical cells from the normal growth 
control and their transformation into a malignant and invasive phenotype. Numerous genetic and 
molecular alterations have been reported to be associated with the development of SCLC, including 
autocrine signalling loops, oncogene activation and loss of tumour-suppressor genes (88). These 
genetic and molecular aberrations result in a lack of response to negative growth regulatory signals 
and the continuous presence of positive signals that regulate growth, motility, and invasion.  
The exact cellular origin of SCLC remains unclear (101). Early work suggested SCLC may arise in the 
bronchial mucosa with displaying some epithelial characteristics. Furthermore, stem cell populations 
of the lung, such as certain Clara cell types associated with neuroendocrine bodies, were identified to 
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be possibly involved into SCLC tumourigenesis. A mouse model was developed in which SCLC 
tumours were initiated by the deletion of RB1 and TP53 tumour suppressor genes in the lung 
epithelium of adult mice (102). Additionally, it was shown by Parks et al that in lung epithelium with 
deletion of TP53 and RB, SCLCs arose where neuroendocrine cells were located and that early lesions 
were mostly composed of proliferating neuroendocrine cells, whereas mice, in which RB and TP53 
were deleted in non-neuroendocrine cells did not develop SCLC (103). Just recently, Sutherland et al. 
demonstrated that loss of TP53 and RB could transform pulmonary neuroendocrine cells (NE) but not 
Clara cells and concluded that NE cells rather than stem cells might be the predominant cellular origin 
and the target of SCLC (104). SCLC tumourigenesis is also thought to be related to deregulations in 
developmental pathways like Hedgehog-, Notch, or Wnt-signalling, which are known play a role in 
developmental processes of the lung (105).  
Multiple neuropeptides and polypeptides promote the growth of SCLC cells in an autocrine/paracrine 
fashion. Amongst the neuropeptides, gastrin-releasing peptide and neuromedin B have been shown to 
be expressed in SCLC, along with their specific receptors (88, 106).  
As seen in many solid tumours, loss of genomic stability does also occur in SCLC. Several 
chromosomal abnormalities have been observed to occur frequently in SCLC. The majority of SCLCs 
show deletions affecting multiple chromosomal sites including losses at 3p, 5q, 13q, and 17p, carrying 
the genetic information for tumour suppressor genes, such as RB and TP53. In contrast, a large number 
of SCLC tumours harbour gains of 1p, 2p, 3q, 5p, 8q, and 19p, regions known to encode for 
oncogenes, such as KRAS and MYC. A more aggressive phenotype was demonstrated in SCLC cells 
bearing coexistent deletion of 18q and amplifications of 1p, 2p, and 3q, underlining once more the 
importance of the genetic and epigenetic disorders of a disease. Allele loss of chromosome 3p occurs 
with a frequency higher than 90% in SCLC and is believed to be an early event in lung cancer 
development. Several genes located on the regions 3p21.3, 3p12, 3p14.2, and 3p24 show tumour 
suppressor activity and lose their expression via epigenetic mechanisms. The fragile histidine triad 
gene (FHIT) encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an 
indirect role in apoptosis and cell-cycle control. The RAS effector homologue (RASSF1) encodes a 
microtubule-binding protein. RASSF1 interacts with microtubules, causing their stabilisation and thus 
inducing G1 and G2/M arrest. The loss of RASSF1 function allows tumour cells to grow more rapidly. 
The third and fourth potential tumour-suppressors are the retinoic acid receptors β, through which 
retinoids trigger the induction of apoptosis and FUS1, found at 3p21.3, which induces cell cycle arrest 
and apoptosis but loses expression of its protein in 100% of SCLCs (88, 105, 107). 
 
TUMOUR SUPPRESSOR GENES 
TP53. Located on chromosome 17p13.1 the tumour suppressor gene TP53 is also called “the 
gatekeeper of the cell”. By regulating cell survival and cell damage response signalling pathways its 
protein product is aimed to protect the cell against genetic disorders and instability. The transcription 
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factor acts as a negative regulator of cell proliferation via targeting genes involved in the control of 
cell cycle regulation, apoptosis, and DNA repair. TP53 is mutated in 50% of human cancers and also 
plays an important role in development of SCLC (108). Inactivating mutations (missense mutations in 
the DNA binding domain and homozygous deletions) of the TP53 gene could be observed in 
approximately 90% of SCLCs (109) and are known to be partially caused by carcinogens found in 
tobacco smoke (110). Additionally, 40-70% of SCLC tumours show an abnormal expression of the 
p53 protein (108). Mutated TP53 was found to be a potential target in cancer immunotherapy due to its 
prolonged half-life and increased expression in cancer cells. In SCLC, a vaccine composed of 
dendritic cells transduced with a human recombinant adenovirus containing wildtype p53 (DC-Ad-
p53) resulted in a partial response in a minority of patients and is currently applied in several clinical 
trials involving ED-staged SCLC patients (105, 111). 
Retinoblastoma. The retinoblastoma gene RB1 located on chromosome 13q14.1-q14.2 encodes for a 
nuclear protein involved in mediating the G1/S transition in cell cycle progression. 
Hypophosphorylation of Rb causes cell cycle arrest and growth suppression by controlling 
transcription factors of the E2F family necessary for cell cycle progression. Phosphorylation of Rb by 
cyclin D1/CDK4 reactivates E2F transcription factors, followed by transition to S-phase and inhibition 
of pro-apoptotic proteins. 90% of SCLCs show abnormalities in RB, with either complete absence of 
protein or expression of a mutated form (112, 113). Together with loss of p53 the loss of Rb is 
suggested to be a major feature in SCLC development. 
 
RECEPTOR TYROSINE KINASES 
Receptor tyrosine kinases are involved in cellular proliferation, survival, and migration, mediating 
positive growth signals via activation of downstream signalling molecules. In SCLC, deregulation of 
RTK signalling often occurs due to overexpression of RTKs and their respective growth factors, 
leading to multiple autocrine/paracrine signalling loops, including stem cell factor (SCF)/c-Kit, 
insulin-like growth factor-I (IGF-I)/IGF-IR, vascular endothelial growth factor (VEGF)/VEGFR, 
fibroblast growth factor (FGF)/FGFR, and hepatocyte growth factor (HGF)/c-Met, which all lead to 
the activation of PI3K/Akt signalling and promote cell growth, survival, and chemotherapy resistance. 
Mutations are observed to a lesser extent pointing to the importance of the translational regulation of 
the RTK signalling pathway in SCLC. 
c-Kit. c-Kit is a member of the PDGF/c-Kit receptor tyrosine kinase family. Upon binding of its 
ligand stem cell factor (SCF) activation of the JAK-STAT, PI3K and MAP kinase pathways are 
initiated, promoting cell growth and differentiation (114). The co-expression of c-Kit and SCF is rare 
in human cancers, but was shown to be a common event in SCLC cell lines and tumours and was the 
first autocrine signalling system described in SCLC (115-117). However, c-Kit expression in SCLC 
patient tumour tissue was found to range from approximately 20-90% and also the association of its 
expression with patient survival resulted in controversial observations, ranging from no relevance or 
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poor prognosis to prolonged survival (118). In preclinical studies the c-Kit inhibitor Gleevec 
(Imatinib, STI571) was partially able to inhibit the SCF-induced activation of Akt and Erk in a cell-
dependent manner (119-123), whereas in clinical trials Gleevec failed to display anti-tumour activity 
in SCLC (124-128). 
IGF-IR. Expression of the IGF-IR and its main ligand IGF-I have been observed in SCLC cell lines 
and in cells derived from SCLC patients, suggesting an autocrine signalling loop by this system (128-
132). Additionally, increased gene copy number and occasional occurrence of gene amplification have 
been identified. Indeed, involvement of the IGF-IR pathway in the development and growth of SCLC 
has been reported and is known to function via activation of the PI3K/Akt pathway stimulating SCLC 
tumour growth, survival, and resistance to chemotherapy. Preclinical studies employing IGF-IR- 
inhibitors (e.g. NVP-ADW742) or neutralizing antibodies (e.g. A12) resulted in growth inhibition and 
apoptosis in SCLC cells. Furthermore, inhibition of IGF-IR signalling synergistically enhanced the 
sensitivity of SCLC to etoposide and carboplatin. This enhancement in sensitivity to chemotherapy 
tightly correlated with inhibition of PI3K-Akt activation (121, 133, 134). 
c-Met. The receptor tyrosine kinase c-Met is activated by its ligand hepatocyte growth factor (HGF) 
triggering positive growth signals via the PI3K/Akt signalling cascade in SCLC and was shown to be 
implicated in the development of an aggressive and invasive metastatic SCLC tumour phenotype (135-
137). Overexpression and amplification of c-Met have been demonstrated in SCLC and indeed, high 
levels of HGF were associated with a poor prognosis. A mutational analysis of c-Met in SCLC 
identified several alterations, upon which mutations in the juxtamembrane domain were shown to 
regulate cell proliferation, cell morphology and adhesion, as well as causing enhanced cell motility 
and migration (138). 
VEGFR. The family of the vascular endothelial growth factors and their corresponding receptor 
tyrosine kinases comprises numerous VEGFs and three distinct receptors. The VEGF signalling 
pathway leads to increased proliferation, migration, and invasion of endothelial cells, thus making 
them key players in mediating tumour angiogenesis. All three VEGFRs are expressed in SCLC (139). 
Autocrine signalling loops of VEGF/VEGFR mediating proliferative and migration signals have been 
shown in SCLC cells and a significant correlation of VEGF expression and vessel density could be 
demonstrated in SCLC xenografts (140). High levels of VEGF were reported to correlate with tumour 
stage, disease progression, and resistance to chemotherapy, thus leading to a poorer outcome in SCLC 
patients (141-144). Whereas an association of microvessel density and tissue VEGF expression could 
be correlated to a poorer prognosis in NSCLC patients, these observations could not be confirmed in 
SCLC, even though higher vascularization was observed in SCLC compared to NSCLC tumours 
(145). 
FGFR. The fibroblast growth factor receptor family comprises four different isoforms. These RTKs 
are activated upon binding of their ligand fibroblast growth factors (FGFs) and interact with numerous 
signalling molecules, triggering signals via the Ras/Raf/MEK/Erk1,2 and PI3K/Akt pathways. 
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Elevated levels of FGF-2 have been found in serum of SCLC patients correlating with poor outcome 
and increased angiogenesis (146). Additionally, FGF-2 was shown to rescue SCLC cells from 
chemotherapy-induced apoptosis by an increased expression of anti-apoptotic proteins, such as BclXL 
and XIAP (147-150). The selective FGFR inhibitor PD173074 was shown to block SCLC proliferation 
and clonogenic growth and to prevent FGF-2-induced chemoresistance in vitro, and displayed not only 
increased apoptosis, but also decreased intratumoural proliferation in vivo (151). 
 
PROTEINS OF THE BCL2 FAMILY IN SCLC 
Alterations in the expression of Bcl2 are involved in the pathogenesis of human malignancies. Anti-
apoptotic Bcl2 proteins are typically overexpressed in many cancers and associated with drug-
sensitivity. Even though no mutations or amplifications in the gene encoding for the Bcl2 protein have 
been identified until now in SCLC, Bcl2 was found to be up-regulated in 70-90% of SCLC tumours 
(152-155), which partially could explain their apoptotic dysfunction and resistance to programmed cell 
death upon treatment with chemo- and radiotherapy. Bcl2 has been shown to be associated with 
increased cell survival in in vitro models of SCLC (149, 156, 157). Upregulation of Bcl2 inhibited 
apoptosis induced by cisplatin, doxorubicin and etoposide and furthermore was required for the 
maintenance of drug resistance (157-161). Conversely, inhibition of Bcl2 resulted in anti-tumour 
activity in SCLC cell lines and xenografts (162-164). However, an in vivo confirmation of an 
important role of Bcl2 in patients with SCLC is rare. No relationship between Bcl2 expression levels 
and patient survival has been demonstrated in SCLC (164). A study employing TMA meta-analysis of 
different former studies, associated a slight survival advantage with low Bcl2 expression, but did not 
show a clear relationship between Bcl2 expression and patient survival (165). Despite this, several 
trials of treatments targeting Bcl2 in SCLC (e.g. the Bcl2 inhibitors ABT737 and obatoclax) are in 
progress and have reached clinical stage (166-173). 
 
PI3K SIGNALLING IN SMALL CELL LUNG CANCER 
Numerous genetic and molecular alterations have been reported to be associated with the development 
of SCLC, including autocrine signalling loops, oncogene activation and loss of tumour-suppressor 
genes (88). These genetic and molecular aberrations result in a lack of response to negative growth 
regulatory signals and the continuous presence of positive signals that regulate growth, motility, and 
invasion.  
Mutation in the PIK3CA gene, known as one of the most common genetic alterations present in human 
cancers, were found in primary SCLC (13%) and in SCLC cell lines (23%) (174). Another study 
performed in 2008 failed to detect any mutations in the exons 9 and 20 of PIK3CA, but reported 
PIK3CA copy number gains (4.7%), which correlated with higher expression of activated Akt in 
SCLC cell lines (175). Chromosome 3q26-ter amplification including the PIK3CA gene locus was also 
shown in 67% of SCLC tumour samples (176). A recently published study showed that genes 
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encoding components of the RTK/PI3K/mTOR axis and apoptosis-regulating proteins harbour high 
frequencies of copy number alterations in both SCLC tumours and SCLC cell lines (177). Copy 
number gains could be identified in the PIK3CA gene in 76% of SCLC tumours and in 54% of the 
SCLC cell lines. The AKT1 gene was amplified in 64% of tumours and 39% of cell lines. In addition, 
the gene FRAP1 encoding the downstream target mTOR was shown to be amplified in more than 50% 
of SCLC tumours. In view of the loss of PTEN in 76% of SCLC tumours, the members of the 
PI3K/Akt pathway were suggested to be potential drug targets of SCLC in this study (177). PTEN 
plays an important role as a negative regulator of the PI3K/Akt signalling pathway by acting as direct 
antagonist of PI3K and is mutated (~15%), or can be deleted in SCLC (178-180). Constitutively 
activated PI3K was found in SCLC cell lines and shown to promote growth and anchorage-
independence due to high levels of basal Akt and p70s6k activity in the late 1990s (181). Differential 
over-expression of several PI3K isoforms and their contribution to Akt activation were demonstrated 
in different SCLC cell lines. In particular, cells over-expressing the PI3K subunit p110α showed 
enhanced Akt activation after growth factor stimulation. PTEN down-regulation could not be observed 
as a plausible reason for the higher Akt activity (182). Additionally, in tumour tissue samples from 
SCLC patients high levels of phosphorylated Akt (~50-70%) were detected by immunohistochemistry, 
supporting the involvement of the activated pathway in disease progression (176, 183). Other studies 
related integrin-induced activation of PI3K/Akt signalling and adhesion on extra cellular matrix 
(ECM) with resistance to various therapies and protection from apoptosis (123, 184). Adherent-
growing SCLC cells, which are those thought to initially survive chemotherapy, were reported to 
activate Akt and thus to increase chemo- and radiotherapy resistance by mechanisms involving over-
expression of anti-apoptotic proteins (185). One possible mechanism by which SCLC cells can escape 
the effects of cytotoxic drugs was discovered in experiments elucidating SCLC responses to cisplatin, 
a DNA-damaging agent. Surprisingly, treatment with cisplatin up-regulated Akt activation and 
contributed to the expression of pro-survival proteins in SCLC cells (186). 
Several autocrine loops have been described in SCLC cells, including stem cell factor (SCF)/c-Kit, 
insulin-like growth factor-I (IGF-I)/IGF-IR, (VEGF)/VEGFR and hepatocyte growth factor (HGF)/c-
Met, which all lead to the activation of PI3K/Akt signalling and promote cell growth, survival, and 
chemotherapy resistance. Direct inhibition of the PI3K/Akt pathway with the PI3K-specific inhibitor 
LY294002 attenuated these effects on cell growth, led to apoptosis, and enhanced the apoptotic effects 
of chemotherapeutic agents, such as cisplatin or etoposide (123, 187). The same effect was observed 
after inhibition of Akt by expression of a dominant-negative mutant of this protein in SCLC cells 
(187). Inhibition of Akt with the small-molecule inhibitor Tricribine (known as AKT/Protein kinase B 
signalling Inhibitor2) resulted in significantly affected growth and colony formation and pointed out a 
higher sensitivity of PIK3CA-mutated SCLC cells compared to PIK3CA wild-type cells (174). 
Moreover, the use of specific RTK inhibitors for c-Met, c-Kit, IGF-IR (121, 133, 188, 189), alkaloids 
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(naltrindole; opioid receptor antagonist) (190) or antibodies (134) were reported to impair SCLC cell 
survival in a PI3K/Akt-dependent manner.  
Targeting PI3K signalling with pharmacological inhibitors has become an important experimental 
therapeutic approach. Targeting the RTK/PI3K/Akt cell survival axis and its downstream mediators 
with small molecule inhibitors (tyrosine kinase inhibitors, TKIs) is, beside treating cancer with 
classical chemotherapeutical agents, one of the most prominent approaches used in cancer therapy and 
has been reviewed in the past for various human cancers. The use of specific TKIs has led to a 
progress in cancer treatment options, especially in cancer types carrying a particular oncogene 
addiction, which leads to dependency on the activity of one particular receptor tyrosine kinase. In lung 
cancer, the knowledge about molecular alterations has predicted the use of TKIs, which are nowadays 
used in the clinics. However, the recurrence and metastasis of tumours, which are associated with a 
switch in the oncogene addiction and changing signalling pathway activation, followed by the 
development of chemoresistance have raised the awareness about other pathways and/or multi-point 
intervention to target different signalling nodes in parallel. Compared to the development and the use 
of TKIs in the clinics, the development of PI3K inhibitors appears to be still in an early clinical phase, 
but is rapidly processing. Looking at current or soon initiating clinical trials in various cancer types, it 
is clear that PI3K inhibitors have arrived to the clinical stage, but clinical data confirming pre-clinical 
results in SCLC are still awaited.  
 
TOBACCO SMOKING AND PI3K SIGNALLING ACTIVATION 
Small cell lung cancer development is almost entirely related to smoking, thus, raising the question 
whether components of tobacco smoke are involved and which pathways are activated during the 
carcinogenic processes. As a traditional model of tobacco-related tumourigenesis the theory has been 
established that tobacco components promote carcinogenesis through multistep processes which lead 
to the accumulation of mutations in key genes, such as TP53, RB or KRAS.  A genomic study of a 
SCLC cell line (NCI-H209), derived from a bone marrow metastasis before chemotherapy, associates 
the carcinogens found in tobacco smoke with genetic alterations (“tobacco smoke-related signature”) 
in the genome of SCLC tumour cells. These genetic aberrations may cause tumour formation through 
circumvention of cell damage-induced cell death. Additionally, nicotine and the tobacco-specific 
carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NKK), both important components of 
tobacco smoke, were associated with early biochemical events occurring in cells exposed to tobacco 
smoke (184, 191, 192). In an in vitro model of normal primary human airway epithelial cells ((i) 
normal human bronchial epithelial cells (NHBEs), precursor of SCC; ii) small airway epithelial cells 
(SAECs), precursor of AC)), activation of the PI3K/Akt pathway was demonstrated to be an early 
event promoting cellular survival due to exposure to nicotine and NKK, suggesting a molecular 
mechanism to overcome cell damage-induced apoptosis involved in lung cancer development (184). 
Consistent with these results, another study identified PI3K pathway activation in normal and 
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Figure 5 NB Imaging. The tumour is 
indicated by arrows. 
premalignant bronchial airway epithelial cells of smokers with airway lesions, thus supporting the 
hypothesis that PI3K signalling activity is induced before the development of lung cancer (193). 
Nicotine was also shown to increase cell proliferation and survival accompanied by activation of the 
PI3K/Akt/mTOR pathway in NSCLC and SCLC cells (191, 192), and was associated with NFκB-
dependent resistance to chemotherapeutic drugs (192). Expression of nicotinic acetylcholine receptors 
(nAChRs), which respond to nicotine and NKK and activate Akt through PI3K, was found in normal 
and in lung cancer cells (184, 191, 192). Another group reported that nicotine increased the expression 
of peroxisome proliferator-activated receptors (PPARβ/δ), which belong to the nuclear hormone 
receptor superfamily of ligand-dependent transcription factors, in a nAChR-mediated 
PI3K/Akt/mTOR-dependent manner, and thereby promoted NSCLC cell growth (194). Furthermore, 
PI3K/Akt activation in response to nicotine exposure led to phosphorylation of Bax through Akt, 
shortening its half-life and abrogating the pro-apoptotic activity of Bax. These events resulted in the 
promotion of cell survival (195). Bad, another pro-apoptotic member of the Bcl-2 family, was shown 
to undergo multi-site phosphorylation involving nicotine-induced activation of the MAPKs Erk1/2, 
PI3K/Akt, and protein kinase A (PKA), leading to suppression of apoptosis (196). Both studies could 
show that inhibition of the PI3K/Akt pathway abrogated nicotine-triggered anti-apoptotic signals and 
blocked lung cancer cell growth, suggesting that PI3K/Akt activation is an important step in nicotine-
induced cancer cell survival (195, 196).  
 
 
3.5 NEUROBLASTOMA 
The embryonal tumour neuroblastoma is the most common 
extracranial solid malignancy in childhood, causing around 
15% of all childhood cancer related mortality (197). 
Embryonal tumours (ET) represent an important group of 
infant malignancies arising from different tissues of fetal 
origin. They are highly malignant and characterized by 
poorly differentiated neuroepithelial cells with the potential 
capacity for divergent differentiation. As a cancer of 
developing tissue, NB most commonly occurs in children 
before the age of 1 year with a median age of diagnosis being 17 month (198, 199). Its cell of origin is 
thought to be a developing precursor cell from the neural-crest (200), thus the tumour is typically 
arising in tissues of the sympathetic nervous system, such as the adrenal gland in 40% of the cases. 
Other localization sites of the primary lesions are common along the chain of the sympathetic nervous 
system (neck, chest, abdomen, or pelvis) (201). The symptoms experienced at clinical presentation 
differ depending on the stage of the disease and tumour localization. Approximately 50-60% of all 
patients show metastatic disease at time of diagnosis. The clinical behaviour of NB shows a 
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remarkable heterogeneity varying from frequently observed spontaneous and complete regression in 
very young patients with localized tumours to metastatic and progressive disease with resistance to 
multimodality treatments, ultimately leading to death (198, 202, 203). Even though advances in 
understanding the biology of neuroblastoma has been made, leading to an improved outcome over the 
last few decades, this improvement has mainly benefited patients with the more benign form of NB. 
The overall survival rate for high-risk NB patients is still less than 40% (204, 205).  
 
STAGING & TREATMENT 
The INSS (International Neuroblastoma Staging System) has identified distinct prognostic stages (1, 
2A, 2B, 3, 4, 4S) (206).  Based on the INSS stage, tumour biology, and age group, patients can be 
assigned to low-, intermediate-, and high-risk disease.  
Initially, all patients with suspected NB undergo surgery to verify the histology and obtain material for 
molecular marker analysis. The exception to this rule are small infants less than 3 month of age in 
good clinical condition, which may stay under observation without surgery because of high rates of 
spontaneous regression. The types of treatments applied to NB patients is the classical oncological 
triad consisting of surgery, combined chemotherapy (cisplatin or etoposide with vincristine, 
doxorubicin, cyclophosphamide, or topotecan), and radiation.  
Low-risk patients include those younger than one year of age at the time of diagnosis with low grade 
tumours lacking MYCN amplification (207). Around 45% of cases are assigned as low-risk patients 
requiring only surgery and/or observation of the disease (208, 209).  
Intermediate risk patients are generally older than one year of age at the time of diagnosis with 
intermediate or high grade tumours. While copy numbers of MYCN are typically normal, other genetic 
alterations, such as 11q loss or 17q gain are often observed. The intermediate-risk group undergoes 
chemotherapy to reach tumour shrinkage prior to surgical resection. In the case of non-resectability, 
patients receive radiation therapy and retinoic acid as maintenance treatment (210, 211). 
High-risk patients account for around 40% of all cases and are characterized by a highly aggressive 
type of NB, which is known to be difficult to cure. They are usually older than one year of age at the 
time of diagnosis and have intermediate- or high-grade tumours. These tumours harbour MYCN 
amplification and a number of other genetic alterations associated with unfavourable outcome. 
Therefore, the treatments applied are multimodality regimens, currently comprising high-dose 
chemotherapy, surgery, and radiation (212, 213). In the case of relapse and acquired drug resistance 
additional radioiodine labelled metaiodobenzylguanidine (I-131 MIBG) therapy with high dose 
chemotherapy is followed by rapid autologous stem cell rescue and retinoic acid maintenance 
treatment (205, 214). 
The overall survival rate of all NB patients is approximately 65%, including an excellent prognosis 
(98%) of very young patients with localized disease, while only about 35% of high-risk NB patients 
survive. 
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GENETIC ALTERATIONS 
NB tumours are formed as a result of genetic mutation and/or changes in epigenetic factors 
responsible for the right programming of the neural crest cells. Several genes have been discovered to 
drive the correct differentiation of the NC cells and are dysregulated in NB. While most NBs arise 
sporadically, a small number, approximately 1%, show familial inheritance (215, 216). Several 
characteristic genetic alterations with prognostic value have been discovered and associated with 
different patient subgroups. Genome-wide studies of NB tumours of different stages has been 
employed to identify genes useful to predict predisposition for NB, clinical outcome and 
understanding the biology of tumour progression (217, 218). 
Genetic alteration in the MYCN gene, localized at 2p23-24, was one of the first aberrations discovered 
in NB and its expression level is used as molecular parameter to predict clinical prognosis in NB. 
MYCN is a member of the MYC family of basic helix-loop-helix transcription factors which control 
cell cycle progression, proliferation, cellular differentiation, DNA damage response, and apoptosis. 
Approximately 20% of NB tumours display amplification of MYCN. High levels of MYCN expression 
correlate with an aggressive tumour behaviour and poor clinical outcome (210). This is illustrated by 
the observation that over 40% of metastatic NB display MYCN amplification, whereas this rate is less 
than 10% for localized tumours (219). 
Unfavourable tumours are further characterized by LOH deletions of 1p or 11q, as their appearance is 
more frequent in intermediate to high-risk tumours. LOH of 1p is often paralleled with MYCN 
amplification (220, 221). The allelic loss of 11q is rarely associated with MYCN amplification but 
occurs with other prognostic features, such as advanced disease and older age (222, 223). The frequent 
gain of 17q, where possible oncogenes such as BIRC5 (survivin), NME1 and PPMID are located, is 
also applied as prognostic factor in NB. Whole chromosomal gain can be associated with low-grade 
disease, whereas segmental gain is observed in high-grade tumours (224-227). 
Additionally, tumours with whole chromosome gains or losses are associated with lower risk disease 
and favourable outcomes, whereas partial chromosomal aberrations are associated with high-risk 
disease and worse outcomes (198, 228). Thus, patient risk stratification due to the analysis of total 
DNA content (ploidy) is frequently used and considered to be a prognostic value (228). 
Loss-of-function mutations in the gene paired-like homeobox 2B (PHOX2B) frequently occur in 
hereditary NB, leading to abnormalities in the neural crest (NC) derived tissue (229, 230). The 
PHOX2B gene encodes a transcription factor, essential for the regulation of neurogenesis (229, 230). 
Furthermore, single nucleotide polymorphism (SNP) variations within the genes FLJ22536 at 6p22.3 
and BARD1 (BRCA1-associated ring domain 1) have been discovered to be enriched in NB patients 
(231, 232). 
The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, which is involved in 
proliferation and differentiation pathways via activation of several signalling pathways in the nervous 
system. Constitutively activated ALK, based on activating mutations in the kinase domain of the ALK 
Introduction 
27 
Figure 6 MB Imaging. The 
tumour is indicated by arrow.  
oncogene, accounts for most cases of familial recurrent NB (233). Additionally, in somatically 
acquired NB the incidence of ALK mutation is still 5-15%, suggesting its importance for NB 
development (234). It has been reported that amplification of the ALK gene only occurs in MYCN-
amplified primary NBs, but the mechanisms how the MYCN overexpression cooperates with the ALK 
amplification still remains elusive (233, 235). Recently, a transgenic zebrafish model has been 
generated in which overexpression of human MYCN in the peripheral sympathetic nervous system 
(PSNS) induces a tumour which closely resembles human NB (236). In this model, MYCN 
overexpression was required for NB development, whereas the expression of ALK was not sufficient, 
even though it has been demonstrated by Mosse et al that germline mutations of ALK can act as an 
initiating event in NB tumours with or without MYCN amplification (233). Co-expression of MYCN 
and an activated ALK enhanced the tumour onset and penetrance by developing a potent anti-apoptotic 
phenotype (236). 
 
3.6 MEDULLOBLASTOMA 
Medulloblastoma is an embryonal tumour of the cerebellum 
with neuroepithelial background and the most common 
malignant brain tumour of childhood (237), accounting for 
approximately 20% of all CNS tumours. Embryonal tumours 
(ET) represent an important group of infant malignancies 
arising from different tissues of fetal origin. Among ET, the 
tumours of the central nervous system (CNS) account for 
approximately 20% of all childhood cancers, ranking second 
only to leukemias (238). They are highly malignant and 
characterized by poorly differentiated neuroepithelial cells 
with the potential capacity for divergent differentiation (239). MB is a highly invasive tumour arising 
in the posterior fossa, where it is thought to originate from several pluripotent precursor cells of the 
ventricular zone. Due to its malignant phenotype MB is considered as a grade IV tumour by the WHO 
(World Health Organization). Medulloblastoma patients can be subdivided into high-risk and 
standard-risk patients based on the clinical criteria and tumour histology. MB shows two peaks of 
incidence. One is at the age between 3 and 4 years, the second between 8 and 9 years of age, with a 
higher incidence in boys than in girls (240). Although MB can also occur in adults, it accounts for less 
than 1% of the adult CNS tumours (241). MB is characterized by an aggressive clinical behaviour and 
a high-risk of leptomeningeal dissemination (242, 243). Clinical symptoms of MB which are 
frequently present in children are ataxia, hydrocephalus, and increased intracranial pressure (ICP), 
paralleled by non-specific symptoms, such as headache, vomiting, and lethargy. The multimodality 
treatments consisting of surgery, radiotherapy, and chemotherapy were able to improve the overall 
survival rate in the past decades. The combination of chemotherapy and radiotherapy has improved the 
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5-year overall survival rate to 55-76% in high-risk patients and 70-80% in standard-risk patients. Even 
though approximately two thirds of patients without disseminated disease can be cured by applying 
currently available therapies, one third of the patients still remain incurable. 
 
GENETIC ALTERATIONS IN MEDULLOBLASTOMA 
The most frequently altered signalling pathways in medulloblastoma are the Sonic hedgehog (Shh) 
and the Wingless (Wnt) pathway. A recent genome-wide sequencing study in MB identified somatic 
mutations in both pathways, confirming their importance for MB development (244).  
Abnormalities of the chromosome 17 are the most common chromosomal aberrations in MB. The 
most frequent chromosomal aberration found in medulloblastomas is the presence of isochrome 
i(17q), in 40%-60% of the cases accompanied by loss of 17p (245). The presence of i17q in tumours is 
associated with a poor clinical outcome, suggesting that it may contribute to the development of 
aggressive variants of MB (246).  
Gene amplification in MYC or MYCN has been reported in 4-8% of MBs (247) and is associated with 
the more aggressive LC/A phenotype and poor outcomes (248). Interestingly, Shh and Wnt tumours 
rarely display abnormalities in chromosome 17 or amplification in MYC or MYCN. 
Gain of chromosome 7 affects approximately 40% of cases (249). Monosomy of chromosome 6 
frequently occurs in tumours with favourable prognosis, mainly classic subtype (250). Other 
chromosomal abnormalities that have been identified are loss of chromosome 10q, 7q and 16q.  
 
MOLECULAR CLASSIFICATION OF MB SUBGROUPS 
The currently used classification schemes of MB are mainly based on characteristic histopathological 
features defining several subtypes of MB, such as desmoplastic/nodular MB, MBEN (MB with 
extensive nodularity), classic MB, large-cell MB, and anaplastic MB (247, 251). However, due to the 
developments in the ability to monitor transcription across the genome, several groups have started to 
sub-classify MBs according to differences within their transcriptome (252). This transcriptional 
approach for tumour sub-classification underlies the assumption that tumours with similar 
transcriptomes will behave in biologically and clinically similar manner. This system is not applied in 
the clinics yet.  
But recently, a new sub-classification for MB has been published according to a consensus conference, 
where members of many laboratories working in the field agreed on four principal molecular 
subgroups of medulloblastoma (253). These four sub-groups were named as follows: Wnt, Shh, 3, and 
4, with the Wnt- and Shh-group named for the signalling pathway thought to play a prominent role in 
the pathology of the disease development in the particular subgroup. Since less is currently known 
about the biology of the remaining subgroups, the agreement was to apply unspecific names until the 
biological background underlying these subgroups was better defined (253). The four sub-groups 
show clearly distinct characteristics in terms of histology, demographics, DNA copy number 
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alterations, and clinical outcome (254) and were highly recommended to be employed in the clinics 
(253). 
 
 
Figure 7 Genetic Alterations and Molecular Subgroups of Medulloblastoma. Content adapted from (253) 
 
 
3.7 THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR  
The insulin-related signalling system, consisting of three distinct receptors (insulin receptors (IRs), 
insulin-like growth factor receptors (IGF-IR and IGF-IIR (also known as IGF-II/mannose 6-phosphate 
receptor (M-6-PR)), two hybrid receptors, the signalling factors insulin, IGF-I, and IGF-II, as well as 
several circulating IGFBPs (insulin-like growth factor binding proteins 1-6) (255-257), has a critical 
role in growth, development, and metabolism. This phylogenetically conserved system evolved 
millions of years ago, predating the appearance of vertebrates. In human, the IR and IGFRs are widely 
expressed in many tissues and cells. Even though IGF-IR shows high homology to IR, each receptor 
has its particular role in the regulation of biological responses, either controlling cell growth, 
differentiation and apoptosis (IGF-IR) or physiological processes such as glucose metabolism (IR) 
(258-260).   
The content of this thesis will emphasize on the signalling axis involving the IGF-IR and the role of its 
downstream mediator, PI3K isoform p110α, in the embryonal tumours NB and MB. 
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The receptor tyrosine kinase IGF-IR is a transmembrane tetrameric receptor with two extracellular α-
subunits and two transmembrane β-subunits that are linked by disulfide bonds. The α-subunits bind to 
IGF, while the two β-subunits show intrinsic tyrosine kinase activity (261). 
The IGF-IR has a high affinity for IGF-I and IGF-II, which are single-chain polypeptide protein 
hormones 60% similar to insulin (261). Insulin, the main ligand for the IR, has an IGF-IR-binding 
affinity which is less than 1% of that of IGF-I (262). Ligand-mediated activation of IGF-IR triggers 
the autophosphorylation of tyrosine residues within the kinase domain of the β-subunit, leading to the 
recruitment of the adaptor proteins IRS1 and Shc to the receptor β-subunit intracellular domains (263, 
264). Phosphorylation of IRS1 activates the PI3K/Akt signalling pathway, the Shc adaptor triggers the 
activation of the RAS/RAF/MAPK pathways, thus controlling cell proliferation, differentiation and 
cell migration, but also regulating the apoptotic machinery (265). 
The biological role of IGF-IR signalling in normal cells and mammalian development has been shown 
in vitro and in vivo, and reviewed numerous times in the past. Its role in normal growth control is 
convincingly demonstrated by the incidence of the congenital Laron-Syndrome also called Laron-type 
dwarfism, which is characterized by impaired development and growth and caused by low levels of 
IGF-I and its specific IGFBP. Additionally, mice harbouring a homozygous deletion of the IGF-IR 
gene are just half of the size compared to wild-type mice at the time of birth and die shortly after 
because of severe organ hypoplasia (266).  
Deregulation of the IGF-IR and its downstream signalling mediators have been demonstrated to 
contribute to carcinogenesis. Epidemiological studies suggested the correlation of high levels of IGF-I 
and IGF-II with a higher risk of cancer (264), whereas patients harbouring a hereditary deficiency of 
IGF-I seemed to be protected from cancer development (267). High expression levels of the IGF-IR 
have been found to be present in several tumours and to be involved in tumour formation and 
metastasis. Therefore, the IGF-IR/IGF signalling system has become a promising target for the 
development of cancer therapeutics and numerous drug candidates are undergoing clinical trials. 
 
3.8 THE IGF-IR/PI3K SIGNALLING AXIS IN NEUROBLASTOMA & 
MEDULLOBLASTOMA 
Neuroblastoma. Insulin-like growth receptor signalling in neuroblastoma has been intensively studied 
in context of cell proliferation, survival, and motility (268-270).  
Functional IGF-IR is expressed on the surface of NB cells and was associated with tumourigenesis and 
metastasis (271). Even though mutations in the IGF1R gene have not been reported, the gene encoding 
its corresponding ligand IGF-II was shown to be abnormally expressed in NB tumour samples. IGF-I 
and IGF-II stimulate the proliferation in NB cells and IGF-II particularly acts in an autocrine/paracrine 
manner on the IGF-IR and triggers NB cell differentiation, cytoskeletal rearrangement, angiogenesis, 
and suppresses apoptosis via the PI3K pathway, contributing to tumourigenesis (272).  
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Even though activating PIK3CA mutations are common events in many cancers, they do not 
frequently occur in neuroblastoma. One report described 2 point mutations in 42 NB samples and 27 
NB cell lines (273, 274). Even though around 80% of the PIK3CA mutations map to one of three hot 
spots, which are characterized by the gain of a single amino acid (E542K, E545K and H1047R), none 
of the aberrations in NB was found to lie within these particular regions, but were located within the 
helical or kinase domain. Subsequently, another study could identify a rarely seen somatic mutation 
located in exon 5 and reported PI3K p110α expression in 92% of NB tissue sections (273). In contrast, 
a recently published report could not confirm any of these results and demonstrated the absence of any 
PIK3CA mutations in the panel of NB samples tested. Amplifications in the PIK3CA locus (3q26) 
could also not be identified by screening a panel of 42 NB cell lines (275). As in the case of PIK3CA, 
genetic alterations in PIK3CD have been shown to be rare (276), only 2/46 primary NB samples 
harboured genetic alterations in the gene encoding p110δ. Elevated mRNA levels of PIK3CD were 
shown to occur in patients younger than 1 year of age and interestingly, the results of the same study 
revealed a negative correlation with MYCN amplification (277). Genetic alterations of PTEN have 
been rarely reported in neuroblastoma and association with the incidence of an aggressive tumour 
phenotype could not be noticed (273, 278, 279). Downstream of the PI3K phosphorylation of the 
serine/threonine kinase Akt was shown to be a marker for poor prognosis in NB, whereas the 
activation of S6 or Erk did not display prognostic values (280).  
Medulloblastoma. Activation of the IGF-IR system has been reported to be present in human and 
mouse MB cell lines, as well as in MB biopsies, and for instance IGF-II is known control the 
proliferation of normal cerebellar neural precursors, as well as MB cells via IGF-IR. The activated 
form of IGF-IR could be detected in approximately 60% of MB patient samples, but did not show any 
correlation with patient prognosis (281). Interestingly, an inverse correlation of phosphorylated IGF-
IR presence and Trk-C protein expression, which was already proposed to be a molecular marker for 
favourable prognosis in MB, was reported (282).  Autocrine IGF-IR/IGF-I signalling promotes 
proliferation signals via the MAPK pathway in MB cells. Activation of the PI3K/Akt signalling 
cascade was detected in primary tumours and MB cell lines. Whereas no amplifications of the PIK3CA 
gene could be detected in one report and another study demonstrated PIK3CA mutations only at low 
frequency (5%) (283, 284), overexpression of the PIK3CA gene and of its product PI3K p110α was 
observed in a subset of MB tumour samples and cell lines, often accompanied by constitutive 
activation of Akt (284). The importance of p110α was proven, as its inhibition led to a decrease in cell 
proliferation and augmented the effects of chemotherapy in a cell line model (284). The remaining 
class IA PI3K (catalytic) isoforms p110β and p110δ did not display significant increases in of the 
expression levels (284), whereas the class IB isoform PI3K p110γ showed overexpression in subset of 
medulloblastoma samples and cell lines and its inhibition led to sensitization to chemotherapeutic 
treatment in vitro (285). PTEN expression was found to be reduced in medulloblastoma (286, 287). 
PTEN mRNA and protein expression levels were significantly lower in primary medulloblastoma 
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samples, when compared to normal cerebellar tissue. In 50% of the tumour samples, reduction of 
PTEN expression was found to be associated with PTEN promoter hypermethylation (286). 
Homozygous loss of PTEN at chromosome 10q was demonstrated in 32% of medulloblastomas (287). 
However, a different study found that the PTEN protein was expressed at higher levels in 
medulloblastoma samples and cell lines as compared to control samples (284). 
Targeting PI3K signalling with pharmacological inhibitors has become an important experimental 
therapeutic approach for cancer. Targeting the RTK/PI3K/Akt/mTOR cell survival axis and its 
downstream mediators with small molecule inhibitors (tyrosine kinase inhibitors, TKIs) is, beside 
treating cancer with classical chemotherapeutical agents, one of the most prominent approaches used 
in cancer therapy and has been reviewed in the past for various human cancers. One of the most 
prominent PI3K-inhibitors is the dual PI3K p110α/mTOR inhibitor PI103, which inhibited 
neuroblastoma growth in vitro and in vivo (288, 289). Apoptosis-resistance in NB cell lines, evoked by 
an IGF-I-induced activation of the PI3K/Akt signalling, could be completely reversed by the PI3K 
inhibitor LY294002 (280). In medulloblastoma cell lines, inhibition of the PI3K isoform p110α with 
the isoform specific inhibitors PIK75 and YM024 was reported to have anti-proliferative effects (284) 
and furthermore, molecules targeting the PI3K/Akt signalling pathway, such as a small-molecule 
inhibitor of the PDK1, affected β-catenin signalling via GSK3β inhibition, resulting in apoptosis and 
suppressed MB tumour growth (290). 
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4 RESULTS 
4.1 SUBJECT OF INVESTIGATION 
 
TARGETING THE PHOSPHOINOSITIDE 3-KINASE P110 ALPHA ISOFORM IMPAIRS CELL 
PROLIFERATION, SURVIVAL, AND TUMOUR GROWTH IN SMALL CELL LUNG CANCER 
In this study we have investigated the role of the class IA PI3K isoform p110α and the potential of 
targeting PI3K signalling in small cell lung cancer, which is the most aggressive of all lung cancer 
types and almost entirely related to smoking.  
The PI3K/Akt/mTOR pathway has been demonstrated to play a key role in SCLC cell proliferation, 
survival, chemoresistance and migration. Mutations in PIK3CA and gene amplification were reported 
in primary SCLC, as well as increased expression of PIK3CA at the mRNA and protein level.  
Thus, we hypothesized involvement of the class IA PI3K isoform p110α in SCLC biology being an 
important mediator for pro-survival signals in SCLC cell responses.  
An immunohistochemistry analysis in primary SCLC tissue samples had revealed over-expression of 
the PI3K downstream target mTOR, leading to the question of the expression level of class IA PI3Ks in 
SCLC patient samples, which was then also studied by immunohistochemical analysis. 
Broad specificity PI3K/mTOR inhibitors have shown anti-tumour activity in SCLC models in vitro 
and in vivo (118). In view to these results, we sought to investigate the potential of isoform-specific 
inhibitors and RNAi targeting class IA PI3K isoforms on SCLC cell responses. By targeting the class 
IA PI3K isoforms with specific pharmacological inhibitors, such as PIK75 and YM024 (p110α), PI103 
(p110α/mTOR), TGX221 (p110β), IC87114 (p110δ) or silencing their expression via siRNA and 
shRNA constructs we have investigated SCLC cell responses, such as PI3K downstream signalling 
activation, cell viability, cell cycle progression and survival, as well as mechanistic processes 
important for tumour growth and maintenance, such as angiogenesis.  
In order to investigate whether the class IA PI3K isoform p110α controls the expression of specific 
gene subsets in SCLC, we performed DNA microarray analysis in H69 cells treated with either 
vehicle, PIK75 targeting p110α, or TGX221 targeting p110β. Inhibition of p110α with PIK75 strongly 
affected gene expression in widespread functional categories, compared to p110β inhibition, which did 
not have any significant effect on the SCLC gene expression.  
This results support a model, in which p110α is the most important class IA PI3K in SCLC and raised 
the question of its downstream targets controlling SCLC cell responses upon p110α inhibition.  
To gain insight into the transcriptional networks affected by silencing p110α in SCLC cells, we 
performed a biostatistics analysis of the gene expression data, using GeneGo. The transcriptional 
networks that were most significantly altered comprised HNF4α, SP1 and c-Myc, the estrogen 
receptor (ER) and also NFκB. We hypothesized NFκB to be a downstream target of p110α controlling 
the expression of Bcl2 and BclXL, found to be down-regulated by p110α inhibitors.  
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Furthermore, to confirm the in vitro results obtained in an in vivo model we performed a tumour 
growth assay on the CAM of chick embryos. SCLC cells were applied on the CAM in presence or 
absence of the p110α inhibitor PIK75 to investigate tumour formation, growth, and vascularization.  
Together, our data strongly suggest the PI3K isoform p110α as a critical mediator for SCLC growth 
and cell survival processes.  
 
 
NOVEL AGENTS TARGETING THE IGF-IR/PI3K PATHWAY IMPAIR CELL PROLIFERATION 
AND SURVIVAL IN SUBSETS OF MEDULLOBLASTOMA AND NEUROBLASTOMA 
Embryonal tumours (ET) represent an important group of infant malignancies arising from different 
tissues of fetal origin. Among ET, the tumours of the central nervous system (CNS) account for 
approximately 20% of all childhood cancers, ranking second only to leukemias. They are highly 
malignant and characterized by poorly differentiated neuroepithelial cells with the potential capacity 
for divergent differentiation. The IGF-IR/PI3K pathway, fundamental for cell proliferation and 
survival, is known to be frequently altered and activated in neoplasia, including embryonal tumours. 
Here, we have investigated the potential of targeting the axis of the IGF-IR and PI3K signalling in two 
common cancers of childhood: 1) Neuroblastoma (NB), the most common extracranial tumour in 
children causing around 15% of all childhood cancer-related mortality and 2) Medulloblastoma (MB), 
the most frequent childhood brain tumour. Activation and deregulation of the IGF-IR/PI3K signalling 
system has been reported to be present in NB and MB, including autocrine signalling loops, over-
expression and genetic alteration found in genes encoding PI3K signalling components. 
By treating NB and MB cells with R1507 (Roche), a specific humanised monoclonal antibody against 
the IGF-IR or targeting the class IA PI3K p110α with the specific inhibitor PIK75, we wanted to 
evaluate their impact on cell proliferation, survival, expression and phosphorylation state of IGF-
IR/PI3K downstream signalling targets, as well as their effects on chemoresistance.  
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Abstract 
 
Purpose: The phosphoinositide 3-kinase (PI3K) pathway is fundamental for cell proliferation and 
survival and is frequently altered and activated in neoplasia, including carcinomas of the lung. In this 
study we investigated the potential of targeting the catalytic class IA PI3K isoforms in small cell lung 
cancer (SCLC), which is the most aggressive of all lung cancer types. Furthermore, SCLC is known to 
commonly display Bcl-2 over-expression or TP53 mutations which could lead to defects in the 
apoptotic machinery. Here, we hypothesized the PI3K p110α to have a regulating role in the 
expression of proteins of the Bcl-2 family. 
Experimental Design: The expression of PI3K isoforms in patient specimens was analyzed. The 
effects on SCLC cell survival and downstream signaling were determined following PI3K isoform 
inhibition by selective inhibitors or down-regulation by small interfering RNA. 
Results: Over-expression of the PI3K isoforms p110α and p110β and the anti-apoptotic protein Bcl-2 
was shown by immunohistochemistry in primary SCLC tissue samples. Targeting the PI3K p110α 
with RNA interference (RNAi) or selective pharmacological inhibitors resulted in strongly affected 
cell proliferation of SCLC cells in vitro and in vivo, while targeting p110β was less effective. 
Inhibition of p110α also resulted in increased apoptosis and autophagy, which was accompanied by 
decreased phosphorylation of Akt and components of the mammalian target of rapamycin (mTOR) 
pathway, such as the ribosomal S6 protein, and the eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1). A DNA microarray analysis revealed that p110α inhibition profoundly affected 
the balance of pro- and anti-apoptotic Bcl-2 family proteins. Finally, p110α inhibition led to impaired 
SCLC tumor formation and vascularization in vivo.  
Conclusion: Together our data demonstrate the key involvement of the PI3K isoform p110α in the 
regulation of anti- and pro-apoptotic proteins of the Bcl-2 family and its particular role in the 
regulation of multiple tumor-promoting processes in SCLC. 
 
Translational relevance 
Small cell lung cancer (SCLC) is a common form of lung cancer and is associated with very 
unsatisfactory survival rates. Novel therapies are thus urgently required and will arise from a better 
understanding of the disease biology. We were interested in gaining further insight into the potential of 
targeting PI3K isoforms in SCLC. In this report, we show that the catalytic p110α isoform is 
overexpressed in a subset of primary SCLC samples. The growth of SCLC cells was impaired on 
targeting p110α using RNA interference or specific pharmacologic inhibitors. Inhibition of p110α also 
induced apoptosis and autophagy, which was paralleled by a decrease in the expression levels of anti-
apoptotic Bcl-2 family proteins. Importantly, SCLC tumors treated with p110α inhibitors displayed 
reduced proliferation and enhanced apoptosis in vivo. Together, the results presented in this study 
show that specific p110α inhibitors may in the future represent new drugs for SCLC. 
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Introduction 
 
Lung cancer is a major cause of death in the developed world and the commonest cancer killer in men. 
Small cell lung cancer (SCLC) represents about 13-15% of all cases of lung cancer and is strongly 
associated with cigarette smoking. Combinatorial chemotherapy regimens with etoposide and 
platinum-based agents, as well as radiotherapy are commonly used for the treatment of SCLC patients. 
However, an initial therapeutic responsiveness is usually followed by disease recurrence within less 
than 1 year and therefore the overall 5-year survival rate is <5%. Consequently, novel therapeutic 
strategies are urgently required for SCLC. In the past years, an increasing number of molecular 
alterations involved in SCLC pathogenesis have been reported, including ectopic expression of 
neuroendocrine regulatory peptides, up-regulation of anti-apoptotic Bcl-2 proteins, overexpression of 
myc family oncogenes and extracellular matrix proteins, as well as genetic abnormalities in the tumor 
suppressor genes TP53 and RB (108, 156). In addition, it has been shown that polypeptide growth 
factors such as hepatocyte growth factor (HGF),  fibroblast growth factor-2 (FGF-2), insulin-like 
growth factor-1 (IGF-1) and stem cell factor (SCF) control key biological responses in human SCLC 
cells, including growth and proliferation, chemoresistance, and migration (106, 147, 149, 182). 
Downstream of activated polypeptide growth factor receptors, activation of two major intracellular 
signaling cascades, the phosphoinositide-3 kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) and the mitogen-activated Erk kinase (MEK)/extracellular signal-regulated kinase (Erk) 
pathway, have been found to be involved in the survival and proliferation of SCLC (147, 149, 182, 
187, 291). Furthermore, it has been reported that mTOR and the ribosomal protein S6 kinases (S6K) 
are over-expressed in SCLC cells compared with normal human type II pneumocytes (147). Therefore, 
targeting these pathways with novel selective pharmacological inhibitors may lead to the development 
of more effective therapies for SCLC. 
The PI3K signaling pathway controls key cellular responses, such as cell growth and proliferation, 
survival, migration and metabolism. Over the last decades, it has been recognized that this intracellular 
signaling pathway is frequently activated by genetic and epigenetic alterations in human cancer, 
including lung cancer. The PI3K family of signaling enzymes comprises eight catalytic isoforms, 
which are subdivided into three classes. The class IA PI3K isoform p110α is considered to be a 
validated drug target in human cancer (5, 11, 292), in particular because activating mutations in the 
PIK3CA frequently occur in human cancer.  In SCLC, amplification and mutations of the PIK3CA 
gene were identified and the p110α and p110β isoforms are over-expressed in cell lines, additionally 
joined by deregulation of the PI3K/Akt/mTOR pathway (293).  
Here we report for the first time that targeting the class IA PI3K isoform p110α blocks SCLC cell 
growth and survival in vitro and in vivo and present evidence that this isoform plays a crucial role in 
Akt/mTOR pathway activation and Bcl-2 family proteins expression. 
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Materials and methods 
 
Antibodies and reagents  
Antibodies: Caspase 3, poly-(ADP-ribose)-polymerase (PARP), Akt, PI3K p110β (Santa Cruz 
Biotechnology), p-AktSer473, p-Bcl2Ser70, Bcl2, BclXL, Bax, Bad, p-4EBP1Thr37/46, p-S6Ser235/236 or p-
S6Ser240/244, S6 protein, PI3K p110α (Cell Signaling Technology), β-actin (Sigma Aldrich), Mcl-1, 
NFκB (Epitomics).  
Etoposide, chloroquine, z-VAD-FMK, IKK inhibitor (wedelolactone)(Calbiochem). RAD001 was 
supplied by the Novartis Institutes for BioMedical Research Basel, Oncology, Switzerland. The PI3K 
inhibitors PIK75, YM024, TGX221, PI103 were the kind gift of Prof. Shaun Jackson. 
 
Cell lines, cell culture, and cell proliferation  
SCLC cell lines were obtained from the American Type Culture Collection (Suppl. Table 3). The 
human SCLC cell lines H69, H209, H510, and SW2 were cultured in RPMI medium containing 10% 
heat-inactivated FCS. Cell viability was analyzed by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay, Promega). 
 
Reverse transcription-PCR and TaqMan analysis 
Total cellular RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the 
manufacturer’s instruction. For each reverse transcription-PCR, 1 µg of total RNA was used with the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The reaction conditions were 
used according to the manufacturer’s protocol. TaqMan Gene Expression Assays for the PI3Ks p110α 
and p110β, as well as for VEGFA were done according to the manufacturer’s instructions (Applied 
Biosystems). As internal control the expression of GAPDH was analyzed in each sample, separately.  
 
Immunohistochemistry 
Immunoreactivity was evaluated on commercial TMA sections of SCLC (Biomax LC10010 (2 cores; 
Female 9 (22.5%), Female age 32-66 yo (mean value 52.5); Male 31 (77.5%), Male age 34-76 yo 
(mean value 53.0); Stage I 11, Stage II 20, Stage IIIa 7, Stage IIIb 2; Node negative 12, Node positive 
28 (22 N1 and 6 N2)) using the PI3K p110α (Cell Signaling Technology, 4249), p110β (Abcam, 
ab55593) and Bcl2 (Cell Signaling) antibodies in a modification of the antigen retrieval technique 
(294). The antibodies were used at 1:200 dilution for 1 hour at room temperature and then processed 
with Polymer-HRP Kit (BioGenex, San Ramon CA) with diaminobenzidine development and Mayer 
haematoxylin counterstaining. Breast cancer tissue was used as positive external control. Negative 
controls were obtained by omitting the primary antibody. Scoring A semi quantitative 
immunohistochemical score (IHS) was used including assessment of both the percentage of positive 
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cells and the intensity of staining. For the intensity, a score of 0 to 3, corresponding to negative, weak, 
moderate and strong positivity, was recorded. The range of possible scores was thus 0 to 300. IHS and 
similar semi quantitative scoring systems have been successfully used for TMA evaluation. Each core 
was scored individually. One observer scored all cases, which were rechecked randomly by the same 
investigator after a period of time. 
Serial sections of paraffin-embedded CAM tumors were dewaxed in xylol and rehydrated through 
graded dilutions of ethanol. Antigen recovery was performed with citrate buffer (10 mM) in a 
microwave (800 watts) for 7 min. Endogenous peroxidase activity was blocked with 3% H2O2. 
Sections were incubated in a humid chamber at 4 °C overnight with or without (negative controls) 
active Caspase 3 (Abcam, ab2302; recognizes the cleaved active p17 fragment) and Ki67 (Novus 
Biologicals, NB110-57147) antibodies. Biotin-conjugated goat anti-Rabbit (Dako, E0432) and avidin-
biotin-horseradish peroxidase complex (Vector Laboratories, Vectastain ABC Kit, PK6100) were 
used. Bound peroxidase was detected with 3, 3'-diaminobenzidine substrate. Sections were 
subsequently counterstained with hematoxylin and mounted in Aquatex (Merck).  
 
Transient transfection and stable transduction of SCLC cells 
SCLC cells were transiently transfected with either non-targeting small interfering RNA (siRNA) or 
SMARTpool siRNA duplexes targeting the PI3K p110α or PI3K p110β, using the Amaxa 
Nucleofector system (Amaxa Biosystems), according to the manufacturer’s protocol. Briefly, 1.5 x 106 
SCLC cells grown in RPMI/10% FCS were transfected with 6 µL of 20 µmol/L siRNA in 100 µL of 
Nucleofector Solution V using the program T-16 on the Amaxa Nucleofector. Following transfection, 
cells were transferred into RPMI/10 % FCS overnight before they were used for experiments. 
Lentiviral vectors expressing small hairpin (sh)RNA constructs specificially targeting the PI3K p110α 
(Sigma-Aldrich) were tested for stable knockdown efficiency. The constructs shPI3KC_2892 and 
shPI3KC_3433 were chosen for further experiments since they most efficiently silenced p110α. The 
non-targeting vector SHC002 was used as control. Lentivirus production and transduction of cells was 
done as described before (295). Vectors contained a puromycin-resistance gene and stably transduced 
cell populations were selected for two weeks using puromycin at the concentration 1.5 µg/ml. 
 
In vivo experiments 
The effect of the PI3K inhibitor PIK75 on the growth and SCLC tumor formation in vivo were 
assessed on the chorioallantoic membrane (CAM) of chick embryos (296). Briefly, 3 x 106 H69 SCLC 
cells were placed in RPMI containing 50% BD Matrigel Matrix (BD Biosciences) on the CAM on 
embryonic day 9. Increasing concentrations of the p110α inhibitors PIK75 were deposited with the 
SCLC cells. Controls received the solvent of the corresponding drug. CAMs were examined for vessel 
formation under a stereomicroscope. Tumor size and density of vessels per area around the tumor were 
Results 
40 
determined using the software Vessel_tracer (297). The application of Matrigel without/with PIK75 on 
the CAM was used as negative control.  
 
SDS-PAGE and Western blotting 
The assays were done as described before (182). 
 
DNA microarray 
The cDNA microarray analysis was performed in collaboration with the Functional Genomic Center 
of the University of Zurich. Gene expression data were obtained by hybridizing Human Genome U133 
Plus 2.0 Affymetrix GeneChips arrays, on which >54000 transcripts were represented. Each 
experiment represented a group of three independent biological replicates. Raw data generated by the 
GCOS Software (Affymetrix) were processed by using the RMA method (298) and further statistically 
analyzed by using the software R and applying Student’s t-test. The GeneGO MetaCore (GeneGO, St 
Joseph, MI, USA) was used to define functional annotations for the selected genes, thus assigning 
them to ontological categories for association with relevant biological processes and pathways. 
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Results 
 
Expression of the PI3K p110α and p110β and the anti-apoptotic protein Bcl2 in SCLC patient 
samples 
Our previous work in SCLC cell lines had revealed that class IA PI3K isoforms are over-expressed in 
comparison to type II pneumocytes, which are one of the precursors of SCLC. To investigate whether 
this finding could be confirmed in primary tumors, a SCLC tissue microarray was stained with 
antibodies specific for p110α or p110β (Fig. 8A). This analysis revealed that, while normal lung tissue 
did not express detectable levels of either PI3K isoforms, p110α and p110β displayed enhanced 
expression in subsets of primary SCLC (Fig. 8A-B). Around 25% of SCLC tumors had over-
expression of p110α, while 18% of cases were positive for p110β (Fig. 8B). In general, SCLC tumors 
did not display concomitant over-expression of p110α and p110β and was only present in 5% of the 
tumors. Additionally, the expression of the anti-apoptotic protein Bcl2 was assessed in SCLC patient 
samples. The IHC staining of a TMA with a specific antibody revealed a high Bcl2 over-expression in 
~90% (35/39 cases) of the SCLC patient samples (Fig. 8C+D) compared to normal lung tissue, which 
did not display detectable levels of Bcl2. 
 
Class IA PI3K p110α inhibition or silencing blocks cell proliferation and Akt/mTOR signaling 
Previous work had shown that targeting the PI3K/Akt/mTOR pathway by using small molecule 
inhibitors impaired SCLC proliferation in vitro and in vivo. Therefore, we investigated the impact of 
isoform-specific inhibitors of class IA PI3K isoforms on the proliferation of SCLC cell lines. The 
potent p110α inhibitor PIK75 (IC50 in vitro = 7.8±1.7 nM) (299) significantly impaired the 
proliferation of 4 SCLC cell lines with IC50 values in the range of 50-100 nM (Fig. 9A). The p110α 
inhibitor YM024, which is much less potent against the enzyme in vitro (IC50 in vitro = 0.3 µM), also 
impaired the proliferation of the SCLC cell line panel, but at higher concentrations (Fig. 9A). The 
potent p110β inhibitor TGX-221 (IC50 in vitro = 8.5±0.9 nM) (299) only partially impaired the 
proliferation of SCLC cell lines, but at high concentrations (Fig. 9B). In contrast, the p110δ inhibitor 
IC87114 did not significantly impair the proliferation of the cell lines under study (Fig. 9B). We also 
evaluated the impact of the dual p110α/mTOR inhibitor PI103 in the panel of SCLC cell lines. PI103 
displayed anti-proliferative activity against the SCLC panel in vitro, with IC50 values in the range of 
100-500 nM (Suppl. Fig. 1A).  
The impact of the selective PI3K inhibitors on the activation status of the Akt/mTOR pathway in 
SCLC cell lines was then investigated by Western blot analysis (Fig. 9C). PIK75 and PI103 strongly 
affected the activation status of Akt and the phosphorylation of the mTOR downstream targets 
ribosomal S6 protein and 4E-BP1 (Fig. 9C; Suppl. Fig. 1B). YM024 also impaired Akt activation and 
partially inhibited mTOR pathway activation (Fig. 9C; Suppl. Fig. 1B). In contrast, TGX221 was less 
effective at blocking the activation of the Akt/mTOR pathway (Fig. 9C; Suppl. Fig. 1B).  
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Figure 8 Expression of the PI3K p110α and p110β an the anti-apoptotic protein Bcl-2 in SCLC patient 
samples. (a) Immunostaining with PI3K p110α and p110β showing negative SCLC staining and representative 
p110α and p110β SCLC positive staining, compared to normal lung tissue. (b) Analysis of the IHC staining 
PI3K p110α and p110β in SCLC patient samples.(c)Immunostaining with Bcl-2 showing negative and 
representative Bcl-2 intermediate and strongly positive SCLC staining. (b) The mean immunohistochemical 
staining scores (IHC scores) Bcl-2 in 20 paraffin-embedded specimens each of normal lung tissue and of 40 
SCLC paraffin-embedded specimens. IHC scores = percentage of positive cells x staining intensity (for details 
see “Material and Methods”).  
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Figure 9 PI3K inhibition blocks cell viability and PI3K downstream signaling. (a+b) The SCLC cell lines 
H69, H209, H510, and SW2 were incubated with increasing concentrations of the class I PI3K inhibitors PIK75, 
YM024 (a), TGX221, and IC87114 (b) in serum-containing medium. Cell viability was assessed using the MTS 
assay after 3 days. The data are mean with SD from four replicates and at least three independent experiments. 
(c) H69 cells were incubated with increasing concentrations of the PI3K p110α inhibitors PIK75, YM024, and 
PI103 (PI3K p110α/mTOR inhibitor) and the PI3K p110β inhibitor TGX221. After 24 hours the cells were 
harvested and whole cell lysates analyzed by SDS-PAGE and Western blotting for the proteins indicated.  
 
To validate our findings with pharmacological inhibitors, we used RNA interference to down-regulate 
the expression of p110α or p110β in SCLC cell lines. Transient down-regulation of p110α strongly 
impaired the activation of Akt and phosphorylation of the ribosomal S6 protein, while p110β silencing 
was ineffective (Fig. 10A). In addition, p110α silencing induced a significant decrease in the 
proliferation of SCLC cells (40% reduction), while p110β down-regulation was less effective (25% 
reduction) (Fig. 10B).  We also used lentiviral delivery of short hairpin RNAs targeting p110α in 
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SCLC cell lines. Also this approach resulted in stable silencing of p110α, robust affected PI3K 
downstream signaling (Fig. 10C) and SCLC cell proliferation was partially impaired by shRNA 
targeting of p110α (Fig. 10D). 
Together these results show that targeting p110α selectively impairs cell proliferation and activation of 
the Akt/mTOR pathway in SCLC cell lines in vitro.  
 
 
Figure 10 Silencing of p110α but not p110β affects cell viability and PI3K downstream signaling 
activation. (a+c) H69 cells were transiently transfected with siRNA constructs targeting p110α or p110β, or 
non-targeting scrambled control (a) or p110α was stably silenced by the lentiviral delivery of shRNA constructs 
(c). Cell lysates were analyzed by SDS-PAGE and Western blotting with antibodies for the proteins indicated. 
(b+d) Cell viability of H69 cells transiently (b) or stably (d) transfected with constructs targeting p110α or p110β 
was assessed using the MTS assay after 2 and 3 days. A non-targeting construct was used as control. 
 
Class IA PI3K p110α inhibition induces apoptosis and autophagy in SCLC cell lines 
Previous work had shown that targeting the PI3K/Akt/mTOR pathway by using small molecule 
inhibitors (187, 300) or RNAi induced apoptosis in SCLC cell lines. Therefore, we investigated the 
impact of isoform-specific inhibitors of class IA PI3K isoforms on the survival of SCLC cell lines. 
Treatment of a panel of SCLC cell lines with PIK75 or YM024 induced cleavage of PARP and 
reduction of pro-caspase 3, which are markers of apoptosis induction (Fig. 11A), whereas TGX221 
was less efficient at inducing apoptosis (Fig. 11A). Apoptosis induction upon p110α inhibition seemed 
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to be stronger in the SCLC cell lines H69 and H209, compared with the effects observed in H510 
(intermediate) and SW2 (low) (Fig. 11A). The caspase inhibitor zVAD-FMK was able to rescue 20% 
of H69 cells from PIK75-induced apoptosis and 10% of the TGX221-induced apoptosis (p<0.01) (Fig. 
11B). Because the strongly affected cell viability in SCLC cells due to p110α inhibition could not only 
be explained by apoptotic cell responses we further wanted to investigate other mechanisms, such as 
autophagy, responsible for SCLC cell death. Whereas the inhibition of p110α with PIK75 or YM024 
was able to induce increased conversion of LC3-I to LC3-II, which is an indicative for autophagic 
activity, it could be less observed in p110β-inhibited cells (Fig. 11C, Suppl. Fig. 2). ATG5, another 
protein used as typical marker for autophagy, was also expressed in SCLC cells. Compared to the 
vehicle-treated control no or just a slightly enhanced expression could be observed in PIK75-treated 
H69 cells (Fig. 11C). Interestingly, at later time points, a decrease in ATG5 expression could be 
observed (data not shown). Chloroquine, a drug actually used as anti-malaria treatment, was 
discovered to inhibit autophagic activity due to deacidification of lysosomes followed by accumulation 
of ineffective autophagic vesicles. Also in H69 cells treated with the PI3K inhibitors PIK75 and 
TGX221 chloroquine was able to rescue 20% (and 10%) of the autophagy-induced decrease in cell 
viability (Fig. 11D), suggesting additive roles or crosstalk between autophagy and apoptosis in p110α-
induced cell death.  
 
Inhibition of the PI3K p110α impairs SCLC tumor formation and vascularization in vivo 
The overview of data collected from our present experiments and the known literature indicates an 
important role of p110α in SCLC cell growth and survival processes in vitro and in vivo. To further 
investigate its impact on tumor formation and maintenance, an in vivo assay was employed to grow 
vehicle- and PIK75-treated H69 cells on the chorioallantoic membrane (CAM) of chick embryos. 
Tumor formation was clearly impaired upon PIK75 treatment pointed out by strongly reduced tumor 
size and tumor weight compared to the control tumors (Fig. 12A). Additionally, IHC of PIK75-treated 
tumor sections showed a decreasing expression of the proliferation marker Ki67 and a rising 
expression of the apoptotic marker cleaved caspase 3 with increasing PIK75 concentrations (Fig. 
12C). Finally, p110α inhibition was able to partially prevent the vascularization on the CAM around 
the tumorigenic area as measured by the vessel density (Fig. 12B). Another hint leading to the 
assumption of an impaired tumor vascularization through p110α inhibition could be the reduced 
VEGFA expression found in DNA-microarray- and quantitative RT-PCR analysis of PIK75-treated 
H69 cells (Suppl. Fig. 3).  
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Figure 11 PI3K inhibition increases apoptosis and autophagy in SCLC. (a+c) H69, H209, H510 and SW2 
cells grown in serum-containing medium were incubated with increasing concentrations of the PI3K p110α 
inhibitors PIK75 and YM024, the PI3K p110β inhibitor TGX221, RAD001 or etoposide/cisplatin. After 24 
hours the cells were harvested and cell lysates analyzed by SDS-PAGE and Western blotting for the proteins 
indicated. (b+d) H69 cells grown in serum-containing medium were incubated with the PI3K inhibitors PIK75 
(0.05 µM) and TGX221 (10 µM), rapamycin (0.1 µg/ml) or etoposide (10 µM) in absence or presence of zVAD-
FMK (50 µM) or chloroquine (20 µM). Cell proliferation was assessed using the MTS assay after 12h. The data 
are mean of four replicates and three independently performed experiments. ** p<0.01, * p<0.05. 
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Figure 12 PI3K inhibition reduces tumor formation and vascularization in vivo. (a) H69 cells were treated 
with vehicle or different concentrations of PIK75 and applied on the CAM of chick embryos. On day 13 pictures 
and tumors were taken to analyze tumor size, weight (a) and vessel density (b). (b) Analysis of the vessel density 
reduction upon PI3P p110α inhibition in vehicle- or PIK75-treated H69 tumors (c) Immunostaining with Ki67 
and cleaved caspase 3 comparing the expression in vehicle- and PIK75-treated SCLC tumor sections. (d) 
Analysis of Ki67 or caspase 3 positively stained tumor cells comparing vehicle- and PIK75-treated H69 tumor 
sections. (positively stained cells [%] = number of positive cells/total number of cells x 100). *** p<0.001, ** 
p<0.01, * p<0.05.  
 
DNA microarray analysis of SCLC cells treated with isoform-specific PI3K inhibitors 
In order to investigate whether the class IA PI3K isoform p110α controls the expression of specific 
gene subsets in SCLC, we performed DNA microarray analysis in H69 cells treated with either 
vehicle, PIK75 targeting p110α, or TGX221 targeting p110β (Fig. 13A). The efficacy of the down-
regulation of the Akt/mTOR by the respective inhibitors was demonstrated by Western blot analysis, 
as well as quantitative RT-PCR for VEGFA expression (Fig. 9C; Suppl. Fig. 1B+3). Inhibiting p110α 
significantly affected the expression of 3411 genes (P-value 0.01; FC ≥ 1.5), while inhibiting p110β 
resulted in significant changes (P-value 0.01; FC ≥ 1.5) in 4 genes, suggesting an important role of 
p110α but not p110β for the regulation of the expression of a subset of genes in SCLC (Fig. 13A). We 
next sought to investigate which genes were selectively affected by p110α inhibition, in comparison to 
p110β. Amongst these genes, in particular anti-apoptotic proteins of the Bcl-2 family of proteins were 
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found to be more significantly down-regulated in SCLC cells treated with p110α inhibitor, than in the 
case of the p110β inhibitor (Table 1).  
 
Fig. 13 The proteins of the Bcl2 family are downstream targets of p110α. (a) Gene expression analysis by 
DNA microarray: Heatmap of gene expression changes caused by p110α inhibition. (b+c+d) H69, H209 and 
SW2 (b) or H69 (c+d) cells grown in serum-containing medium were incubated with increasing concentrations 
of the PI3K p110α inhibitors PIK75 and YM024, the PI3K p110β inhibitor TGX221, RAD001 and 
etoposide/cisplatin or the IKK inhibitor wedelolactone (d). After 24 hours the cells were harvested and cell 
lysates analyzed by SDS-PAGE and Western blotting for the proteins indicated. 
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The proteins of the Bcl-2 family are downstream targets of p110α  
In order to validate the Bcl-2 family proteins as targets of p110α in SCLC cell lines, we used antibody 
arrays and Western blot analysis to confirm the results obtained from the DNA microarrays. A 
commercially available phosphorylation-antibody array revealed beside an impaired Akt pathway 
activation a down-regulation of anti-apoptotic Bcl2-family proteins (Suppl. Fig 5). Down-regulation of 
the expression and impaired activation of the anti-apoptotic Bcl2 family proteins could indeed be 
demonstrated at the protein level upon p110α inhibition (Fig. 13B). As it could be already observed 
before in the apoptotic response, the SCLC cell lines under study responded individually to the p110α 
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inhibition. In particular the cell lines H69 and H209 showed a strongly decreased expression of the 
Bcl-2 family members Bcl-2, Bcl-XL and Mcl-1, whereas SW2 cells seemed to be more resistant.  In 
addition, p110α inhibition induced the levels of the pro-apoptotic family members Bad and Bax (Fig. 
13B). In contrast to the inhibitors of p110β, TGX221 had little effect on the expression levels of Bcl-2 
family proteins (Fig. 13B). The anti-apoptotic Bcl2-family proteins Bcl2 and BclXL are targets of the 
transcriptional network of the transcription factor NFκB, which is controlling differential cell 
responses including immune response, cell proliferation and survival (301). To gain insight into the 
transcriptional networks affected by silencing of p110α in SCLC cells, we performed a biostatistics 
analysis of the gene expression data, using GeneGo. The transcriptional networks that were most 
significantly altered comprised HNF4α, SP1 and c-Myc, the estrogen receptor (ER) and also NFκB 
(Suppl. Table 1). By Western blot analysis of a whole cell lysate of H69 cells treated with PIK75 and 
YM024 targeting p110α we could observe deregulation of the NFκB expression, whereas p110β did 
not have any effect (Fig. 13C). These results suggested NFκB to be a downstream target of PI3K 
p110α signaling in SCLC and we assumed that its deregulation may have also an effect on the 
expression of the anti-apoptotic proteins Bcl2 and BclXL. This could be confirmed by a decreased 
expression level of Bcl-2 in H69 cells treated with wedelolactone, an inhibitor of the IκB-kinase (IKK) 
(Fig. 13D).  
 
 
Discussion 
The PI3K/Akt/mTOR pathway has been demonstrated to play a key role in SCLC cell proliferation, 
survival, chemoresistance and migration. Mutations in PIK3CA and gene amplification were reported 
in primary SCLC, as well as increased expression of PIK3CA at the mRNA and protein level. Broad 
specificity PI3K/mTOR inhibitors have shown anti-tumor activity in SCLC models in vitro and in vivo 
(118). In this report, we have investigated the impact of isoform-specific inhibitors and RNAi 
targeting class IA PI3K isoforms on SCLC cell responses. In general, agents targeting p110α reduced 
SCLC cell proliferation in vitro, impaired the SCLC tumor formation, which was accompanied by 
affected vascularization in vivo, and decreased the activation status of classical PI3K downstream 
targets, such as Akt, mTOR and S6K. Targeting p110α by RNAi or isoform-specific inhibitors had 
more pronounced effects on SCLC cell responses than in the case of p110β or p110δ, indicating a 
selective role for p110α in SCLC. This hypothesis was also confirmed by the observation that p110α 
was over-expressed in advanced stage SCLC, which was not the case for p110β. In view of these 
observations, we hypothesized that p110α may control the expression of a selective subset of genes 
implicated in SCLC cell proliferation and/or survival. The comparative DNA microarray analysis of 
SCLC cell lines in which either p110α or p110β were inhibited by selective compounds identified such 
a gene subset. The Bcl-2 family of proteins was validated as a downstream target of p110α by a 
combination of approaches. The observation that Bcl-2 expression was elevated in primary SCLC, in 
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comparison to normal lung tissue further supports this model, in view of the over-expression of p110α. 
Importantly, the Bcl-2 family of proteins has been previously shown to play a crucial role in the 
survival of SCLC cell lines in vitro and in vivo (149, 160, 302-305). The p110α inhibitors induced 
increases in both SCLC apoptosis and autophagy, which is consistent with Bcl-2 family proteins being 
a target of p110α. Bcl-2 family proteins are key regulator of both apoptosis and autophagy (306) and 
their reduction via the inhibition of the p110α/NFκB pathway may play an essential role in the effects 
of the p110α inhibitors in SCLC.  
 We have previously evaluated the mTOR inhibitor everolimus in SCLC cell lines and found 
that it was effective in a subset of SCLC cell lines characterized by activation of the Akt/mTOR 
pathway and low expression levels of anti-apoptotic Bcl-2 family proteins (304). In view of the results 
obtained with isoform-selective inhibitors of p110α, it can be speculated that these agents may be 
more potent, since they induce a down-regulation of anti-apoptotic Bcl-2 family proteins and of the 
activity of the Akt/mTOR pathway. This may be particularly relevant for SCLC tumors bearing 
activating mutations in the PIK3CA gene. 
 Interestingly, our previous work in neuroblastoma has shown that the class IA PI3K isoform 
p110δ contributes to cell proliferation and survival by controlling the activation of the mTOR pathway 
and the expression levels of anti-apoptotic Bcl-2 family proteins. Over-expression of p110δ was found 
in a subset of primary neuroblastoma and cell lines, and p110δ was essential for signal transduction by 
receptor tyrosine kinases, such as the IGF-1R and EGFR (277). In contrast, in SCLC cell lines, p110α 
appears to play a more important role in the activation of the Akt/mTOR pathway, which may explain 
the impact of agents targeting this isoform on SCLC proliferation and survival. A previous report has 
shown that the activity of any class IA PI3K isoform can maintain cell survival (307). Therefore, the 
relative importance of class IA PI3K isoforms in selected cancer types may be, in part, attributed to 
differences in expression levels. 
 Thus, targeting PI3K p110α signaling may represent an attractive novel approach to develop novel 
therapies for SCLC. Indeed, there now exist different pharmacological inhibitors of this isoform, 
which will soon enter clinical trials in oncology, and could, in the future, be developed as new drugs 
for SCLC.  
 
 
 
 
 
 
 
 
 
Results 
52 
 
Supplementary Data 
 
 
Supplementary Fig. 1. PI3K inhibition 
blocks SCLC cell viability and PI3K 
downstream signaling. (a) The SCLC 
cell lines H69 and SW2 were incubated 
with increasing concentrations of the 
dual PI3K p110α/mTOR inhibitor PI103. 
Cell viability was assessed using the 
MTS assay after 3 days. (b) H209, H510 
and SW2 SCLC cells were incubated 
with increasing concentrations of the 
PI3K p110α inhibitors PIK75, YM024, 
and PI103 (PI3K p110α/mTOR 
inhibitor) and the PI3K p110β inhibitor 
TGX221, and cisplatin. After 24 hours 
the cells were harvested and whole cell 
lysates analyzed by SDS-PAGE and 
Western blotting for the proteins 
indicated. (c) Stable Silencing of p110α 
affects cell viability and PI3K 
downstream signaling activation. In 
H69 cells p110α was stably silenced by 
the lentiviral delivery of shRNA 
constructs. Cell lysates were analyzed by 
SDS-PAGE and Western blotting with 
antibodies for the proteins indicated. 
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Supplementary Fig. 2. PI3K inhibition increases autophagy in SCLC. Analysis of the ratio of LC3II/LC3I. 
H69 cells grown in serum-containing medium were incubated with increasing concentrations of the PI3K p110α 
inhibitors PIK75 and YM024, the PI3K p110β inhibitor TGX221, RAD001 or etoposide/cisplatin. 
 
 
 
Supplementary Fig. 3. PI3K p110α inhibition decreases VEGFA in SCLC. Analysis of the relative VEGFA 
mRNA expression in H69 cells grown in serum-containing medium treated with the PI3K p110α inhibitor 
PIK75. 
 
 
Supplementary Fig. 4. PI3K inhibition reduces vascularization in vivo. As negative control Matrigel with 
vehicle or PIK75 (0.5 µM) was applied on the CAM of chick embryos. On day 13 pictures were taken to analyze 
the vessel density. 
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Supplementary Fig. 5 Antibody array analysis of PIK75 treated H69 cells. Qualitative ratio of the 
expression/phosphorylation of the indicated proteins of H69 cells treated with 0.1 µM PIK75 or DMSO. The 
effect of the PI3K inhibitor PIK75 on the phosphorylation and expression of proteins of the PI3K/Akt pathway 
was assessed by employing a commercially available phospho-antibody array slides containing proteins of the 
PI3K/Akt pathway (Phospho-Akt Antibody Array PAA137; Fullmoon Biotechnology). Briefly, H69 cells were 
treated with 0.1 µM PIK75 for 24h and the antibody array slides were pre-treated and then incubated with the 
biotinylized whole cell protein lysate according to the recommended protocol with minor changes by using an 
automated hybridization station HS4800. 
 
 
 
 
Supplementary Fig. 6 Expression of Bcl2 and L-myc in SCLC cell lines. Whole cell lysates of the SCLC cell 
lines H69, H209, H510 and SW2 were analyzed by SDS-PAGE and Western blotting with antibodies for the 
proteins Bcl2 and L-myc. The expression of β-Actin was used as internal control.  
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Abstract 
The receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K) pathway is fundamental for 
cancer cell proliferation and is known to be frequently altered and activated in neoplasia, including 
embryonal tumors. Based on the high frequency of alterations, targeting components of the PI3K 
signaling pathway is considered to be a promising therapeutic approach for cancer treatment. Here, we 
have investigated the potential of targeting the axis of the insulin-like growth factor-1 receptor (IGF-
1R) and PI3K signaling in two common cancers of childhood: neuroblastoma, the most common 
extracranial tumor in children and medulloblastoma, the most frequent malignant childhood brain 
tumor. By treating neuroblastoma and medulloblastoma cells with R1507, a specific humanized 
monoclonal antibody against the IGF-1R, we could observe cell line-specific responses and in some 
cases a strong decrease in cell proliferation. In contrast, targeting the PI3K p110α with the specific 
inhibitor PIK75 resulted in broad anti-proliferative effects in a panel of neuro- and medulloblastoma 
cell lines. Additionally, sensitization to commonly used chemotherapeutic agents occurred in 
neuroblastoma cells upon treatment with R1507 or PIK75. Furthermore, by studying the expression 
and phosphorylation state of IGF-1R/PI3K downstream signaling targets we found down-regulated 
signaling pathway activation. In addition, apoptosis occurred in embryonal tumor cells after treatment 
with PIK75 or R1507. Together, our studies demonstrate the potential of targeting the IGF-1R/PI3K 
signaling axis in embryonal tumors. Hopefully, this knowledge will contribute to the development of 
urgently required new targeted therapies for embryonal tumors.   
Results 
59 
Introduction 
Second to accidents, cancer is still the leading cause of death for children. Embryonal tumors represent 
approximately 30% of childhood malignancies and often display resistance to current therapeutic 
regimens. Therefore, embryonal tumors are associated with lower survival rates compared to other 
childhood cancers. Treatment failure for disseminated disease is frequent, and results in survival rates 
< 20%. Thus, novel therapeutic options are urgently needed for this group of tumors to improve 
survival rates and quality of life of patients. Embryonal tumors are dysontogenetic tumors whose 
pathological features resemble those of the developing organ or tissue of origin and include the entities 
medulloblastoma and neuroblastoma. Medulloblastoma is the most common malignant brain tumor in 
children and accounts for approximately 20% to 25% of all pediatric central nervous system tumors. 
Neuroblastoma is an embryonal tumor that originates from developing neural crest tissues. It is the 
most common extracranial solid tumor and is responsible for 15% of all cancer-related deaths in 
childhood. The fact that these cancers occur in infants and young children suggests that only a limited 
number of genetic changes may lead to tumor development, making these cancers an attractive model 
to identify new molecular targets. The development of novel targeted therapies is of particular 
importance for embryonal tumors, as these malignancies are orphan diseases. Common intracellular 
signaling pathways and chromosomal deletions including 1p36 and 11q loss have been previously 
identified in different embryonal tumors, including medulloblastoma and neuroblastoma (308-317).  
Several intracellular signaling pathways have indeed been demonstrated to play a key role in 
embryonal tumor biology. Indeed, polypeptide growth factors such as insulin-like growth factor-1 
(IGF-1), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), neuregulins and 
neurotrophins have been shown to control embryonal tumor proliferation, survival, differentiation and 
metastasis (272, 318-321) by binding to specific receptor tyrosine kinases (RTKs). Moreover, 
expression of the ErbB-2 and ErbB-4 RTKs in embryonal tumor samples was shown to correlate with 
reduced patient survival, while Trk receptor expression correlated with a less aggressive tumor 
phenotype (319). Therefore a better understanding of the involvement of RTKs and their downstream 
targets in human embryonal tumor biology may yield important clues for the development of new 
drugs for the disease. Targeting receptor tyrosine kinases such as the IGF-1R is a promising approach 
to develop novel anti-cancer therapies in embryonal tumors, such as neuroblastoma and sarcoma (321-
329). Indeed the first results from clinical trials evaluating the safety and efficacy of IGF-1R 
neutralising antibodies in children and adolescents with embryonal tumors have been reported (330, 
331). In these trials, the humanized IGF-1R neutralizing antibody R1507 displayed minimal toxicities 
and some responses in ESFT were observed (330, 331). Importantly, no dose-limiting toxicities were 
identified and the maximum tolerated dose was not reached (330). Human embryonal tumor cells have 
been reported to express a variety of growth factor receptors, some of which can be activated by 
mutations, over-expression and/or establishment of autocrine loops (319). Amongst these polypeptide 
growth factor receptors are the RTKs IGF-1R, EGFR, ALK, ErbB-2, ErbB-4, c-Kit, PDGFR, Trk and 
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fibroblast growth factor receptor (FGFR) (233, 234, 332-345). Therefore, given that embryonal tumor 
cells express a variety of different growth factor receptors, targeting individual receptors may not 
provide a successful therapeutic strategy in all embryonal tumor entities. A potentially complementary 
approach would be to identify signaling molecules which lie downstream of several different growth 
factor receptors and which are essential for transmitting their proliferative and/or survival message. 
Combinatorial targeting of receptor tyrosine kinases (such as the IGF-1R) and their downstream 
signaling mediators is a very promising approach to develop more efficient anti-cancer therapies (322, 
323, 328, 346-348).  
The phosphoinositide 3-kinase (PI3K) plays a crucial role in controlling cell proliferation, survival and 
motility/metastasis downstream of many different growth factor receptors and oncogenic Ras mutants 
(1, 349-351). PI3K signaling activates a crucial intracellular signaling pathway involving 
phosphoinositide-dependent protein kinase-1 (PDK1), Akt, the mammalian target of rapamycin 
(mTOR) and the ribosomal protein S6 kinase (S6K), which controls cell growth, proliferation and 
survival (1, 349, 350). The importance of PI3K/Akt/mTOR signaling in cancer is highlighted by the 
fact that mutations in the tumor suppressor gene PTEN occur frequently in human tumors, including 
glioblastoma (1, 352-354). PTEN is a phosphatase that antagonizes the action of PI3K by de-
phosphorylating the D-3 position of poly-phosphoinositides (1, 352, 353). Reduced expression of 
PTEN resulting in activation of PI3K signaling was recently described in embryonal tumors such as 
medulloblastoma and neuroblastoma (286, 355). Moreover, various reports have described activating 
mutations in the PIK3CA gene encoding the catalytic p110	 isoform of PI3K in a variety of human 
cancers, including, breast, colon and ovarian cancer, as well as embryonal tumors (283, 354, 356). In 
addition, PI3K/Akt/mTOR signaling has been demonstrated to mediate the proliferation of embryonal 
tumor cells (357, 358) and to contribute to signaling by ErbB-2 and IGF-1R (281, 359, 360). 
Activation of Akt was also reported in embryonal tumors, correlating with poor outcome in some 
entities (280). Thus, targeting the PI3K/Akt/mTOR signaling pathway may represent an attractive 
novel approach to develop novel therapies for embryonal tumors (361). Indeed, there now exist 
multiple pharmacological inhibitors of the PI3K/Akt/mTOR pathway which have entered clinical trials 
for adult and pediatric cancer (292, 348, 349, 351, 362, 363). The PI3K/Akt/mTOR pathway is also an 
important contributor to the resistance of human tumors to drugs targeting receptor tyrosine kinases 
(364-366). Inhibitors of the PI3K/Akt/mTOR signaling pathway have also been shown to be effective 
in combination with IGF-1R inhibitors (326, 347). 
In the present report, we have evaluated the anti-proliferative potential of the humanized anti-IGF-1R 
antibody R1507 and of PIK75, a class IA PI3K inhibitor, in medulloblastoma and neuroblastoma cell 
lines. We present evidence that these agents are effective as monotherapies in subsets of embryonal 
tumor cell lines and can be effectively combined with standard chemotherapeutic drugs. 
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Materials and methods 
Antibodies & Reagents 
Antibodies specific for IGF1Rβ, PI3K p110α, Akt1/2/3, ERK 1/2, S6 protein, Caspase-3 (Santa Cruz 
Biotechnology, CA, USA), phospho-ERK1/2 (Thr202/Tyr204), phospho-Akt (Ser473; Thr308), poly (ADP-
ribose) polymerase (PARP), S6 protein,phospho-S6 (Ser235/Ser236; Ser240/Ser244) p-IGF-1R(Cell 
Signaling Technology), β-actin (Sigma Aldrich). 
The PI3K inhibitor PIK-75 (299) was dissolved in DMSO (Sigma, Buchs, Switzerland) at 10 mM and 
diluted into cell culture medium just before use. R1507, a fully human IgG1 monoclonal antibody to 
IGF-1R, was obtained from Roche, and was diluted directly into the medium immediately before use. 
The chemotherapeutic agents cisplatin (Bristol-Myers Squibb), doxorubicin (Pfizer) and etoposide 
(Calbiochem) were used in combination with PIK75 or R1507 at the indicated concentrations. 
 
Cell lines, cell culture, cell proliferation and apoptosis  
Human neuroblastoma cell lines were kindly provided by Dr. Brodeur, Children’s Hospital of 
Philadelphia. The cells were grown in RPMI (Life Technologies/Invitrogen) supplemented with 10% 
(v/v) fetal calf serum (FCS) and penicillin/streptomycin/L-glutamine and passaged every 3-5 days by 
trypsinization (277, 326). 
The medulloblastoma cell lines’ provenience has been previously described. DAOY, UW-228 and 
PFSK human cell lines were purchased from the American Type Culture Collection. D341 Med and 
D458 Med medulloblastoma cells were the kind gift of Dr. Henry Friedman (Duke University, 
Durham, NC). Cell lines that were not purchased from the American Type Culture Collection in 2009 
were tested for their authentication by karyotypic analysis using molecular cytogenetic techniques, 
such as comparative genomic hybridization. DAOY medulloblastoma cell line was grown in Richter’s 
MEM Zinc option medium (Invitrogen) with 10% FCS (fetal bovine serum; Sigma) and 
penicillin/streptomycin (Invitrogen). PFSK primitive neuroectodermal tumor (PNET) cell line was 
grown in RPMI 1640 (Invitrogen) with 10% FCS and penicillin/streptomycin/L-glutamine. The UW-
228 medulloblastoma cell line was grown in DMEM (Dulbecco’s modified Eagle’s medium; 
Invitrogen) with 10% FCS and penicillin/streptomycin/L-glutamine.D341 Med and D458 Med 
medulloblastoma cell lines were grown like DAOY but with the addition of 100M non-essential amino 
acids (GIPCOTM MEM Invitrogen). All cells were grown in a humidified atmosphere at 37° and 5% 
CO2 (284, 367). 
For cell viability assays neuroblastoma and medulloblastoma cells were seeded in 96-well plates at a 
density of 3’000-10´000 cells/well and grown for 48-118 hrs in cell culture containing high (10%) 
serum. Cell proliferation was analyzed by the CellTiter 96®AQueousOne Solution Cell Proliferation 
Assay (Promega) according to the manufacturer’s instructions. For detection of apoptosis, NB and MB 
cells were seeded on 6-well plates and incubated for 24 h in the presence or absence of PIK75, R1507 
or cisplatin. After lysis of the cells the protein samples were analyzed by SDS-PAGE and Western blot 
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with anti-PARP and anti-caspase-3 antibodies. Additionally, apoptosis was analyzed by caspase 3/7 
activation using the Caspase-Glo 3/7 Assay (Promega), according to the manufacturer’s instruction.  
 
Western blotting 
Cell lysates were prepared in RIPA buffer (50mM Tris-Cl, pH 6.8, 100mM NaCl, 1% Triton X-100, 
0.1% SDS) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche Applied Sciences) 
and with the phosphatase inhibitors β-glycerophosphate (20mM) and Na3VO4 (200 mM) and 
normalized using a bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). Cell lysates 
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to a hydrophobic polyvinylidenedifluoride (PVDF) membrane (Hybond-P; Amersham 
Biosciences,GE Healthcare, UK) and immunoblotted with the indicated antibodies prior to 
chemiluminescent detection (SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher 
Scientific Inc., Rockford, IL, USA).  
 
Statistical analysis 
Analysis of variance was used to assess statistical significance of differences between groups. p values 
<0.05 were considered as significant. 
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Results 
Anti-proliferative activity of R1507 and PIK75 in panels of neuroblastoma and medulloblastoma 
cell lines 
We have previously described panels of neuroblastoma and medulloblastoma cell lines, which were 
characterized for expression of components of the IGF-1R/PI3K signaling pathway (277, 284, 326). In 
the present study, the impact of the humanized anti-IGF-1R antibody R1507 was evaluated on cell 
proliferation in vitro in the panels of neuroblastoma and medulloblastoma cell lines (Fig. 14). The 
antibody displayed anti-proliferative activity in 2 out of 8 neuroblastoma cell lines, namely SH-SY5Y 
and LAN1 (Fig. 14A and 22A). In SH-SY5Y, R1507 induced a maximal decrease in cell viability of 
60% at 12.5 µg/ml (Fig. 14A). In LAN1 a maximal activity of ~25% reduction in cell proliferation was 
observed (Fig. 22A). R1507 showed anti-proliferative activity in 2 out of 5 medulloblastoma cell lines, 
namely PFSK and D458 (Fig. 14B). In D458, a maximal decrease in cell proliferation (60%) was 
observed at 15 µg/ml, while in PFSK the maximal effect was 40% inhibition of the response (Fig. 
14B). In NB and MB cell lines, the activity of R1507 was cell-line specific and the antibody had a 
profile similar to the IGF-1R tyrosine kinase inhibitor NVP-AEW541 (326). NVP-AEW541 was more 
active in SH-SY5Y and LAN-1 than in other neuroblastoma cell lines (326), and PFSK were more 
sensitive to NVP-AEW541 than DAOY and UW228 cells.  
 
 
Figure 14. The effect of R1507 on cell proliferation of NB and MB cells. A panel of NB cell lines (A) and 
MB cell lines (B) were incubated with increasing concentrations of the antibody R1507 inhibiting the IGF-IR in 
serum-containing medium. Cell viability was assessed using the MTS assay after 2 days. The data represent the 
mean with SD from at least 6 replicates and 3 independent experiments. 
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The impact of the class IA PI3K inhibitor PIK75 was evaluated on cell proliferation in vitro in the 
panels of neuroblastoma and medulloblastoma cell lines (Fig. 15). The inhibitor displayed strong anti-
proliferative activity in the neuroblastoma cell line panel, with IC50 values in the range of 50-100 nM 
(Fig. 15A). In medulloblastoma cell lines, PIK75 was more active in D341 and D458 cells (IC50= 20 
nM) than in UW228 cells. The activity of PIK75 in DAOY and PFSK cells was previously described 
(284). 
 
Figure 15. Cell proliferation of NB and MB cells after inhibition of the PI3K p110α. A panel of NB cell 
lines (A) and MB cell lines (B) were incubated with increasing concentrations of the specific pharmacological 
PI3K p110α inhibitor PIK75 in serum-containing medium. Cell viability was assessed using the MTS assay after 
2 (NB) or 3 (MB) days. The data represent the mean with SD from at least four replicates and 1-3 independent 
experiment. 
 
Impact of R1507 and PIK75 on intracellular signaling pathway activation 
The impact of R1507 and PIK75 on the activation status of the Akt/mTOR pathway in NB cell lines 
was investigated by Western blot analysis (Fig. 16). R1507 strongly affected the activation status of 
Akt and the phosphorylation of the mTOR downstream target ribosomal S6 protein in the R1507-
responsive NB and MB cell lines. (SH-SY5Y in Fig. 16A, LAN1 cells Fig. 16B, as well as in 
medulloblastoma PFSK cells Fig. 16D). Concentrations of 6.25-100 µg/ml R1507 reduced AktSer473 
phosphorylation, whereas only concentrations of more than 6.25 or 12.5 were needed to reduce 
S6Ser235/236 phosphorylation. The R1507-insensitive NB cell line WAC2 did not show comparable 
responses on the PI3K pathway signaling activation upon R1507 treatment (Fig. 16C). 
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Also PIK75 was able to inhibit Akt/mTOR activation, as seen on the decreases in the phosphorylation 
of S6 protein in both NB cell lines treated (Fig 16A+B), although only in LAN-1 cells the 
phosphorylation of AktSer473 was affected (Fig. 16B). The inhibitory effects of PIK75 in Akt/mTOR 
signaling in MB cell lines cells were previously described in (284) and correlate with the effects 
observed in neuroblastoma cells. 
 
Figure 16. PI3K and IGF-IR inhibition impair receptor activation and downstream signaling. The NB cells 
SH-SY5Y (A), LAN1 (B); WAC2 (C) and the MB cells PFSK (D) grown in serum-containing medium were 
incubated with increasing concentrations of the PI3K p110α inhibitor PIK75 and the IGF-IR antibody R1507. 
After 24 hours the cells were harvested and whole cell lysates analysed by SDS-PAGE and Western blotting for 
the proteins indicated. (E+F) Serum-starved DAOY (E) and LAN1 (F) cells were pre-treated with vehicle or 
R1507 at the concentrations indicated for 1h and stimulated with IGF-I (50 or 100 ng/ml) for 10 min at 37°C. 
Cell lysates were analyzed by SDS-PAGE and Western Blot for phosphorylated IGF-IR beta and total receptor. 
 
IGF-IR expression and activation in neuroblastoma and medulloblastoma cell lines 
Further, we wanted to investigate the impact of R1507 and PIK75 on the expression and activation 
state on the IGF-I receptor in MB and NB cell lines. Pre-treatment with R1507 inhibited the 
phosphorylation but not the expression level of IGF-IR in DAOY cells after IGF-I stimulation (Fig. 
16E). In LAN1 cells the activation state of the IGF-IR was not only decreased by its direct inhibition 
with R1507 (Fig. 16F) but also by targeting its downstream signaling molecule p110α (data not 
shown). 
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Combination of R1507 with standard chemotherapeutic agents in neuroblastoma and 
medulloblastoma cell lines 
We have previously shown that the IGF-IR tyrosine kinase inhibitor NVP-AEW541 enhances the 
effects of cisplatin on cell proliferation and apoptosis in neuroblastoma cell lines (326). In support of 
this finding, the concomitant treatment of the R1507-responsive SH-SY5Y neuroblastoma cell line 
with R1507 and cisplatin resulted in additive effects on cell proliferation (Fig. 17A). For 
neuroblastoma WAC2 cells that did not respond to R1507 in single treatment (Fig 14A), there was no 
additional effect of R1507 in combination with cisplatin, doxorubicin or etoposide (Suppl. Fig. 7). In 
medulloblastoma PFSK and UW228 cells, the combination of R1507 and cisplatin was more effective 
than the single agents (Fig. 18 A+B). This is not surprising for PFSK, that also showed sensitivity to 
R1507 alone, but in UW228, cisplatin seems to confer R1507 sensibility. In R1507-insensitive DAOY 
cells no such effect was observed (Fig. 18C). 
 
Figure 17. Treatment of NB cells with R1507 or PIK75 in presence of chemotherapy results in additive 
effects. NB cells grown in serum-containing medium were incubated with the IGF-IR antibody R1507 (0.1 
µg/ml) (A) or the PI3K inhibitor PIK75 (0.05 µM) (B+C) in presence or absence of cisplatin (1 µM), etoposide 
(1 µM), or doxorubicin (0.1 µM). Cell proliferation was assessed using the MTS assay after 48h. The data 
represent the mean of 8 replicates with SD from3 independent experiments. (*p < 0.05). 
 
Combination of PIK75 with standard chemotherapeutic agents in neuroblastoma cells 
In the neuroblastoma cell lines LAN1 and WAC2, the concomitant treatment with PIK75 and 
doxorubicin or etoposide resulted in additive effects on cell proliferation (Fig. 17B+C). At selected, 
relatively low concentrations, where PIK75, doxorubicin or etoposide alone reduced cell proliferation 
to 60-80%, combination treatments of PIK75 and one of the chemotherapeutic agents brought 
reductions to 40-50%. Our previous work on medulloblastoma has shown that PIK75 sensitizes 
medulloblastoma cell lines to doxorubicin (284). 
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Figure 18. Additive/sensitization effects after combinatorial treatment with R1507 and chemotherapy in 
MB cells. The MB cell lines PFSK (A), UW228 (B) and DAOY (C) grown in serum-containing medium were 
incubated with increasing concentrations of cisplatin in presence or absence of the IGF-IR antibody R1507 (25 
µg/ml or 50 µg/ml). Cell proliferation was assessed using the MTS assay after 48h. The data represent the mean 
of 6 replicates with SD from 3 independent experiments 
 
Inhibitors of the RTK-PI3K-mTOR signaling in medulloblastoma 
Beside classical chemotherapeutic agents used for cancer treatment, targeted therapies involving 
inhibitors of the RTK-PI3K signaling axis are considered to be a promising approach in cancer 
treatment. To investigate the role of receptor tyrosine kinases signaling in medulloblastoma, the effect 
of different targeted therapies was additionally studied. In vitro, the IGF-IR inhibitor NVP-AEW541 
reduced the cell viability of the MB cell line DAOY with an IC50 of 2.5 µM and a maximal reduction 
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of cell proliferation to 5% (Fig. 19A, 20C), whereas in UW228 cells concentrations higher than 10 µM 
were needed to provoke a response (Fig. 19B). Also targeting the EGFR with gefinitib or erlotinib was 
more effective in DAOY than in UW228 cells (Fig. 19A+B), with DAOY responding from 
concentrations higher than 2.5 µM. In UW228 cells erlotinib did not cause any effect, whereas 
gefitinib treatment reduced cell viability to 5% at the highest concentration tested (20 µM) (Fig. 19B). 
Rapamycin, a commonly used mTOR inhibitor, led to 50% reduction in cell proliferation in DAOY 
cells (0.0625 µg/ml) (Fig. 20D). UW228 cells responded to rapamycin with a maximum decrease in 
cell viability of 30% (2 µg/ml) (Fig. 19B). Imatinib, an inhibitor of the RTKs PDGFR and c-Kit, was 
able to reduce the cell proliferation in DAOY cells to 15% (Fig. 19A, 20B) and in UW228cells to 40% 
(Fig. 19B). Before, it could be shown that the concomitant treatment of the IGF-IR antibody R1507 
with cisplatin resulted in additive effects in R1507-responsive cell lines, or even was able to sensitize 
the R1507-non-responsive cell line UW228, but not DAOY (Fig. 18). Furthermore it was of interest, 
whether a concomitant treatment of different RTK/PI3K/mTOR inhibitors and R1507 could cause 
sensitization effects in non-responsive DAOY cells. Co-targeting EGFR (gefitinib) or PDGFR and c-
Kit (imatinib) together with the IGF-IR (R1507) was not able to sensitize DAOY cells, and 
interestingly, even caused negative effects, meaning the combination treatment was less effective than 
the single agent (Fig. 20A+B). R1507, in combination with the IGF-IR inhibitor NVP-AEW541 or the 
mTOR inhibitor rapamycin could not further increase the effect of the single treatment (Fig. 20C+D). 
 
The role of the IGF-IR/PI3K/Akt signaling axis on cell survival in neuroblastoma and 
medulloblastoma 
The impact of the IGF-IR/PI3K/Akt signaling axis on survival of NB and MB cells was investigated 
by treating the cells with increasing concentrations of R1507 or PIK75, and apoptosis was measured 
by PARP cleavage and caspase-3activation, both markers of apoptotic activity. Whereas PIK75 
treatment led to enhanced PARP and an increase of cleaved caspase 3 expression in LAN1 or 
respectively a decrease of the pro-caspase 3 expression in SH-SY5Y cells (Fig. 21A+B) or to an 
increase in the caspase 3/7 activity in WAC2 NB cells (Fig. 21C), these apoptotic signals could not be 
observed with R1507 treatment in NB cells or by treating the MB cell line PFSK (Fig. 21A+B) and its 
impact on apoptotic pathways needs further investigation. 
 
Activity of R1507 and PIK75 in chemoresistant NB cell lines 
We next investigated whether R1507 or PIK75 had also anti-proliferative effects in neuroblastoma cell 
lines with acquired resistance to standard chemotherapeutic agents (LAN1R). R1507 displayed no 
significant anti-proliferative activity in LAN1 cells with acquired resistance to doxorubicin (Fig. 22A), 
a result which also could be observed in parental LAN1 cells where silencing reduced the expression 
level of IGF-IR (Fig. 22D). In contrast, PIK75 displayed almost comparable anti-proliferative activity 
in either parental LAN1 or their chemoresistant counterparts (Fig. 22B). Western blot analysis of the 
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protein expression of LAN1R cells showed that these cells express reduced levels of IGF-IR and 
p110α compared to the parental cell line LAN1. In addition, the phosphorylation levels of ERK1/2 and 
AKT at the positions Ser473 and Thr308 were also lower in LAN1R than in LAN1 (FIG 22C). 
 
 
 
Figure 19. Targeted therapies in medulloblastoma. The MB cell lines Daoy (A) and UW228 (B) were 
incubated with increasing concentrations of the EGFR inhibitors gefinitib or erlotinib, the Abl inhibitor imatinib, 
the IGF-IR inhibitor NVP-AEW541 and the mTOR inhibitor rapamycin. Cell proliferation was assessed using 
the MTS assay after 72h. The data represent the mean of 6 replicates with SD from 3 independent experiments. 
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Figure 20. Effects of R1507 in combination with targeted therapies in medulloblastoma. The R1507-
insensitive cell line DAOY was incubated with increasing concentrations of the EGFR inhibitor gefinitib (A), the 
Abl inhibitor imatinib (B), the IGF-IR inhibitor NVP-AEW541 (C) and the mTOR inhibitor rapamycin (D) in 
presence or absence of the IGF-IR antibody R1507.Cell proliferation was assessed using the MTS assay after 
72h. The data represent the mean of 6 replicates with SD from 3 independent experiments. 
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Figure 21. Apoptosis upon PI3K inhibition. (A+B) The NB cell lines LAN1 (A, left panel; B, left panel) and 
SH-SY5Y (B, right panel) as well as the MB cell line PFSK (A, right panel) grown in serum-containing medium 
were incubated with increasing concentrations of the PI3K p110α inhibitor PIK75 and the IGF-IR antibody 
R1507, or cisplatin. After 24 hours the cells were harvested and whole cell lysates analysed by SDS-PAGE and 
Western blotting for the proteins indicated. (C) The NB cell line WAC2 grown in serum-containing medium was 
incubated with increasing concentrations of the PI3K p110α inhibitor PIK75. Caspase 3/7 activity was assessed 
using the Caspase 3/7 Glo assay after 48h. 
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Figure 22. Sensitivity to R1507 and PIK75, and presence of IGFR in neuroblastoma cell lines LAN1 and 
LAN1R, a LAN1 cell line resistant to doxorubicin. A) R1507 treatment for 48 hours. B) PIK75 treatment for 
48 hours. Error bars represent ±S.D. of means from 3 experiments, each with 3 replicates, except that there was 
only one experiment with 500 nM PIK75 in B. C) Western blot analysis of components of the IGF-IR/PI3K 
pathway in LAN1 and LAN1R whole cell extracts. Src was used as internal loading control. D) Treatment of 
LAN1 cells with siRNA targeting the IGF-IR. (A non-targeting construct was used as control). Expression level 
of IGF-IR was assessed via Western blot analysis in LAN1 whole cell lysates after 96h. Cell proliferation in 
LAN1 cells upon IGF-IR silencing was assessed in absence or presence of R1507 after 96h by MTS. (*p < 0.05). 
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Discussion 
In the present report we have evaluated the anti-proliferative activity of the humanized anti-IGF-1R 
antibody R1507 in the embryonal tumors neuroblastoma and medulloblastoma in vitro. As a single 
agent, R1507 was effective in a subset of neuro- and medulloblastoma cell lines, while a majority of 
cell lines did not respond. The profile of R1507 in neuro- and medulloblastoma was similar to the 
IGF-1R tyrosine kinase inhibitor NVP-AEW541 in terms of the identity of the cell lines which were 
sensitive to the single agent (326). In neuroblastoma cell lines that were sensitive to R1507 as single 
agent, the effects of R1507 and chemotherapy (cisplatin, doxorubicin and etoposide) were additive, a 
result which was also observed with NVP-AEW541 (326). However, neuroblastoma cells which were 
not sensitive to R1507, showed also no additive effects in cell growth inhibition to when combined 
with chemotherapies. By contrast, in medulloblastoma R1507 showed strong additive effects with 
cisplatin not only in MB cells which were initially sensitive to R1570 (PFSK), but also MB cells 
which were insensitive to R1507 as a single agent (UW228). Analysis of the mechanisms of action 
revealed that R1507 inhibits cell growth by attenuation of the AKT/mTOR signaling pathway in 
neuroblastoma and medulloblastoma cells. Similar observations were obtained by inhibition of IGF-
1R with NVP-AEW541 [20]. Interestingly, the concomitant treatment with R1507 and inhibitors of 
the RTK/PI3K/mTOR signaling could not overcome the resistance of insensitive DAOY cells, resulted 
in combination with gefitinib and imatinib even in negative effects, compared to when they were used 
as single agent. Generally, DAOY cells responded to single treatments targeting the RTK/PI3K/mTOR 
signaling, such as IGF-IR (NVP-AEW541), EGFR (gefinitib, erlotinib), PDGFR and c-Kit (imatinib), 
and mTOR (rapamycin). Cell growth of the cell line UW228 was mostly not affected or higher 
concentrations were needed to induce a response by use of the same agents. 
Our previous work using RNAi targeting of classIA PI3K isoforms has revealed that targeting these 
enzymes in neuroblastoma and medulloblastoma cell lines can induce apoptosis and decrease cell 
proliferation (277, 284). These results are supported by the findings presented here, which show that 
PIK75 displays a broad anti-proliferative activity in neuroblastoma cell lines. Also in 
medulloblastoma, we observed that PIK75 has anti-proliferative activity, but one cell line (UW228) 
was rather resistant to the drug. The exact mechanism(s) underlying this observation are at present 
unclear, but may be caused by an enhanced activation of Erk1/2. A decrease in activity of class IA 
PI3K inhibitors has been observed previously in cell lines with mutant KRAS and attributed to the 
enhanced activation of the Erk pathway (368). The combination of PIK75 with chemotherapy 
(doxorubicin and etoposide) showed enhanced cell growth inhibition as compared with single agent 
treatment in neuroblastoma cell lines. Consistent with these findings, a recent report demonstrated that 
PI103 a dual inhibitor against p110α and mTOR strongly synergizes with various chemotherapeutics 
including doxorubicin, etoposide and cisplatin (369). In medulloblastoma, our previous work has also 
demonstrated the anti-proliferative effects for PIK75 in combination with different chemotherapeutic 
agents (284). 
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Because neuroblastoma and medulloblastoma cells may express a variety of different growth factor 
receptors, we and others have postulated that targeting individual receptors may not always provide 
the best therapeutic option (277, 284, 326). To overcome this problem, an alternative approach was 
proposed, which is based on targeting downstream signaling molecules that are regulated by different 
growth factor receptors to transmit the proliferative message. Our findings support this approach, since 
we observed that generally a bigger number of NB and MB cell lines most likely responded to PIK75 
than to R1507. Importantly, PIK75 effectively inhibited proliferation in a chemoresistant 
neuroblastoma cell line in a comparable manner as in the parental cell line, demonstrating its broad 
anti-proliferative activity. By contrast, R1507 was ineffective in the chemoresistant neuroblastoma 
cells, which was most likely caused by reduced expression of the IGF-1R. The activation status of the 
AKT/mTOR pathway was also found to be reduced in the chemoresistant cells, pointing that this 
signaling pathway may not be responsible for the acquired chemoresistant phenotype of the cells. 
However, our previous findings in medulloblastoma cells showed elevated levels of phosphorylated 
Akt as a consequence of short time exposure with doxorubicin (284). The molecular mechanisms 
underlying these observations are at present unclear, but may be of importance, in view of the fact that 
some clinical trials have been initiated with R1507 in patients previously treated with chemotherapy 
(370). 
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Supplementary Data 
 
 
Supplementary Figure 7. Neuroblastoma WAC2 cells treated with R1507 in combination with chemotherapy, 
incubated for 48 hours. Already shown to be insensitive to R1507 alone (Fig. 1A), WAC2 cells are here shown 
also to be insensitive to R1507 in combination with chemotherapeutic agents A) doxorubicin and B) cisplatin. 
Error bars represent ±S.D. of means from 1 to 2 experiments, each with 8 replicates. For combination 
experiments with R1507-sensitive neuroblastoma cell lines, see Figure 4. 
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5 CONCLUSION & FUTURE PERSPECTIVE 
5.1 TARGETING PI3K SIGNALLING IN SMALL CELL LUNG CANCER 
In the present study, we demonstrated the class IA PI3K isoform p110α to be a critical mediator in 
controlling SCLC tumour growth, proliferation, and survival processes.  
The PI3K/Akt/mTOR pathway has been demonstrated to play a key role in SCLC cell proliferation, 
survival, chemoresistance and migration. Mutations in PIK3CA and gene amplification were reported 
in primary SCLC, as well as increased expression of PIK3CA at the mRNA and protein level. Broad 
specificity PI3K/mTOR inhibitors have shown anti-tumour activity in SCLC models in vitro and in 
vivo (118).  
Thus, we sought to investigate the potential of isoform-specific inhibitors and RNAi targeting class IA 
PI3K isoforms on SCLC cell responses.  
We found, that cell viability and the activation status of classical PI3K downstream targets were 
highly impaired by agents and RNAi approaches targeting p110α, compared to those targeting p110β 
or p110δ, which had less or no effect, suggesting a crucial role for p110α in SCLC.  
Furthermore, p110α silencing resulted in G1 cell cycle arrest, affected expression of proteins 
controlling cell cycle progression and to sensitization of commonly used chemotherapeutic agents, 
such as etoposide and carboplatin.  
The important role of p110α and the impact of its inhibition on SCLC survival and tumour growth 
found in our in vitro studies were additionally confirmed in an in vivo model. Previously, a significant 
correlation of VEGF expression and vessel density has been demonstrated in SCLC xenografts and 
high levels of VEGF were reported to correlate with tumour stage, disease progression, and resistance 
to chemotherapy, thus leading to a poorer outcome in SCLC patients. We found that angiogenesis in 
vivo and expression of VEGFA in vitro were decreased upon p110α inhibition, suggesting p110α 
signalling to be involved in SCLC angiogenesis.  
High expression levels of p110α in the SCLC cell lines under study had been demonstrated before, 
suggesting its involvement in SCLC biology. Indeed, we also found overexpression of both p110α and 
p110β in SCLC patient tissue samples, when compared to normal lung tissue. Interestingly, advanced-
staged SCLC was accompanied by increased overexpression of p110α, further pointing out its 
selective role in SCLC.  
In view of these observations, we hypothesized that p110α may control the expression of a selective 
subset of genes implicated in SCLC cell proliferation and/or survival. The comparative DNA 
microarray analysis of SCLC cell lines in which either p110α or p110β were targeted by selective 
inhibitors identified such a gene subset.  
Among the widespread affected biological categories we identified and validated the Bcl2 family of 
proteins as a downstream target of p110α, which displayed an imbalance in the expression of anti-
apoptotic and pro-apoptotic Bcl2 proteins upon p110α silencing. The Bcl2 family of proteins has been 
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previously shown to play a crucial role in the survival of SCLC cell lines in vitro and in vivo (227). 
Bcl2 inhibition was already shown to suppress SCLC growth and survival which is consistent with the 
results presented in this study.  
In view of the overexpression of p110α in SCLC tumours, the observation that Bcl2 expression was 
elevated in primary SCLC further supports the model of Bcl2 as a downstream target of p110α in 
SCLC. Bcl2 is a key regulator of both apoptosis and autophagy (306) and its transcription is known to 
be regulated by the transcription factor NFκB. Indeed, we did not only find induction of SCLC cell 
death via apoptosis and autophagy by the p110α inhibitors, but also a deregulated transcriptional 
network of NFκB. Thus, revealing the transcription factor NFκB being a downstream target of p110α 
and suggesting an essential role of the p110α/NFκB signalling axis mediating pro-survival signals in 
SCLC.  
Interestingly, PIK3CA transcription has been already demonstrated to be positively controlled by the 
NFκB (371), thus, giving rise to the speculation of the existence of feedback loops and their regulation 
in SCLC. In contrast, the tumour suppressor p53 acts as negative regulator on PIK3CA transcription. 
The majority of SCLC tumours display mutations in the TP53 gene (90%) and dys-functionality of its 
protein product p53 (40-70%), which could lead to the assumption of a correlation between the 
activation and overexpression of p110α and the dysfunctional expression of p53 in SCLC. 
We have previously evaluated the mTOR inhibitor everolimus in SCLC cell lines and found that it was 
effective in a subset of SCLC cell lines characterized by activation of the Akt/mTOR pathway and low 
expression levels of anti-apoptotic Bcl2 family proteins (227). In view of the present results obtained 
with isoform-selective inhibitors of p110α, it can be speculated that these agents may be more potent, 
since they induce a down-regulation of Bcl2 and of the activity of the Akt/mTOR pathway. 
Our previous work has shown that the class IA PI3K isoform p110δ contributes to cell proliferation 
and survival in neuroblastoma by controlling the mTOR pathway activation and the expression levels 
of anti-apoptotic Bcl2 family proteins. Over-expression of p110δ was found in a subset of primary 
neuroblastoma and cell lines, and p110δ was essential for signal transduction by receptor tyrosine 
kinases, such as the IGF-IR and EGFR (277). In contrast, in SCLC cell lines, p110α appears to play a 
more particular role for mediating RTK signalling, which may explain the impact of agents targeting 
this isoform on SCLC proliferation and survival. A previous report has shown that the activity of any 
class IA PI3K isoform can maintain cell survival (227). Therefore, the relative importance of class IA 
PI3K isoforms in selected cancer types may be, in part, attributed to differences in expression levels.  
Taken together, targeting PI3K p110α signalling may represent an attractive novel approach to 
develop novel therapies for SCLC. Indeed, there now exist several pharmacological inhibitors of this 
isoform, which will soon enter clinical trials in oncology, and could, in the future, be developed as 
new drugs for SCLC.  
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5.2 TARGETING THE IGF-IR/PI3K SIGNALLING AXIS IN EMBRYONAL TUMOURS 
In the present study, we demonstrated that targeting the class I PI3K isoform p110α in embryonal 
tumours clearly displays advantage as anti-cancer approach over the inhibition of the IGF-IR in vitro.  
We have evaluated the anti-proliferative activity of the humanized anti-IGF-IR antibody R1507 in the 
embryonal tumours neuroblastoma and medulloblastoma in vitro. By targeting the IGF-IR/PI3K 
signalling axis we observed cell line-specific responses and for some cell lines a strong decrease in 
cell proliferation. 
As a single agent, R1507 was effective in a subset of neuro- and medulloblastoma cell lines, while a 
majority of cell lines did not respond. The response profile of R1507 in neuro- and medulloblastoma 
was similar to the IGF-IR tyrosine kinase inhibitor in terms of the identity of the cell lines which were 
sensitive to the single agent. Additionally, the mechanisms of action revealed that R1507 inhibits cell 
growth by attenuation of the AKT/mTOR signalling pathway in neuroblastoma and medulloblastoma 
cells, as it was the case for NVP-AEW541 (372) Interestingly, NB cells which were sensitive to single 
agent R1507 could be sensitized to chemotherapeutic agents, which was also observed with NVP-
AEW541 (372). However, R1507-resistant neuroblastoma cells, showed also no additive effects in cell 
growth inhibition to when combined with chemotherapies.  
By contrast, concomitant treatment with R1507 and cisplatin resulted in strong additive effects not 
only in sensitive but also in MB cells which were initially resistant to R1570 as single agent.  
Surprisingly, the concomitant treatment with R1507 and inhibitors of the RTK/PI3K/mTOR signalling 
could not overcome the resistance of insensitive DAOY MB cells, caused even negative effects in 
combination with gefitinib and imatinib, even though positive responses could be observed by the use 
of single agent RTK inhibitors.  
Our previous work using RNAi targeting of class IA PI3K isoforms has revealed that targeting these 
enzymes in neuroblastoma and medulloblastoma cell lines can induce apoptosis and decrease cell 
proliferation (227). These results are consistent with the findings presented here, which show that 
p110α inhibition displays a broad anti-proliferative activity in NB and MB cell lines, with one single 
MB one cell line being rather resistant to the drug. The exact mechanism(s) underlying this 
observation still remain unclear, but may be caused by an enhanced activation of the MAPK/Erk1/2 
signalling. A decrease in activity of class IA PI3K inhibitors has been observed previously in cell lines 
with mutant KRAS and attributed to the enhanced activation of the Erk pathway (227).  
In MB, our previous work has demonstrated the anti-proliferative effects for p110α inhibition in 
combination with different chemotherapeutic agents (227). Here, these results could be confirmed in 
NB. The combination of PIK75 with chemotherapy resulted in enhanced cell growth suppression as 
compared with single agent treatment. Consistent with these findings, a recent report demonstrated 
that PI103 a dual inhibitor against p110α and mTOR strongly synergizes with various 
chemotherapeutics including doxorubicin, etoposide and cisplatin (227).  
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We observed, that generally a larger number of NB and MB cell lines responded to PIK75 than to 
R1507. This might be due to the activation of PI3K downstream of numerous RTKs expressed in NB 
and MB, suggesting that targeting one single RTK may not be the best treatment approach (227). 
Additionally, p110α inhibition caused anti-proliferative effects in a chemoresistant NB cell line, 
whereas R1507 was ineffective, which was most likely caused by the reduced expression of the IGF-
IR. The activation status of the AKT/mTOR pathway was also found to be reduced in the 
chemoresistant cells, pointing that this signalling pathway may not be responsible for the acquired 
chemoresistant phenotype of the cells. However, our previous findings in medulloblastoma cells 
showed elevated levels of phosphorylated Akt as a consequence of short time exposure with 
doxorubicin (227). The molecular mechanisms underlying these observations are at present unclear, 
but may be of importance, in view of the fact that some clinical trials have been initiated with R1507 
in patients previously treated with chemotherapy (370). 
 
5.3 CONCLUDING REMARKS 
The importance of the PI3K signalling pathway, which controls cell survival and proliferation 
processes, and its impact on cancer development have been demonstrated in the last two decades in 
various human neoplasms. The escape of atypical cells from the normal growth control, in addition to 
deregulation of PI3K signalling and closely related pathways drives cells into a malignant and invasive 
phenotype. Deregulation of these pathways results in a lack of response to negative growth regulatory 
signals and the continuous presence of positive signals involving the RTK/PI3K/Akt pro-survival axis. 
Therefore, targeting RTK/PI3K/Akt signalling with small molecule inhibitors has become an 
interesting and promising approach in cancer therapy development. Indeed, there are now several 
targeted agents directed against the PI3K/Akt/mTOR pathway which have entered clinical trials in 
numerous cancer types. The use of targeted therapies in addition to commonly administered 
chemotherapy could improve clinical benefit for patients, especially in patients with cancer types 
depending on the presence of one particular oncogene. Because cancer cells may express a variety of 
different growth factor receptors it was postulated that targeting individual receptors may not always 
provide the best therapeutic option. To overcome this problem, an alternative approach was proposed, 
which is based on targeting downstream signalling molecules that are regulated by multiple growth 
factor receptors to transmit their proliferative message. The findings presented here and in numerous 
studies support this model. Additionally, even though the whole “cancer cell machinery” is not yet 
adequately understood and there exist many “missing links”, the growing knowledge about genetic 
alterations driving cancer development and maintenance provides the possibility to identify predictive 
molecular markers, which are of importance for further therapy development and future translation to 
clinical trials. 
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6 LIST OF ABBREVIATIONS 
4EBP1   eukaryotic translation initiation factor 4E binding protein 1 
Akt  v-akt murine thymoma viral oncogene homolog 1 
AT/RT   atypical teratoid/rhabdoid tumors 
ATP   adenosine triphosphate 
Bad  Bcl2-associated death promoter 
Bax  Bcl2-associated X protein 
Bcl2  B-cell leukemia/lymphoma 2 
BclXL   B-cell leukemia/lymphoma extra large 
BIRC5   survivin 
cDNA  complementary DNA 
c-Met  mesenchymal epithelial transition factor receptor (hepatocyte growth factor receptor) 
CNS  central nervous system 
EGFR   epidermal growth factor receptor 
ErbB2  erythroblastic leukemia viral oncogene homolog 2 
Erk1/2   extracellular signal-regulated kinase 1/2 
GPCR   G protein-coupled receptor 
GSK  glycogen synthase kinase 
HGF   hepatocyte growth factor 
IGF  insulin-like growth factor 
IGFBP  insulin-like growth factor binding protein 
IGFIR  insulin-like growth factor I receptor 
INSS   International Neuroblastoma Staging System 
IR  insulin receptor 
IRS  insulin receptor substrate 
LOH  loss of heterozygosity 
MAPK  mitogen-activated protein kinase 
mRNA   messenger ribonucleic acid 
mTOR   mammalian target of rapamycin 
mTORC1  mammalian target of rapamycin complex 1 
mTORC2  mammalian target of rapamycin complex 2 
MB  medulloblastoma 
NB  neuroblastoma 
NSCLC  Non-small cell lung cancer 
PDGF   platelet-derived growth factor 
PDK1   phosphoinositide-dependent kinase 1 
PIK3C  genes encoding for the PI3K 
PI   phosphatidylinositol 
PI3K   phosphatidylinositol 3-kinase 
PI(3)P   phosphatidylinositol 3-phosphate 
PI(3,4)P2  phosphatidylinositol (3,4)-bisphosphate 
PI(3,4,5)P3  phosphatidylinositol (3,4,5)-trisphosphate 
PI3K   Phosphatidylinositol 3-kinase/phophoinositide 3-kinase 
PTEN   phosphatase and tensin homolog 
qRT-PCR  quantitative real-time PCR 
Rheb   Ras homologue enriched in the brain 
RNAi   RNA interference 
RT   radiotherapy 
RTK   receptor tyrosine kinase 
S6K   ribosomal protein S6 kinase 
SCF   stem cell factor 
SCLC   small cell lung cancer  
SH2   Src homology-2 
Shh   sonic hedgehog 
shRNA   small-hairpin RNA 
siRNA   small-interfering RNA 
TSC1   TSC2 tuberous sclerosis complex 1, 2 
WHO   World Health Organization 
Wnt   wingless 
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Abstract
Lung  cancer  is the  leading  cause of  cancer-related  mortality  worldwide  and  more  than 1  million  people  annually  die  in consequence  of lung
cancer.  Although  an  improvement  in lung  cancer  treatment  could  be  achieved,  especially  in the last  decade,  the  development  of  additional
therapeutic  strategies  is urgently  required  in  order  to provide  improved  survival  benefit  for patients.  Lung  cancer  formation  is  caused  by  genetic
modifications  commonly  caused  by  tobacco  smoking.  Numerous  studies have  demonstrated  the  role  of  extracellular  growth  factors  in lung
cancer  cell  proliferation,  metastasis,  and  chemoresistance.  Mutations  and  amplifications  in  molecules  related  to  receptor  tyrosine  signalling,
such  as  EGFR,  ErbB2,  c-Met,  c-Kit,  VEGFR,  PI3K,  and  PTEN  are  only  some  of the alterations  known  to  contribute  to the development  of lung
cancer.  The  phosphoinositide  3-kinase  (PI3K)  pathway,  fundamental  for cell  development,  growth,  and  survival,  is known  to be  frequently
altered  in  neoplasia,  including  carcinomas  of  the lung.  Based  on  the high  frequency  of  alterations,  which  include  mutations  and  amplifications,
leading  to  over-activation  of  certain  upstream/downstream  mediators,  targeting  components  of  the  PI3K  signalling  pathway  is considered  to
be  a  promising  therapeutic  approach  in  cancer  treatment.  In  this  article  we will  summarize  the current  knowledge  about  the involvement  of
PI3K  signalling  in  lung  cancer  and  discuss  the development  of  targeted  therapies  involving  PI3K  pathway  inhibitors.
©  2011  Elsevier  Ireland  Ltd.  All  rights  reserved.
Keywords: Non-small cell lung cancer; Small cell lung  cancer; Phosphoinositide 3-kinase; Akt; Mammalian target of rapamycin
1.  Introduction  –  lung  cancer
Lung cancer  is still  the  leading  cause of  cancer-related
mortality in the  Western world  and  every  year  approximately
1.4 million  people  are  diagnosed  with lung  cancer  [1].  Most
∗ Corresponding author. Tel.: +41 31  308 8029; fax: +41 31 308 8028.
E-mail address: alexandre.arcaro@dkf.unibe.ch (A. Arcaro).
commonly,  lung cancer  development  is related  to  multi-
ple genetic changes  caused  by  exposure to carcinogens,  for
instance those  found  in tobacco  smoke.  Lung  cancer  can be
divided  into  two main  subtypes  – non-small  cell lung  car-
cinoma  (NSCLC)  and small-cell  lung  carcinoma  (SCLC).
These subtypes  differ  not only in frequency  of occurrence
and prognosis,  but also  in biological  behaviour,  histological
background,  and  characteristic  genetic alterations.
1040-8428/$ – see front matter ©  2011 Elsevier Ireland Ltd. All rights reserved.
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Non-small  cell  lung cancer  accounts  for  approximately
85% of  all lung cancer  cases,  and is  commonly  related to
tobacco smoking.  In  9–15% of cases  it  is caused  by  exposure
to other  carcinogenic  factors,  such  as polycyclic  hydrocar-
bons, asbestos,  or radon.  Squamous  cell carcinoma  (SCC),
adenocarcinoma (AC),  and large  cell lung carcinoma  (LCLC)
are the three  most  common  types  of NSCLC.  The  current
treatment of NSCLC  includes surgery,  radiotherapy,  and
platinum-based chemotherapy.  At  the  time  of presentation
at least 40%  of patients  are  diagnosed  with  an advanced
stage of disease  [2], whereas  less  than 25% show  early  stage
disease (stage  I)  [3]. Surgery,  with  lobectomy  or pneumonec-
tomy being  the most  common  surgical  resections,  remains  the
standard  of care  for  patients  with  early  stage  NSCLC able
to safely  undergo  surgery  [3]. The  treatment  of  advanced
NSCLC, which  is  mostly  inoperable  and  therefore  incurable,
is aimed  at  controlling  the  disease  to prolong  life  and  sustain
life  quality,  and  commonly  includes  a combination  of  radio
and  chemotherapy.  An increasing  progress in  the optimisation
of chemotherapeutic  regimens  in combination  with  targeted
therapies  against individually  activated  oncogenes  has  led  to
an improvement  of  NSCLC  outcome,  but  the  median  5-year
survival rate  nowadays  is  still  only 15% [4].
Small  cell  lung  cancer  accounts  for  approximately  15%
of all lung  cancer  cases  and  is  almost  entirely  related  to
tobacco smoking  [5].  It  is characterized  by  rapid  growth
and early  metastasis.  Thus,  surgical  resection  is  rarely  possi-
ble.  Chemotherapy  with  etoposide  and platinum-based  agents
and  in  some  cases  also  radiotherapy  remain as the  treatment
options of choice  [5–7]. Although SCLC  initially  responds
to therapy  most  of the patients  relapse.  Due  to  metastasis  and
resistance  to  chemotherapy  the clinical  outcome  is  very  poor
and  SCLC  patients  show  an  overall  5-year  survival of less
than 5%  [6].
The  molecular  mechanisms  responsible  for lung  cancer
formation have  been  extensively  studied. A striking  event
in the  development  of cancer  is  the  escape of atypical  cells
from the normal  growth  control turning into  a malignant  and
invasive  phenotype.  A growing  body  of evidence  suggests
that receptor  tyrosine  kinases  (RTK)  and  their  downstream
effectors possess  a high  oncogenic  capacity  and that  lung
tumours  selectively  up-regulate different  signalling  path-
ways  involving  RTKs.  The  deregulation  of survival  pathways
downstream of  several  RTK,  such as  EGFR, c-Met,  c-Kit,
VEGFR or IGF-1R  is  associated  with  lung cancer  progres-
sion [8,9].  Deregulation  of these  pathways  results  in  a lack  of
response  to  negative growth  regulatory  signals and  the con-
tinuous  presence  of  positive  signals  involving  the  PI3K/Akt
pro-survival  pathway  that  controls  growth,  motility  and inva-
sion.
2. Introduction  – PI3K/Akt  signalling
The phosphoinositide  3-kinase  (PI3K)  pathway,  funda-
mental for  cell  development,  growth,  and  survival,  is  known
to play  an important  role  in  development  of  neoplasia.  Its
deregulation  and contribution  to  carcinogenesis  has been
well  documented  and reviewed  in  the  past,  including  in  car-
cinomas  of the  lung.  The  PI3Ks  are  lipid kinases,  which
can be activated  downstream  of  receptor  tyrosine  kinases
(RTKs). The  binding  of specific  growth  factors  to their
corresponding receptors  leads  to activation  of several  down-
stream  signalling  cascades  through  important  mediators,  such
as PI3K/Akt/mTOR  or Ras/Raf/MEK/Erk,  triggering  sig-
nals  to  promote  cell proliferation,  prevent  apoptosis,  and
increase  cell  migration.  Targeting  different  molecules  of
the RTK/PI3K  pathway  with pharmacological  inhibitors  has
already been shown  to be a promising  approach  in cancer
treatment [10–12].  Inhibitors  of  the  RTK/PI3K  pathway  have
reached  the clinical  stage  in some  cases  and the development
of new small  molecule  inhibitors  is  still  an  ongoing  process.
Activation of PI3K  takes place  by  binding  of various
growth factors  to  their  specific  receptors.  Class  IA PI3K
are recruited  to RTKs at  the plasma  membrane  as  het-
erodimers, consisting  of  a  regulatory  (p85;  Fig.  1) and a
catalytic subunit (p110;  Fig.  1).  The  p85  regulatory  sub-
unit binds  to  phosphotyrosine  residues  in the  cytoplasmic
domain of  RTKs  through  its  Src-homology  2  (SH2)  domains,
which leads  to PI3K  activation.  Then  the second  mes-
senger phosphatidylinositol-3,4,5-trisphosphate  (PIP3) is
generated  through  phosphorylation  of phosphatidylinositol-
4,5-bisphosphate  (PIP2).  A  direct  antagonist  of  PI3K  is the
phosphatase  and tensin homologue  deleted  on  chromosome
10 (PTEN).  PTEN  directly  reverses  the activity  of PI3K  by
dephosphorylating  PIP3 into  PIP2 and therefore  plays  an
important  role  as a negative controlling  element  of  incom-
ing signals.  PIP3 transduces  activating  signals  by  binding
to pleckstrin  homology  (PH) domains  of proteins,  thereby
recruiting  them  to the  cell membrane.  One  centrally  impor-
tant  downstream  mediator  of the PI3K  signalling  cascade  is
the serine threonine  kinase  Akt. Akt  is  recruited  to  the  mem-
brane  via  PIP3 which  is  binding  to  its  PH  domain,  followed
by phosphorylation  leading  to  its activation  by  PDK1  (3-
phosphoinositide-dependent  kinase  1)  at  threonine  308  and
at serine  473  by  mTORC2  (mammalian  target  of rapamycin
complex  2).  Activated  Akt  then  mediates  signals  promoting
cellular growth  and  survival  and suppresses  pro-apoptotic
signals. Akt  phosphorylates  several  intracellular  proteins,
including forkhead  box  O  transcription  factors  (FoxO),  the
BCL2-associated  agonist  of cell death  (BAD),  and  the glyco-
gen synthase  kinase  3 (GSK3),  to  promote cell  cycle  entry
and cell  survival.  The  proteins  TSC1  (Hamartin)  and TSC2
(Tuberin) form a  complex  that  inhibits  the activity  of  the  small
G-protein  ras  homologue  enriched  in brain  (Rheb),  which  is
necessary  for  mTORC1  activation.  The  Akt-mediated  phos-
phorylation  of  TSC2 releases  Rheb  from  its  inhibited  state.
Rheb  then  accumulates  in GTP-bound  state  and can directly
activate  mTORC1,  which  phosphorylates  the  p70S6  kinase
(S6K1)  and  the  eukaryotic  translation  initiation  factor  4E
binding  protein  1  (4EBP1), leading  to increased  protein  trans-
lation (Fig.  1).
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Fig. 1. PI3K Signalling.
3.  Tobacco  smoking  and  PI3K  signalling  activation
Lung  cancer  development  is  in  most  of the  cases  related
to smoking,  thus,  raising  the question  whether  components
of tobacco smoke are  involved  and  which  pathways  are
activated during  the carcinogenic  processes.  As  a tradi-
tional model  of tobacco-related  tumourigenesis  the theory
has been established  that  tobacco  components promote  car-
cinogenesis  through  multistep processes  which  lead  to the
accumulation  of  mutations  in key  genes,  such as  TP53
or KRAS.  These  genetic aberrations  may cause  tumour
formation through  circumvention  of  cell  damage-induced
cell death.  Additionally,  nicotine  and the  tobacco-specific
carcinogen  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NKK),  both  important  components  of tobacco  smoke,  were
associated  with  early  biochemical  events  occurring  in  cells
exposed  to  tobacco  smoke [13–15].  In an in  vitro  model
of normal  primary  human  airway epithelial  cells  (i) nor-
mal human  bronchial  epithelial  cells (NHBEs),  precursor  of
SCC; (ii)  small  airway epithelial  cells (SAECs),  precursor
of AC activation  of  the  PI3K/Akt  pathway was demon-
strated to  be an early  event  promoting  cellular  survival  due
to  exposure  to  nicotine and  NKK, suggesting  a  molecu-
lar mechanism  to overcome  cell damage-induced  apoptosis
involved in  lung  cancer  development  [15].  Consistent  with
these results  another  study  identified PI3K  pathway  activa-
tion in  normal and premalignant  bronchial  airway  epithelial
cells of smokers  with  airway  lesions,  thus  supporting  the
hypothesis that  PI3K  signalling  activity  is  induced before
the development  of lung  cancer  [16].  Nicotine  was  also
shown to  increase  cell  proliferation  and survival  accom-
panied by  activation  of  the  PI3K/Akt/mTOR  pathway in
NSCLC and  SCLC  cells  [13,14],  and was associated  with
NFkB-dependent  resistance  to  chemotherapeutic  drugs [14].
Expression  of  nicotinic  acetylcholine  receptors  (nAChRs),
which  respond  to nicotine  and  NKK  and activate  Akt  through
PI3K, was  found  in normal and  in  lung cancer  cells  [13–15].
Another group  reported  that  nicotine  increased  the  expression
of peroxisome  proliferator-activated  receptors  (PPARb/d),
which  belong  to the  nuclear  hormone  receptor  superfamily  of
ligand-dependent transcription  factors, in  a nAChR-mediated
PI3K/Akt/mTOR-dependent  manner,  and thereby  promoted
NSCLC cell growth  [17]. Furthermore,  PI3K/Akt  activation
in response  to  nicotine  exposure  led to phosphorylation  of
A.  Wojtalla, A.  Arcaro / Critical Reviews in Oncology/Hematology 80 (2011) 278–290 281
Bax  through  Akt,  shortening  its half-life  and abrogating the
pro-apoptotic activity  of Bax. These  events resulted  in the
promotion of  cell survival  [18].  Bad, another  pro-apoptotic
member  of the  Bcl-2  family,  was shown  to undergo  multi-site
phosphorylation involving  nicotine-induced  activation  of the
MAPKs Erk1/2,  PI3K/Akt,  and protein  kinase  A  (PKA), lead-
ing to suppression  of  apoptosis [19].  Both  studies could  show
that  inhibition  of  the  PI3K/Akt  pathway  abrogated nicotine-
triggered anti-apoptotic  signals  and blocked  lung cancer  cell
growth, suggesting  that  PI3K/Akt  activation  is  an important
step in nicotine-induced  cancer  cell survival  [18,19].
4. The  role  of PI3K signalling  in  non-small  cell lung
cancer
Over-expression of both  the  regulatory  subunit p85  and
the catalytic  p110a subunits  of  PI3K  was  demonstrated  in
primary lung carcinomas  and their  metastases,  but not in nor-
mal lung  tissue samples  and  was  linked  to  lower  grades  of
tumour  differentiation  [20].  Additionally,  genomic  amplifica-
tion of PIK3CA was shown  to occur  in a substantial  number
of NSCLC  tumours  (70%  squamous  cell  carcinoma,  38%
large cell carcinoma,  19%  adenocarcinoma)  and pre-invasive
lesions, suggesting  the  involvement  of  the  PI3K/Akt  pathway
in early lung  cancer  progression  [21].  However,  mutations
in the PIK3CA  gene seem  to be rare  in  NSCLC  (∼2% pri-
mary tumours;  ∼5% NSCLC  cell lines) [22].  Downstream
mediators of the  PI3K/Akt  pathway, like  Akt, mTOR,  or the
tumour  suppressor  PTEN,  are  also  genetically  (and epige-
netically) altered  or deregulated  in NSCLC,  which  supports
the importance  of the  PI3K/Akt  pathway  for proliferative
and anti-apoptotic  signalling  in  NSCLC.  Several  groups  have
reported  that  Akt  can  be activated  by  either  amplification  of
upstream molecules  of the PI3K  pathway,  or  directly  through
over-expression or  over-activation  of the Akt  protein  itself.
Notably,  EGFR  mutations  led  to  activation  of anti-apoptotic
pathways  through  Akt  and Stat  pro-survival  signalling,  but
not Erk signalling  [23,24].  Expression  of  all  three  isoforms
of Akt  (Akt1/2/3)  was present in normal  and tumour  tissue  of
the lung  [25].  Only 2.5%  of  NSCLC tumours  harboured  muta-
tions in  the  AKT2  gene,  which  could contribute  to  NSCLC
tumourigenesis [26].  Therefore,  deregulation  of  the  pathway
seems to  occur  more  frequently  at the post-transcriptional
level. PI3K-dependent  constitutively active  Akt  was  reported
in a panel  of NSCLC  cell lines  and correlated  with  cellu-
lar survival  and  resistance  to  chemotherapy  [27].  Increased
activation (phosphorylation)  of Akt  was  also  reported in pre-
malignant  and malignant  human  bronchial  epithelial  (HBE)
cells, but not in  normal  bronchial  cells  [28].  Additionally,
high levels  of  phosphorylated  Akt  (SCC  68%;  AC  62%)  were
detected  in tumour  tissue  samples  by  immunohistochemistry
[21,29–31],  supporting  PI3K  pathway  activation  as a progres-
sive event  in  lung  tumourigenesis.  Activation  of Akt  was  also
observed  in primary  NSCLC  lung  tumours,  suggesting  a role
of activated  Akt in  the conversion  of  a pre-malignant  lesion
to lung cancer  [29,30,32]. Moreover,  over-expression  or acti-
vation  of Akt  was reported to  be a poor  prognostic  factor
for NSCLC patients  with  primary  tumours  or stage  I  disease
[33,34].  Several  studies  have shown  that  Akt  over-activation
is associated  with low  expression  of the  tumour-suppressor
PTEN  and that  cells in which  the  PTEN  gene is deleted
or its expression  is  down-regulated  display constitutively
activated PI3K  signalling  [35–40].  PTEN  plays  an impor-
tant role  as negative regulator of the  PI3K/Akt  signalling
acting as direct antagonist  of  PI3K.  Mutations  or homozy-
gous deletion  of  the  PTEN  gene  frequently  occur  in  many
different cancers  but are rare  in  NSCLC  [41–44].  Instead,
reduced protein or  complete  loss  of  PTEN  protein  expres-
sion (70%)  has  been  described  in several  studies  [35,37].
The  hypothesis of  loss  of  heterozygosity  and epigenetic  alter-
ations,  such  as promoter  hypermethylation as regulators  of
PTEN  expression  in  lung  cancer  was replaced  by  the  idea
of transcriptional  or translational  mechanisms,  but the  exact
molecular  mechanism  still  remains  elusive  [35].  Another
downstream  target  of  PI3K  signalling,  the  mammalian  tar-
get of rapamycin  (mTOR),  was shown to be  activated  in
lung  cancer  cell lines  [32,45]  and  interestingly,  activation
occurred more  frequently  in  tumours  with genetic alter-
ations, such  as EGFR  mutations  or  PI3K/Akt  over-expression
[46]. Furthermore,  mTOR  phosphorylation  was  shown  to
increase with  malignant  progression  and  was  demonstrated
to be implicated  in the metastatic  development  of  NSCLC
in KRAS-mutated  models [47].  Additionally,  it  was shown
that PI3K/Akt  signalling  contributes  to  chemo  and radiother-
apy resistance  [27]  and  that, conversely,  NSCLC  cells with
resistance  to  the  tyrosine  kinase  inhibitor  gefinitib  show  an
increased  PI3K/Akt  activation  [5,39].  Accordingly,  target-
ing the  PI3K/Akt  pathway  in NSCLC  was  suggested  to  be
a promising  approach  to  impair  survival,  chemoresistance,
and metastasis.  Manipulation  of  Akt  activity  by  inhibition
of PI3K  with  the small molecule  inhibitors LY294002  or
wortmannin,  or  transfection  of kinase-dead  Akt  into  cells
with  highly  active  Akt  dramatically  increased  NSCLC  cell
sensitivity  to  chemotherapy-  or  radiation-induced  apopto-
sis [24,27].  Plant  flavonoids,  such  as  deguelin  were  shown
to selectively  block  Akt  activity  in  a PI3K-dependent  or
-independent  manner,  thereby  attenuating  the  activity  of
Bcl-2  by  increasing  the expression  of  proapoptotic  Bax
[28]. In genetic  mouse  models of oncogenic  KRAS-induced
lung cancer  bronchioalveolar  stem  cells (BACS),  expansion
and malignant  progression  could be  blocked by  pharma-
cological inhibition  of PI3K  with PX866  and  enhanced  by
genetic inactivation  of PTEN,  suggesting  PI3K  as  a  critical
mediator of BACS  expansion [48]. In  NSCLC  models car-
rying  an oncogenic  KRAS mutation,  NVP-BEZ235,  a dual
pan-class  I PI3K, mTORC1  and mTORC2  inhibitor,  had
anti-proliferative  effects  in vitro  and  in  vivo  and sensitized
the tumour  cells  to  the  pro-apoptotic  effects  of  radiotherapy
[49]. Another group reported that  murine lung cancers  driven
by  mutant  KRAS did  not  substantially  respond  to  single-
agent BEZ235  alone.  No  tumour shrinkage  was  observed,
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even though  decreased  Akt  phosphorylation  was  observed  by
Western blot  and immunohistochemical  analysis.  Combined
inhibition of PI3K  (BEZ235)  and MEK (ARRY-142886)
however,  resulted  in marked  synergistic  tumour regression
in this  KRAS-mutant  lung cancer  [50].  In the same  study,  a
mouse model  of lung  adenocarcinoma,  initiated  and main-
tained by expression  of  a somatic  mutation  in the  p110a
kinase domain  (H1047R), showed  marked  tumour regression
after treatment  with  the PI3K  pathway inhibitor  BEZ235  [50].
Therefore,  PI3K  inhibition  could  be  a promising  approach  in
lung cancer  tumours  driven  by  PIK3CA mutations,  and,  in
combination with  MEK  inhibitors,  it  could  also  be useful  in
KRAS-mutated lung cancers,  suggesting  that  KRAS-mutant
lung cancers  depend on  both  PI3K  and MAPK  signalling
[50]. This  hypothesis was  confirmed  by  another  group using
a chemo-genomics  approach  in a  panel  of 84  NSCLC  cell
lines and  associating  specific  genetic alterations  with PI3K
or MAPK  pathway  activation  [51].  It  was shown  that  tumours
with genetically  activated  RTKs depend  on  PI3K  signalling,
whereas mutations  in the RAS/RAF  axis  lead to a depen-
dency on MAPK  signalling  [51].  A  study  in  NSCLC  models
with activating  mutations  in the  epidermal  growth  factor
receptor (EGFR)  could  not  detect induction  of apoptosis
when cells  were  treated  with the  dual  PI3K/mTOR  inhibitor
BEZ235, in  contrast  to  HER2-amplified  breast cancers.  How-
ever, apoptosis  was  induced  in these  EGFR-addicted  cancers
through  simultaneous  inhibition  of  PI3K/mTOR  (BEZ235)
and MEK  (AZD6244)  in vitro  and  tumour shrinkage  could
be observed  in vivo,  suggesting that  simultaneous  inhibi-
tion of PI3K/mTOR  and MEK/ERK  pathways  could also  be
effective  in EGFR-addicted  lung  cancers  [52].  Another  study
showed that  inhibition  of mTOR  signalling  with  rapamycin
alone induced  the  pro-survival  PI3K/Akt  pathway in  NSCLC
cells, whereas  LY294002  suppressed  this effect,  supporting
the importance  of  PI3K  in NSCLC [53].  It  was  also  reported
that the PI3K  and MKK4/JNK  (mitogen-activated  protein
kinase kinase-4/c-Jun  NH2-terminal  kinase)-dependent  path-
ways  cooperate  to maintain  cell  survival  in  wild  type  PTEN
NSCLC cells  and that  simultaneous  inhibition  of both path-
ways  increased  apoptosis  compared  to  targeting  one pathway
alone [54,55].  Accordingly,  another  group reported  activator
protein-1  (AP1) and PI3K/Akt-dependent  growth  in a panel
of NSCLC  cells.  In this study  simultaneous inhibition  using
a double-negative mutant  of c-Jun  (TAM67)  and LY294002,
did not result  in  the induction of apoptotic  signals  [56].  Taken
together, these  data suggest  that  up- and  de-regulation  of  the
PI3K/Akt  pathway  play  a significant  role  in  development,
growth, and  chemoresistance  of NSCLC,  but also  indicate
the importance  of closely related  pathways.
5. The  role  of  PI3K  signalling  in small  cell lung
cancer
Small cell  lung  cancer  (SCLC)  accounts  for  approxi-
mately  15%  of all  lung  cancers,  with  90–95% of affected
individuals  dying  of  the  disease  within  5 years [5].  This
type of  lung  cancer  is initially  a highly  chemotherapy-  and
radiotherapy-responsive  disease.  However,  the initial  ther-
apeutic response  is followed  by  relapse  and progressive
development  of chemotherapy  resistance,  and  therefore  the
outcome  is  still  very  poor  [57,58].  Numerous  genetic  and
molecular  alterations  have  been  reported  to  be associated  with
the development  of  SCLC,  including  autocrine  signalling
loops, oncogene  activation  and loss  of tumour-suppressor
genes [5]. These  genetic  and molecular  aberrations  result
in a lack  of response  to  negative growth regulatory  signals
and the  continuous  presence  of  positive  signals  that  regu-
late growth,  motility,  and  invasion.  Mutation  in  the  PIK3CA
gene, known  as  one of the most  common  genetic  alterations
present in  human  cancers,  were found in primary  SCLC
(13%) and in SCLC  cell lines (23%)  [59].  Another  study  per-
formed in 2008  failed  to detect  any mutations  in  the exons
9 and 20  of PIK3CA,  but reported PIK3CA  copy number
gains (4.7%),  which  correlated  with higher  expression  of
activated Akt  in  SCLC  cell lines [22]. Chromosome  3q26-
ter amplification  including  the  PIK3CA gene locus  was  also
shown in 67% of  SCLC  tumour  samples  [21].  A  recently
published study  showed  that  genes  encoding  components
of the  RTK/PI3K/mTOR  axis  and  apoptosis-regulating  pro-
teins harbour  high  frequencies  of copy number  alterations  in
both SCLC  tumours  and SCLC  cell lines [60].  Copy  num-
ber gains could  be  identified  in  the  PIK3CA  gene  in 76%  of
SCLC  tumours  and in  54%  of the SCLC  cell lines.  The  AKT1
gene was amplified  in 64% of tumours  and 39%  of cell  lines.
In addition,  the gene  FRAP1  encoding  the  downstream  tar-
get mTOR  was shown  to be  amplified  in more  than  50%  of
SCLC  tumours.  In  view  of  the loss  of  PTEN  in 76%  of SCLC
tumours, the members  of  the PI3K/Akt  pathway  were  sug-
gested  to  be  potential  drug  targets  of SCLC  in  this  study [60].
PTEN  plays  an important  role  as negative regulator  of the
PI3K/Akt  signalling  acting  as direct  antagonist  of  PI3K  and
is mutated  (∼15%)  or can be deleted  in  SCLC  [42–44].  Con-
stitutively activated  PI3K  was found  in  SCLC  cell lines and
shown to  promote  growth  and anchorage-independence  due
to high levels  of basal  Akt  and p70s6k activity  in  the  late 1990s
[61].  Differential  over-expression  of several  PI3K  isoforms
and their  contribution  to  Akt  activation  were  demonstrated  in
different SCLC  cell lines.  In particular,  cells  over-expressing
the PI3K  subunit p110a  showed  enhanced  Akt  activation
after growth  factor  stimulation.  PTEN  down-regulation  could
not be observed  as a plausible  reason  for  the  higher  Akt  activ-
ity [62].  Additionally,  in  tumour  tissue  samples  from  SCLC
patients high  levels  of  phosphorylated  Akt  (∼50–70%)  were
detected by  immunohistochemistry,  supporting  the  involve-
ment  of the  activated  pathway  in  disease progression  [21,63].
Other studies  related  integrin-induced  activation  of PI3K/Akt
signalling and adhesion  on  extra  cellular  matrix  (ECM)  with
resistance  to various  therapies  and protection  from apopto-
sis [15,64].  Adherent-growing  SCLC  cells,  which  are those
thought  to initially  survive  chemotherapy,  were reported  to
activate Akt  and  thus  to  increase  chemo  and radiotherapy
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resistance  by  mechanisms  involving  over-expression  of anti-
apoptotic  proteins  [65]. One  possible  mechanism  by  which
SCLC  cells  can escape  the effects  of cytotoxic  drugs  was
discovered in experiments  elucidating  SCLC  responses to  cis-
platin, a DNA-damaging  agent.  Surprisingly,  treatment  with
cisplatin  up-regulated  Akt  activation  and contributed  to  the
expression  of  pro-survival  proteins  in  SCLC  cells [66].
Several  autocrine  loops  have  been  described  in SCLC
cells, including  stem cell factor  (SCF)/c-Kit,  insulin-like
growth factor-I  (IGF-I)/IGF-IR,  and  hepatocyte  growth fac-
tor (HGF)/c-Met,  which  all  lead  to  the activation  of PI3K/Akt
signalling and promote  cell growth, survival, and  chemother-
apy resistance.  Direct  inhibition  of the PI3K/Akt  pathway
with the  PI3K-specific  inhibitor  LY294002  attenuated  these
effects  on cell growth,  led to  apoptosis,  and  enhanced  the
apoptotic  effects  of chemotherapeutic  agents, such  as  cis-
platin or etoposide  [64,67].  The  same  effect was observed
after inhibition  of Akt  by  expression  of  a dominant-negative
mutant  of this  protein  in  SCLC  cells [67].  Inhibition  of
Akt with  the  small-molecule  inhibitor  tricribine  (known  as
AKT/protein  kinase  B  signalling  inhibitor  2) resulted  in  sig-
nificantly  affected  growth  and colony  formation  and  pointed
out a higher  sensitivity  of  PIK3CA-mutated  SCLC  cells com-
pared  to  PIK3CA  wild-type  cells  [59]. Moreover, the use of
specific RTK inhibitors  for  c-Met,  c-Kit,  IGF-IR  [68–71],
alkaloids  (naltrindole;  opioid  receptor  antagonist)  [72]  or
antibodies  [73]  were reported  to impair  SCLC  cell survival
in a  PI3K/Akt-dependent  manner.
6. Targeting  the  PI3K signalling  in  lung  cancer  –
PI3K pathway  inhibitors  in clinical  trials
Targeting PI3K  signalling  with  pharmacological
inhibitors has become  an  important  experimental  therapeutic
approach.  Targeting  the  RTK/PI3K/Akt  cell survival axis
and its downstream  mediators  with small  molecule  inhibitors
(tyrosine kinase  inhibitors,  TKIs)  is,  beside  treating  cancer
with classical chemotherapeutical  agents,  one  of the most
prominent  approaches  used  in cancer  therapy  and has been
reviewed  in  the  past  for  various  human  cancers.  The  use
of specific  TKIs  has  led  to a progress  in cancer  treatment
options, especially  in  cancer  types  carrying  a particular
oncogene addiction,  which  leads  to  dependency  on  the
activity of one particular  tyrosine  kinase.  In lung  cancer
the knowledge  about  molecular  alterations  has predicted
the use  of TKIs,  which  are nowadays  used in  the clinics.
However, the  recurrence  and metastasis  of tumours,  which
are  associated  with  a switch  in the  oncogene addiction,
changing in signalling  pathway  activation,  followed  by  the
development  of  chemoresistance  have raised  the  awareness
about other  pathways  and/or  multi-point  intervention  to
target different signalling  nodes  in parallel.  Compared  to
the development  and the  use  of TKIs  in the  clinics,  the
development  of PI3K  inhibitors  appears  to be  still  in an  early
phase,  but is rapidly  processing.  Looking  at current  or  soon
initiating  clinical  trials  in  various  cancer  types,  it  is clear  that
PI3K  inhibitors have  arrived  to  the clinical  stage.  Below,  we
will  describe  various  PI3K  pathway inhibitors,  which  have
reached  clinical  trials  for  the  potential  treatment  of NSCLC
and SCLC.
The  orally available  selective  class I PI3K  inhibitor  GDC-
0941 was  identified to  be a potent  agent  for  the  treatment
of cancer  [74]  and will  soon enter  phase  I,  open-label,  dose-
escalation  studies  for  the  treatment  of patients  with advanced
NSCLC, in  combination  with  paclitaxel  and  carboplatin,  with
or without  the monoclonal  VEGF-antibody  bevacizumab
(Table 1) [75],  and in  combination  with  the  EGFR  inhibitor
erlotinib (Table  1) [76].  GDC-0941  was already  tested  in
phase  I clinical  trials  in patients  with advanced  solid  tumours
Table 1
Selection of clinical trials targeting PI3K signalling with emphasis on lung cancer.
Compound Trial Cancer Mechanism Reference
GDC-0941 + paclitaxel +  carboplatin
with/without bevacizumab
Phase I;  recruiting NSCLC Class I PI3K inhibitor Study NCT00974584 [75]
GDC-0941 + erlotinib Phase I;  recruiting NSCLC +  others Class I PI3K inhibitor Study NCT00975182 [76]
GDC-0941 Phase I  Solid tumours Class I PI3K inhibitor Von Hoff et al. [78]
GDC-0941 Phase I  Solid tumours Class I PI3K inhibitor Baird et al. [77]
XL147 Phase I  NSCLC +  others Class I PI3K inhibitor Edelmann et al. [87]
XL147 +  paclitaxel and carboplatin Phase I;  recruiting NSCLC Class I PI3K inhibitor Study NCT00756847 [85]
XL147 +  erlotinib Phase I;  recruiting NSCLC Class I PI3K inhibitor Study NCT00692640 [86]
BEZ235 Phase I  Solid tumours PI3K +  mTOR inhibitor Burris et al. [111]
rad001 (Everolimus) +  docetaxel Phase I  NSCLC mTOR inhibitor Ramalingam et al. [93]
RAD001 (Everolimus) Phase II  NSCLC mTOR inhibitor Soria et al. [95]
RAD001 (Everolimus), carboplatin,
etoposide
Phase I;  recruiting SCLC +  others mTOR inhibitor Study NCT00807755 [107]
RAD001 (Everolimus) +  paclitaxel Phase I;  recruiting SCLC mTOR inhibitor Study NCT01079481 [108]
RAD001 (Everolimus) Phase II; ongoing SCLC mTOR inhibitor Study NCT00374140 [109]
TS-1, cisplatin (CDDP) and RAD001
(Everolimus)
Phase I;  not yet recruiting Solid tumours mTOR inhibitor Study NCT01096199 [98]
Temsirolimus + vinorelbine ditartrate Phase I;  recruiting SCLC +  others mTOR inhibitor Study NCT01155258 [105]
Metformin and temsirolimus Phase I;  recruiting SCLC +  others mTOR inhibitor Study NCT00659568 [106]
MK-2206 + gefinitib Phase I;  not yet recruiting NSCLC Akt inhibitor Study NCT01147211 [117]
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(breast, ovarian,  melanoma)  and was generally  well  tol-
erated. GDC-0941  treatment  resulted  in  effects  on  PI3K
pathway activation  shown  by  decreased  levels  of pAkt  and
pS6 in tumour  biopsies,  and signs  of anti-tumour  activity
could be  observed  (Table  1) [77,78].  In  a preclinical  model
of HER2-amplified  breast  cancer  cells,  which  often  show
resistance to  HER2-targeted  therapy  due  to PI3K  pathway
activation, GDC-0941  showed  significant  activity  in more
than 70%  of  breast  cancer  cell lines.  In combination  with
the HER2-specific  antibodies  trastuzumab  and  pertuzumab
treatment  with  GDC-0941  resulted  in enhanced  growth inhi-
bition  and suppression  of the  Akt  and MAPK pro-survival
pathways [79].  In  another  study  GDC-0941  inhibited  the cell
proliferation  of  both trastuzumab-sensitive  and -insensitive
cells and  induced  apoptosis  in combination  with  trastuzumab
[80]. Additionally,  in a trastuzumab-insensitive  breast can-
cer xenograft  model  single-agent  GDC-0941  could inhibit
the growth  of  a HER2-amplified  tumour  harbouring  PIK3CA
mutation, whereas  combined  treatment  with  GDC-0941  and
trastuzumab  did not result in significant  benefit  [80].  Inhi-
bition of the  PI3K  pathway and tumour  growth  could  be
observed also  in  various  xenograft  models of  breast cancer
[81,82],  lung  cancer,  glioblastoma  [74,83],  ovarian  cancer
[83], and  prostate  cancer  [82]. Furthermore,  oncogenic  alter-
ations,  such  as  activating  mutations  in  the  PIK3CA  gene and
amplification of  the  HER2  gene,  could  be identified  as molec-
ular predictors  for the  sensitivity  of GDC-0941-response  in
vitro and in vivo,  suggesting  PI3K  signalling  addiction  in
tumours harbouring  these  alterations  and  therefore  being
promising candidates  for  PI3K-targeted  therapies  [84].
XL147  (SAR245408)  is a selective  inhibitor  of  class  I
PI3K and  will  enter  a phase  I,  dose-escalation  study  in  solid
tumours, such  as NSCLC,  ovarian cancer,  and endometrial
cancer in  combinatorial  treatment  with the  accepted  treat-
ment regimen  of paclitaxel  and  carboplatin  (Table  1) [85]
Another phase  I study  currently  recruiting participants  will
evaluate  the  efficacy of XL147  in  combination  with  the  EGFR
inhibitor  erlotinib  in patients  with NSCLC  or  other  solid
tumours (Table  1) [86].  In a phase  I  dose-escalation  study
in patients  with  NSCLC,  lymphoma and  other  solid  tumours,
daily treatment  with  XL147  resulted  in a reduction  in PI3K
signalling and  phosphorylation  of MEK  and ERK  in tumour
tissue samples,  reduction  in the  target  lesion,  and prolonged
stable disease  (Table  1)  [87].
RAD001 (Everolimus),  a rapamycin  derivative,  is an
orally available  mTOR  inhibitor.  Various  studies tested
RAD001 as a monotherapy,  or in  combinatorial  treatments
in diverse  tumours.  Here we  will  focus  on  RAD001  in  the
treatment  of lung  cancer  (Table  1).  In preclinical  studies
RAD001 has  shown  anti-tumour  activity  in  in  vitro  and
in vivo  models,  including NSCLC  [88–92].  In  a  phase  I
clinical trial,  a  combinatorial  treatment  of docetaxel  and
RAD001  was  administered  to patients  with advanced  NSCLC
[93]. Docetaxel  is  a semisynthetic  taxane  and an approved
treatment for advanced  NSCLC,  but was shown  to  cause
activation of the  PI3K/Akt/mTOR  axis  as  a resistance  mech-
anism  to taxane  therapy  [94].  Following  these  observations,
the hypothesis is  to combine  the  treatment  of docetaxel
with RAD001  to  overcome  this resistance  mechanism  [93].
Twent-four  patients  with  advanced  stage  NSCLC  and pro-
gression after  platinum-based  chemotherapy  were treated
with escalating  doses of docetaxel  (intravenous,  day  1)  and
everolimus  (orally  daily,  days 1–19)  in  a 3-weeks  treatment
cycle until  progression  of disease.  Sixteen  patients  received
>1 cycle  of  therapy.  One  patient  (adenocarcinoma)  expe-
rienced  a partial  response  with regression  in the  primary
tumour mass.  Ten patients  experienced  disease stabilisa-
tion. Overall,  the  combination  of docetaxel  and  everolimus
was feasible  and  demonstrated  promising  results  in NSCLC
patients [93].  RAD001  as single-agent  treatment  was inves-
tigated in a phase II  clinical  study  in patients  with advanced
NSCLC previously  treated  with chemotherapy  alone  (stra-
tum 1),  or  with  chemotherapy  and  EGFR  inhibitors  (stratum
2). Patients  received  10  mg everolimus  daily.  The  PFS  was
79  days  (stratum  1) and 81  days (stratum  2)  [95].  Patients
showed partial  response  or disease  stabilisation,  demonstrat-
ing a modest efficacy  for the  treatment  in  patients  in whom
multiple lines of systemic  therapy  had failed  [95].  Another
phase I clinical  trial  employed  the  combinatorial  treatment  of
gefinitib and everolimus  in patients  with advanced  NSCLC
to restore  gefinitib  sensitivity.  Five  or ten  milligrams  of
everolimus  and 250  mg  gefinitib were given  to 10  patients
orally daily. The  maximum  tolerated  dose  in  combination
with 250  mg gefinitib  was 5 mg  everolimus  and 2  patients
experienced  a  partial  response  under  these  treatment  condi-
tions  [96].  Based  on  these  results,  a following  phase  II  clinical
study assessed the efficacy  of  the  combination  of gefinitib
and everolimus  in  patients  with  advanced  NSCLC,  either
without  prior  chemotherapeutic  treatment,  or with platinum-
based chemotherapy.  Patients  received  5 mg  everolimus  and
250  mg gefinitib  daily.  Partial  responses were seen in 8  of
62  patients  (response  rate  13%)  and the  median  time to pro-
gression was  4 months.  The  median  overall  survival  was  12
months, 27  months  for  patients  with no  prior chemotherapy,
and 11  month  for  patients  previously  treated with chemother-
apy [97].  In another  phase  I  clinical  study  RAD001  will
be tested  in patients  with  advanced,  metastatic  or  recurrent
solid malignancies  in combination  with TS-1/cisplatin  ther-
apy (Table  1) [98].  Up-regulation  of  the PI3K/Akt/mTOR
pathway was  found to  be an  important  mechanism  for resis-
tance to cisplatin  [66,99,100]  and could  be reversed  by  mTOR
inhibition  in  lung  cancer  cells  [101], suggesting  a therapeutic
approach  consisting  of platinum-based  chemotherapy  in  par-
allel with  inhibition  of  the  PI3K/Akt/mTOR  axis  to  overcome
(acquired)  cisplatin-resistance  in  human  cancers.
In SCLC  cell lines  and tumour  tissue samples of  SCLC
patients, mTOR  expression  was  found  to be over-expressed,
compared  to normal  lung  epithelial  cells  and normal  lung
tissue [102].  Additionally,  RAD001  was  able  to  inhibit  cell
growth in a panel  of  SCLC  cell lines in  vitro  and also
in a xenograft  model  of SCLC  [102,103]. RAD001  down-
regulated  the  basal  and  growth  factor-stimulated  activation
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of  downstream  targets  of  mTOR,  and sensitized  SCLC  cells
to chemotherapy  (etoposide)  [102].  Furthermore,  SCLC  cells
which displayed  an enhanced  or constitutive  activation  of the
Akt/mTOR signalling  were shown  to  be more  sensitive  to
RAD001  treatment,  suggesting mTOR  inhibition  as  poten-
tial therapeutic  target  in patients  with  SCLC  [102].  In a phase
II clinical  study,  temsirolimus,  another  rapamycin  derivative
and mTOR  inhibitor,  was  evaluated  as a single-agent  in SCLC
patients  after  chemotherapy  to study  the  progression  free  sur-
vival  (PFS)  and  toxicities.  Forty-four patients  received  25  mg
and  41  patients received  250  mg temsirolimus  (CCI-779)
intravenously  every  week  until  disease progression.  The  over-
all median  PFS  was 2.2 months  and a difference  between  low
dose and  high  dose  treated  patients  could be  observed only  for
males  (median  PFS  for  low  dose:  1.7 months;  median  PFS  for
high dose  arm:  3  months).  One patient  (1.2%)  experienced  a
partial response  and  6  patients  (7.2%)  stable  disease,  whereas
74 patients  (89.2%)  experienced  progressive  disease.  The
median overall survival  was 8  months,  with  a significant
difference between  low  dose  (6.6  months)  and high dose
(9.5  months)  treatment.  In  conclusion,  temsirolimus  given  to
responding or stable  patients  with extensive-stage  SCLC  after
chemotherapy  did  not  seem  to result  in  a prolongation of PFS
in  these patients  [104].  Currently,  RAD001  is,  beside  a few
clinical studies  involving  temsirolimus  (Table 1)  [105,106],
the  only  PI3K  pathway  inhibitor  which  has  entered  clinical
trials for patients  with SCLC  (Table  1)  [107–109].  Two  phase
I dose-escalation  studies are recruiting  participants  to  test
RAD001  in  combinatorial  treatment.  A  first  trial  will  com-
bine RAD001  with  paclitaxel,  and another  one  with etoposide
or carboplatin,  the  chemotherapeutic  drugs  commonly  used
in SCLC  patients  (Table  1) [107,108].  In an ongoing  phase
II clinical  study  RAD001  is  administered  as a  monother-
apy to patients  with  previously  treated SCLC  to determine
overall and progression-free  survival,  objective  response,  and
toxicities  (Table  1)  [109].  This study  was the first  phase  II
trial  evaluating  single-agent  everolimus  in  previously  treated,
relapsed  SCLC.  Everolimus (10 mg)  was given  orally daily
to 40 patients  until  disease progression.  Among  35  evaluable
patients, all progressed.  One  patient  showed  partial  response
(3%), 8  (23%) stable  disease.  The  median  survival  was 6.7
month and the  median  time to progression  1.3 month. Over-
all, in this  study  the duration  until  disease progression  was
relatively short  and everolimus  showed  limited activity  as  a
monotherapy  [110].
BEZ235,  an  imidazo-quinoline  derivative,  is  an orally
available dual  PI3K/mTOR  inhibitor,  which  inhibits  the
kinase activity  by  binding  to the  ATP-binding  site of  both
of the  enzymes.  In a  first-in-human  phase  I  study  the treat-
ment of patients  with  advanced,  unresectable  solid  tumours
(e.g., breast  cancer  and colorectal  cancer)  with  single-agent
BEZ235  resulted  in  anti-cancer  activity,  especially  in  patients
with PI3K  dysregulated  tumours  (Table  1) [111].  In pre-
clinical studies  its anti-tumour  activity  was shown  already
in vitro  and  in  vivo  [49,50,112–114]. In  various  cancer  cell
lines BEZ235  treatment  resulted  in  a decrease  in proliferation
[49,50,113,114],  in  enhanced  block  of  Akt  activity,  compared
to the  PI3K  inhibitor  LY294002,  and in  a  G1  cell cycle arrest
[113]. In xenograft  models of these  cancer  types  BEZ235
inhibited tumour  growth in  a dose-dependent  manner  [113].
Inhibition  of PI3K  and  mTOR  with  BEZ235  also  reversed
hyperactivation of the PI3K/mTOR  pathway  in trastuzumab-
resistant p110a-mutated  (H1047R)  breast  cancer  cells and
reduced  tumour growth  in a H1047R  xenograft  [114].  Addi-
tionally, BEZ235 was shown  to  block  growth of tumour  cells
more  effectively  in  vitro  and  in vivo  than single-inhibition  of
mTORC1  with rapamycin  [112].  BEZ235  could also  inhibit
proliferative  signalling  in PI3K/Akt/mTOR-addicted  lym-
phomas  by  suppression  of autocrine  and paracrine  growth
factors [115]  and  overcome  the RAD001-induced  negative
feedback activation  of  Akt  in neuroendocrine  tumours  [116].
Another phase I clinical  trial  will  test MK-2206,  an  orally
active inhibitor  of human  AKT1,  AKT2, and AKT3,  in
combination  with  the EGFR  inhibitor  gefitinib  in  patients
with advanced  NSCLC  tumours  harbouring  EGFR  mutation
(Table 1) [117].  In  preclinical  studies  treatment with  MK-
2206  inhibited  tumour  cell proliferation  synergistically with
molecular  targeted  therapies,  such  as erlotinib  or  lapatinib,
or cytotoxic  agents, such as doxorubicin,  docetaxel,  and  car-
boplatin  in  vitro  and in vivo [118].
Taken  together,  targeting  mTOR  as a novel  treatment strat-
egy  seems to  show  promising  effects  in NSCLC.  In SCLC,
comparable effects  are  still  missing,  but  this might  be because
of fewer  results  of completed  clinical  trials. Generally,  and
due to  the  little amount  of completed  clinical  studies,  com-
pared  to the use  of  other  targeted  therapies  in  lung cancer,
further clinical  studies  using targeted  therapy  of  the PI3K
signalling pathway  are  required to evaluate  the  pharmacoki-
netics and the anti-cancer  activity  of these  agents.
Even though  the potential  advantages  of  targeting  PI3K
signalling seem  to be obvious,  judging  from preclinical  and
clinical  studies,  it  is  also  important  to evaluate the  potential
critical toxicities  and side  effects  for patients.  By target-
ing components  of  a pathway  controlling  crucial signalling
events of cell metabolism  various  adverse  events  are likely
to happen.  From  different  clinical  studies  in lung  cancer
patients treated  with  the rapamycin  derivates everolimus  or
temsirolimus,  it  is  known  that  patients  experience  randomly
hematologic  side effects,  such  as neutropenia  and thrombocy-
topenia, and  non-hematologic  adverse  events,  such  as  fatigue,
stomatitis,  mucositis,  nausea,  infection,  hyperglycemia, and
pneumonitis [93,95,96,104,110].  The  severity  of the  adverse
events  was  also  depending  on  whether  everolimus  was
administered as a monotherapy  or as part  of a combination
therapy,  where  toxicities  were overlapping  [96].  Two  stud-
ies characterising  the effects  of  everolimus  or  temsirolimus
on lung  toxicities  in  NSCLC  patients  reported  drug-related
pneumonitis in 25%  and 36% in evaluated  patients,  respec-
tively [119,120]. In  a preclinical  study,  the inhibition  of
Akt1  and  Akt2  with  a  specific  small  molecule  resulted  in
transient  insulin  resistance  and reversible,  dose-dependent
hyperglycemia and hyperinsulinemia [121].  Akt1  and  Akt2
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are known  to  play  essential  roles in  insulin signalling  and glu-
cose homeostasis.  Akt  inhibitors  have  been  shown  to cause
hyperglycemia in  mice [122–124].  In addition,  AKT2  knock-
out mice are  glucose  intolerant  and show  an insulin-resistant
phenotype [125].  PI3K  isoforms  also  play  important  roles
in insulin  signalling  and glucose  uptake.  Double  heterozy-
gous knock-out  of  the  PI3K  catalytic subunits p110a and
p110b led  to impaired  insulin responses  in mice,  resulting  in
slight glucose  intolerance  and hyperinsulinemia [126].  Mice
carrying a  heterozygous  knock-in  mutation  (D933A)  that
abrogates p110a  kinase  activity,  showed  hyperinsulinemia,
glucose  intolerance,  and increased  adiposity  [127].  Addi-
tionally,  the  PI3K subunit  p110d plays  an  important role
for the proper  regulation of  immune  responses.  Mice  defi-
cient in p110d  had severely  impaired  B and T cell function
[128,129]. Mice  expressing  a catalytically  inactive  form  of
p110d (p110dD910A) showed  attenuated  immune  responses  in
vivo and the antigen  receptor  signalling  in B and T  cells  was
impaired  [129].  The  phenotypes  described in gene-targeted
mice may  be  used  to  extrapolate  toxicities  which  are  likely  to
occur upon  inhibition  of PI3K  isoforms  as a therapeutic  strat-
egy in  human  patients. However  and surprisingly,  in a first
phase I  study  in cancer  patients, BEZ235,  a dual PI3K/mTOR
inhibitor, was  well  tolerated  and  showed  only mild or mod-
erate adverse  effects,  such  as  nausea,  vomiting,  fatigue,  and
anorexia  and  no  dose-limiting  toxicities  were observed  [111].
In addition,  other  PI3K  inhibitors,  such  as  GDC-0941  or
XL147, were  reported  to be well  tolerated  without  or  only
a few  DLTs  [77,78,87].
7. Conclusion  and  perspective
The importance  of the PI3K  signalling  pathway,  which
controls cell  survival  and  proliferation  processes,  and its
impact on  cancer  development  has  been  demonstrated  in  the
last two  decades  in various  human neoplasms,  including  lung
cancer.  The  escape  of atypical  cells from the  normal growth
control, in addition  to  deregulation  of PI3K  signalling  and
closely  related  pathways  drives cells  into  a malignant  and
invasive phenotype.  Deregulation  of these  pathways  results
in a lack  of response  to  negative growth regulatory  signals
and the  continuous  presence  of  positive  signals  involving
the RTK/PI3K/Akt  pro-survival  axis.  Therefore,  targeting
RTK/PI3K/Akt signalling  with  small  molecule  inhibitors
has become  an interesting  and promising  approach  in lung
cancer therapy  development.  Indeed,  there  are now  sev-
eral targeted  agents  directed  against the  PI3K/Akt/mTOR
pathway  which  have  entered  clinical  trials  in NSCLC  and
SCLC.  The  use of targeted  therapies  in  addition  to commonly
administered chemotherapy  could  improve  clinical  benefit
for patients,  especially  in  patients  with  cancer  types  depend-
ing on the  presence  of one  particular oncogene,  such as  EGFR
in NSCLC.  Additionally,  even  though  the  whole “cancer  cell
machinery”  is not  yet adequately  understood  and  there  exist
many  “missing  links”,  the growing  knowledge  about  genetic
alterations  driving  cancer  development  and maintenance  pro-
vides the  possibility  to  identify  predictive  molecular  markers,
which  are of  importance  for  further  therapy  development  and
clinical  benefit.
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